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Abstract
Background
The e↵ect of varying oxygen tension on the outcome of critically ill patients is
contentious. Many interventions employed in the intensive care unit aimed at in-
creasing oxygen delivery can cause harm. During the natural history of critical
illness, adaption to tissue hypoxia may occur to a greater or lesser extent. I used
the principle of Near Infrared Spectroscopy (NIRS) with a vascular occlusion test
to investigate forearm muscle oxygen consumption.
Methods
The relationship between arterial oxygenation and mortality in critically ill chil-
dren was explored with a retrospective observational study, a national survey and
xii
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a systematic review in chapter 3.
Chapter 4 describes a study of Near infrared spectroscopy with a vascular occlusion
test (NIRS VOT) in children with suspected mitochondrial disease. The aim was
ascertain if NIRS VOT as a technique is able to reflect tissue oxygen consumption.
Chapter 5 covers the Young Everest Study 2. Healthy volunteers (8-16 years) who
travelled to Nepal and trekked to 3525 meters altitude were tested at two altitudes
(sea level and 3525 meters). The aim was to investigate the physiological response
to a hypobaric hypoxic environment including the NIRS VOT.
Chapter 6 covers studies conducted on critically ill children admitted to the PICU
in GOSH. These include serial NIRS VOT study, an in-vivo measure of oxygen
consumption of peripheral blood mononuclear cells and the expression of oxidative
phosphorylation (OXPHOS) genes changes in the first 48 hours after admission to
the PICU in children with meningococcal septic shock.
Page xiii
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Results
Chapter 3
The epidemiological study of the children admitted to the intensive care unit
showed that 40 children had a PaO2 of less than 20 mmHg (2.6 kPa) out of a
total 7751 admissions in a 9 year period. Of these, 33 children survived to hospital
discharge. There was a U shaped relationship between arterial oxygen tension and
mortality.
The results from the survey showed a varied practice. Of the total, 21 respon-
dents (42%, 95%CI : 29.3   55.7%) stated that they do not follow specific PaO2
targets. Of the rest, as equal number (21, 42%) aimed for targets between 8.1
(61 mmHg) and 10 kPa (76 mmHg). Only 8(16%) aimed for what would be con-
sidered a normal range (10.1   13kPa). A majority of the units (96%) reported
having an alarm target on their oxygen saturation monitor. However, 73% of the
respondents worked in units that did not have an oxygen weaning protocol for
mechanically ventilated patients. In acute respiratory distress syndrome, cardiac
arrest and sepsis, there was a tendency to aim for lower PaO2 (<10 kPa) as the
FiO2 increased. Following traumatic brain injury and in pulmonary hypertension,
there was a propensity to aim for normal PaO2 (10.1-13 kPa) even as the FiO2
rose (28-33% when FiO2 >0.4).
Page xiv
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The systematic review identified 11 studies (n=5280) related to hypoxia with com-
bined odds ratio (OR) for death of 3.13 (95%CI: 1.79-5.48, p <0.001) compared
to normoxia. Six studies (n=2012) investigated the e↵ect of hyperoxia and suggest
no e↵ect on mortality compared to normoxia: OR 1.15 (95%CI: 0.42-3.17, p =
0.77).
Chapter 4
A DropTOI value of 14 was noted to have the least crossover between the mito-
chondrial disease group and controls. This was empirically set as the cuto↵ for
the 2x2 table. The Fisher exact test statistic was 0.22 and showed that NIRS
VOT is unable to di↵erentiate between mitochondrial disease and controls. The
NIRS VOT was able to exclude mitochondrial disease in healthy children with a
high degree of certainty (positive LR - 5.66, 95%CI:0.84-38, negative LR - 0.61,
95%CI:0.47-0.80).
Chapter 5
The SpO2 at rest decreased from 99±0.79 to 89±2.54 % from London to Namche
(p=0.0009). The SpO2 after exercise decreased from 93.5 ± 7.16 to 83.3 ± 5.06
% from London to Namche (p=0.008). The heart rate Z-scores at rest changed
from  0.44±0.70 to 0.10±0.76 bpm (p=0.30) whilst the heart rate Z-scores after
Page xv
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exercise increased from 1.20 ± 1.30 to 2.07 ± 1.46. Cardiac index (at rest) did
not show a statistically significant change with an ascent to moderate altitude.
Respiratory rate after exercise increased consistently from sea level (22.2± 4.4) to
Namche Bazaar (27.6± 10.9).
With a multilevel functional regression analysis, the baseline TOI was significantly
lower in Namche Bazaar than London (-4.05, 95%CI: -3.23, -4.86, p <0.001). The
lowest TOI was also significantly lower in Namche Bazaar (-1.95, 95%CI: -1.13,
-2.76, p <0.001). The DropTOI at Namche bazaar compared to sea level was 2.1
points lower (p <0.0001).
Chapter 6
Tissue Oxygen Index varied during the first 5 days of illness. The DropTOI de-
creased until day 4 (3.02 lower) and showed relative increase on day 5 (0.93 lower)
compared to day 1. The net routine control ratio (measured with oroboros anal-
yser) dropped from day 1 to day 5. On the group level analysis (all five patients
assessed together), with a false discovery rate (FDR) at <25% and ranked ac-
cording to their Normalised Enrichment Score (NES), 1039 out of 3655 gene sets
showed a decreasing profile with time. The respiratory electron transport chain
gene set was ranked 75th of the 1039 gene sets.
Page xvi
CONTENTS
Conclusions
The oxygen administration practices in the paediatric intensive care units in the
UK vary widely. Of note, admission PaO2 has a ‘U-shaped’ relationship to mor-
tality in children admitted to the paediatric intensive care unit. Healthy children,
when exposed to hypobaric hypoxic conditions, show a tendency to decrease oxy-
gen consumption from forearm muscle. There was some evidence that critically ill
children demonstrate similar signs of early adaptive response by reducing oxygen
consumption.
Page xvii
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Chapter 1
Introduction
1.1 Introduction
Critical illness in children may have a long-term impact. Over a three year period
(Jan 2010 - December 2012), 57,949 children were admitted across 30 paediatric
intensive care units (PICU) in the UK. Although outcomes are improving the
number of admissions is increasing. [1] There is a need for research into the most
common therapeutic interventions instigated in paediatric intensive care. Supple-
mental oxygen is one such strategy. Oxygen is usually administered in the setting
of hypoxia. Is there enough evidence to support this strategy?
In this thesis, I explored the hypothesis that children adapt to hypoxic condi-
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tions during critical illness. In this introduction chapter, evidence on the e↵ect of
hypoxia and hyperoxia on outcome in critically ill patients is reviewed. Next, I
describe the current theories around hypoxic adaptation in more detail.
I have covered this under the sections:
1. Role of reactive oxygen species
2. How might the body adapt to hypoxic states?
2.1. Animal studies
2.2. Oxygen sensing and Hypoxia Inducible Factor system
3. Studies in Healthy Humans
4. Studies in patients
5. Potential future research strategies
A brief discussion of cardiovascular physiology, oxygen delivery and techniques to
measure cardiac output follows. The next section describes the physiology of oxy-
gen consumption and methods of its measurement.
Later I detail the near infrared spectroscopy with a vascular occlusion test (NIRS
VOT). The results of this non-invasive technique may be extrapolated to ascer-
tain regional oxygen consumption status. Next, I discuss how oxygen is utilised
in mitochondria to generate energy. This is followed by a brief description of the
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genetics of mitochondrial diseases. Finally I write a section on my hypothesis for
each of the chapters.
1.2 Does Hypoxia Kill?
Hypoxia is defined as the condition where the body is deprived of adequate oxygen
supply. Hypoxia causes injury due to the cessation of cellular aerobic respiration.
Severe hypoxia can lead to cell death and eventually death of the organism. High
altitude balloonists were amongst the first to clearly describe the e↵ects of acute
hypoxia. These e↵ects were attributed to the low barometric pressure and low par-
tial pressure of oxygen (hypobaric hypoxia). [2] Barcroft classified hypoxia into 3
sub-categories: anoxic type (hypobaric hypoxia), anaemic type (inability to carry
oxygen) and stagnant type (hypoxia secondary to circulatory failure). [3] He wrote
“Anoxaemia not only stops the machine, but wrecks the machinery”
He hypothesised that chronic hypoxia must elicit an acclimatising e↵ect from the
human body in the form of an increase in haemoglobin or blood flow. [4] The
physiological e↵ects of acute hypoxia, especially when associated with increasing
altitude, have been clearly described in the last few decades. Unconsciousness
was noted to be a pre-terminal sign of acute severe hypoxia reflecting inadequate
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brain oxygenation. [5] Figure 1.1 describes the impact of worsening hypoxia (due
to increasing altitude) on the body. It also shows the rapidity of onset of uncon-
sciousness from about 6000 metres above sea level. Although the e↵ects of acute
hypoxia are understood, it has been more di cult to delineate the e↵ects of chronic
hypoxic exposure.
Figure 1.1: E↵ect of Hypoxia on the Senses with Increasing Altitude
The x-axis denotes increasing altitude in metres. The vertical arrows point to the
approximate altitudes where each of the neurological symptoms manifests. Above
6000 metres, humans lose consciousness. The y-axis denotes the amount of time
needed to lose consciousness with increasing altitude. Reproduced from an article
by Sharp et al. [5]
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The e↵ects of acute and chronic hypoxia on the human body are relevant in the
critically ill patient. A recent study in adult intensive care patients demonstrates
a direct link between poor oxygenation and eventual outcome. [6] Eastwood et
al investigated the Australian - New Zealand adult intensive care unit database.
They reviewed PaO2 in the first 24 hours in 152,680 mechanically ventilated pa-
tients. This revealed an increase in the adjusted odds ratio of death with decreasing
PaO2. [7]
But the level at which hypoxia becomes fatal is unclear. Despite the variation
among patients admitted to an intensive care unit, an arterial PaO2 of 2.6 kPa
(20 mmHg) was thought to be the threshold below which survival was impossi-
ble. [8] Gray et al published a case series of adult acute medicine admissions. They
reviewed all arterial blood gas records over a two-year period comprising measure-
ments from 1,700 hospitalised patients. These patients did not receive intensive
care. They found 22 patients with one or more PaO2 values below 2.6 kPa (20
mmHg). Of the 22 cases, 13 (59%, 95%CI: 39-77%) survived to hospital discharge.
Six (50%) of these patients were reported to have a good neurological outcome.
But the functional outcome of these survivors is not clear. [9]
Grocott et al addressed functional status following exposure to hypoxia. A team
of researchers climbed Mount Everest over a 2 month period. They collected ar-
terial blood samples from the femoral artery at an altitude of 8400 metres. The
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ability to draw femoral arterial blood, perhaps suggests a good functional status.
Incredibly, the results showed that one of the investigators had an arterial PaO2
of 2.54 kPa (19.1 mmHg). This could be partly explained by acclimatisation. By
improving the e ciency of oxygen utilisation humans seem to function even with
a lower arterial partial pressure of oxygen. This paper provides further evidence
that there are exceptions to the threshold set by Campbell. [10] The evidence to
set a lower safe limit of arterial PaO2 is, therefore, equivocal.
Hypoxia is one end of the spectrum of oxygenation status seen in the critically ill
patient. However, a proportion of resuscitated patients in intensive care tend to
be hyperoxic. To achieve these values intensivist might resort to aggresive thera-
peutic startegies. A better definition of the upper limit of PaO2 might limit the
harm caused by these interventions. Therefore, the evidence relating to hyperoxia
is addressed below.
1.3 Does Hyperoxia Kill?
Studies in humans report harm due to hyperoxia. Kilgannon et al looked at 4459
patients (>17 years) admitted to 120 US hospitals following cardiopulmonary re-
suscitation. They observed a linear relationship between in-hospital mortality and
post-resuscitation arterial PaO2 (Odds ratio - OR-1.8, 95%CI: 1.5-2.2). The ar-
terial PaO2 was included as a continuous measure in this study. Therefore, the
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odds ratio refers to any hyperoxia as opposed to per unit change. [11] In a study in
children, Ferguson et al reported a non-linear relationship between PICU mortality
and hyperoxia (OR-1.25, 95%CI: 1.17-1.37) in those admitted following a cardiac
arrest. [12] A recent paediatric study does not support the above findings. [13]
In the last decade, the value of supplemental oxygen in acute coronary syndromes
has been questioned. [14] A recent randomised controlled trial in patients with
ST-elevation myocardial infarction compared supplemental oxygen (8 L/min) to
no oxygen. They found a statistically significant increase in creatine kinase (sur-
rogate for infarct size), troponin I, reinfarction rate and arrythmias in the oxygen
treated group. [15] Similarly, adult stroke patients had no di↵erence in 1-year sur-
vival between no oxygen and supplemental oxygen therapy. [16] Damiani et al have
synthesised these studies in a systematic review. They report increased mortality
due to hyperoxia in post-cardiac arrest patients (OR = 1.42, 95%CI: 1.04-1.92),
patients following a stroke (OR = 1.23, 95%CI: 1.06-1.43) and patients who suf-
fered traumatic brain injury (OR = 1.41, 95%CI: 1.03-1.94). [17]
1.4 Role of Reactive Oxygen Species
The harm from hypoxia and hyperoxia maybe mainly due to the action of reactive
oxygen species (ROS). Reactive oxygen species are chemically reactive molecules
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involved in oxidation and reduction reactions. The majority of ROS are gener-
ated in the electron transport chain in the mitochondria. The most important of
these are the superoxide radical (O· 2 ), the hydroxyl radical (OH
·) and hydrogen
peroxide (H2O2). [18] Reactive oxygen species are produced by all cells in minute
quantities in health. They are needed for redox signaling and homeostasis in cells.
Normally, anti-oxidants - such as the superoxide dismutase (SOD) - neutralise
these ROS molecules. But in hypoxic and hyperoxic conditions ROS production
overwhelms the scavenging system (anti-oxidants). This creates a milieu for cell
damage. Reactive oxygen species damage cells by causing oxidative damage to de-
oxyribonucleic acid (DNA) and cellular proteins and by lipid peroxidation. [19] [20]
Oxygen rich environments cause increased production of ROS. [21] Equally, oxy-
gen poor states may also cause ROS production due to reverse electron transport
from complex III of the electron transport chain. [22]
1.5 HowMight the Body Adapt to Hypoxic States?
The theories behind potential adaptations have been devised from basic physiol-
ogy research. The Hypoxia Inducible Factor (HIF) pathway is detailed first. I will
follow this by discussing animal studies and studies in healthy humans. Finally, I
will describe research in patients.
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1.5.1 Oxygen Sensing and Hypoxia Inducible Factor Sys-
tem
Semenza, Ratcli↵ and Kaelin discovered the oxygen sensing system in humans. [23]
They noted that cobalt poisoning caused an increase in erythropoietin. It was
known that hypoxia stimulates erythropoiesis probably through the activation of
an oxygen sensor molecule. Therefore, the suspicion was that cobalt acts on this
molecule. This molecule was thought to be limited to cells that produce erythro-
poietin. Both the Semenza and Ratcli↵ groups worked on understanding the regu-
lation of erythropoietin gene expression. Eventually, the Semenza group identified
the Hypoxia Inducible Factor and realised that it acts on numerous cell types.
Another seemingly unrelated observation was in Von-Hippel Lindau (VHL) dis-
ease patients. These patients are prone to develop tumors. The cores of these
tumors are hypoxic regions but also stimulate angiogenesis. Some of these pa-
tients also demonstrated erythrocytosis. Kaelin hypothesised that the expression
of VHL gene caused the downstream e↵ects of angiogenesis and erythrocytosis.
He named the proteins formed from this gene expression VHL product (pVHL).
In addition, the Kaelin group demonstrated the dysregulation of several hypoxia
inducible mRNAs in VHL disease. Therefore, there was a relationship between
pVHL and the HIF system. [24]
The Ratcli↵ group reported the link between pVHL and HIF↵. They noted that
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a physical binding of pVHL and HIF↵ was necessary for the oxygen dependent
instability of HIF↵. These findings have led to the current definition of the HIF
system. [25]
The HIF is a DNA binding complex. It is made up of ↵ and   heterodimeric pro-
teins. HIF ↵ transduces oxygen sensitive signaling. Before HIF can be deactivated
by VHL protein, it undergoes an oxygen dependent post-translational modifica-
tion. This reaction is catalysed by prolyl hydroxylase enzyme and requires iron,
oxygen and ascorbate. Cobalt inhibits this reaction. Therefore, cobalt stabilises
HIF and causes an increase in erythropoietin. [23] (Figure 1.2)
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Figure 1.2: Oxygen Sensing in Tissues
The Hypoxia Inducible Factor (HIF) is stabilised in the absence of oxygen. This
leads to stimulation of glycolytic gene expression and release of erythropoietin
and vascular endothelial growth factor. The Von-Hippel-Lindau protein destroys
activated HIF. HIF is activated by prolyl hydroxylase in the presence of oxygen.
1.5.2 Animal Studies
Drosophila melanogaster species have been widely employed in the investigation
of hypoxic adaptation. They have certain characteristics that make them suitable.
These flies have a short life cycle, a short genome and, incredibly, share hypoxia
response genes with humans. Furthermore, they have an inherent variable hypoxia
tolerance. Interestingly, 70% of known human disease genes are present in their
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genome.
Researchers incubated Drosophila flies in 4% oxygen environment. Over genera-
tions a hypoxia adapted strain was created. The metabolomics profile was com-
pared between naive flies and hypoxia adapted flies. They observed an increase in
glucose, oxaloacetate and alanine in the hypoxia-adapted flies. Furthermore, an
increase in ATP production (surrogate indicator of hypoxia-tolerance) with rela-
tively lower oxygen consumption was observed in the hypoxia group. Following
this, enzymatic pathways were investigated. They noted an increase in glycolysis.
In addition, the flux through complex I increased and there was a suppression of
mitochondrial biosynthesis. [26]
The next methodology employed was a reverse gene approach. With this approach,
a specific gene expression is altered first. The resulting change in phenotype is
analysed. Zhou et al produced hypoxia tolerant flies by exposing them throughout
their life cycle to increasingly hypoxic environments over 32 generations. The last
generation was able to survive, function and reproduce at 4% oxygen chambers.
Some embryos of the hypoxia-tolerant flies were incubated in normoxic conditions
for 8 further generations. Incredibly, the embryos of the 9th generation were able
to function and reproduce in the 4% oxygen environment. This demonstrated
that hypoxia tolerance gene expression was heritable. In addition, gene expression
related to carbohydrate and peptide metabolism was down regulated. Phenotypi-
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cally, these flies with down regulated gene expression were relatively smaller flies.
Furthermore, they noted down-regulation of gene expression of the respiratory
electron transport chain, especially complexes I and IV. [27] Mammals also have
shown adaptive characteristics to hypoxic stimulus. Investigators have observed
increased oxygen carrying capacity, red cell mass and blood volume in animals that
are able to cope with hypoxic conditions such as deep sea diving whales. These
were in addition to a decrease in basal metabolic rate. These changes are perhaps
due to alterations in Hypoxia Inducible Factor (HIF) dependent pathways. [28] I
will discuss the HIF system in the next section.
Individual organ systems have also been investigated in mammals. Zhao et al bred
rats in a hypoxic environment. This enabled preconditioning of rat neuronal cells.
This was followed by a hypoxic-hypoglyceamic insult. They assessed peroxisome
proliferator activated receptor     co-activator 1  ↵ (PGC1  ↵) and HIF 1  ↵
expression. PGC1   ↵ is a transcription co-factor. It is found in high concentra-
tions in mitochondria-rich tissues. It is a regulator of cellular energy metabolism.
The hypoxia preconditioned cells demonstrated less cell damage, more expression
of PGC 1   ↵, HIF 1-↵ and vascular endothelial growth factor. This protection
from hypoxic pre-conditioning was not noted in HIF 1   ↵ deficient cells. [29]
In a di↵erent experiment, wistar rats were housed in 11% oxygen environment.
They showed an increase in haematocrit but no decrease in cardiac mass. Sub-
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sarcolemmal mitochondria showed decreased activity of electron transport chain
complexes I, II and IV. Significantly, there was a reduction in ROS production and
opening of Mitochondrial Permeability Transition Pore (MPTP). The opening of
MPTP is associated with ischaemic-reperfusion injury. [30] Therefore, hypoxic pre-
conditioning may protect against ischaemic-reperfusion injury.
Hochachak described the possible mechanisms by which hypoxic adaptation may
occur in hypoxia-tolerant animal species (aquatic turtles and fishes). The primary
mechanism might be a reduction in ATP turnover in tandem with a decrease in
metabolic rate. The balance between ATP demand and supply is perhaps achieved
by a decrease in protein turnover and a decrease in urea and glucose biosynthe-
sis. [31] Animals that are not usually exposed to hypoxic environment have also
shown adaptive physiology when subjected to low oxygen settings. Beneficial phe-
notype of hypoxic adaptive response has been noted in rats bred in 10% oxygen
environment. These rats demonstrated a 36% increase in red blood cells. This
suggests chronic hypoxic adaptation. Stem cells from donor rats from a normoxia
group and the hypoxia-adapted group were infused into rats whose bone mar-
row was ablated with radiation. Both haematopoietic stem cell function and bone
marrow engraftment were better when donor rats were from the hypoxia-adapted
group. [32]
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In summary, evidence from animal studies suggests hypoxic adaptive responses
maybe advantageous.
1.5.3 Healthy Human Studies
Healthy humans were exposed to acute hypoxia under strict glucose and lactate
control conditions. They demonstrated a reduction in resting energy expenditure.
This reduction persisted even after 2.5 hours of cessation of hypoxia. In addi-
tion, the glucose requirement was lower in hypoxia group compared to normoxic
controls. This suggests that hypoxic adaptive physiology is instigated very early
on in the hypoxic phase and remains active well after normoxia is achieved. [33]
Another study investigated 7 healthy volunteers housed in a hypoxic environment
for 10 days. They observed a significant increase in erythropoietin, haemoglobin
and haematocrit levels by day 2 of exposure. These findings are similar to animal
studies and probably secondary to the activation of the HIF system. [34]
The human respiratory system responds to hypobaric hypoxic conditions by the
hypoxic ventilatory response (seen in sojourners to high altitude). Hypoxia in-
ducible factor causes an increase in erythropoietin and augments erythropoiesis.
Hypoxia leads to angiogenesis by stimulating VEGF. Prolonged hypoxia can stim-
ulate changes in the pulmonary vasculature and result in the development of pul-
monary arterial hypertension. [35] Although these changes are noticed in di↵erent
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organ systems the adaptive pathway at the level of the organism is still unclear.
Understanding these mechanisms may help us comprehend the changes occurring
during critical illness in humans. [36]
1.5.4 Studies in Patients
Cystic fibrosis is a chronic life-limiting condition that involves recurrent chest in-
fections and bronchiectatic changes of lung architecture. This leads to chronic
hypoxaemia. In the Boning study, haemoglobin-oxygen a nity between adult pa-
tients and healthy controls was compared. The oxygen dissociation curve (ODC)
that depicts the relationship between haemoglobin oxygen saturation and partial
pressure of oxygen - was shifted to the right. The ODC can shift to the right due
to acidosis, hyperthermia and increased 2,3-diphophoglycerate (DPG) concentra-
tions. In fact, Boning observed an increase in 2,3-DPG. These findings suggest
a decrease in haemoglobin-oxygen a nity and a relatively easier oxygen release
at the tissues. It was postulated that this shift might be secondary to increased
erythrocytic glycolysis and red cell turnover that cause a rise in 2,3-DPG. [37]
However, a study in a similar chronic hypoxia population shows a di↵erent mech-
anism. [38]
Asthma is a chronic inflammatory condition that might recurrent episodes of hy-
poxaemia. Hallmarks of the disease are bronchoconstriction and a reduction in
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oxygen uptake in the lungs. Of note, there is an increased generation of reactive
oxygen and nitrogen species due to the inflammation. Airway cells have fewer
mitochondria and seem to be more e cient in an experimental murine asthma
model. [38] The oxygen consumption rate from platelets was measured in a study
comparing 12 asthma patients (not severe) and 13 healthy controls. The mito-
chondrial DNA copy number per platelet was not di↵erent between the groups.
The basal respiration, proton leak and ATP linked respiration remained equal.
The oxygen consumption rate in the asthma patients was stable and indepen-
dent of glycolysis. Increased aconitase levels were observed in asthma patients.
This suggests increased tricarboxylic acid cycle (TCA) activity. The substrates
of TCA cycle fuel the oxidative phosphorylation in mitochondria: potentially this
can augment oxygen utilisation in the mitochondria. [39] In patients with severe
obstructive sleep apnoea and nocturnal hypoxia, VEGF levels were higher com-
pared to healthy controls. Furthermore, there was a linear correlation between
oxygen saturation and level of VEGF. [40] The elevated levels of VEGF might be
secondary to activation of the HIF system. If VEGF was stimulated then, other
e↵ects of the HIF system might also be activated such as erythropoietin release.
Hence, VEGF levels may potentially be a marker of hypoxic adaptation. These
studies concur in part with evidence from animal research. [26] Unfortunately, the
metabolomic changes in chronic hypoxia patients have not been well investigated
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and need further research.
1.6 Potential Future Research Strategies
Several avenues are currently being explored to delineate hypoxic adaptation path-
ways. I will mention a few promising areas here.
1. Nitric oxide (NO) is central molecule in several metabolic pathways including
hypoxic adaptation. Nitric oxide causes vasodilation under conditions of tissue hy-
poxia. The aim is to increase oxygen delivery. Studies on Sherpas concur with this
theory. The level of circulating NO and forearm blood flow in Sherpas was noted
to higher compared to low landers. [41] The complimentary e↵ect to vasodilation
is an inhibition of cellular metabolism. NO inhibits complex I and competes with
oxygen at the cytochrome c oxidase site in the electron transport chain. These
e↵ects have led researchers to augment NO synthesis and investigate its impact
on oxygen consumption. Di↵erent research groups have reported contradictory
findings. [42] This suggests that the pathways that interact with NO synthesis and
function are still unclear. Research in this area is being actively pursued. [43]
2. Micro Ribonucleic acids (miRNA) are present in all eukaryotes. They are
non-protein coding and regulate gene expression. Recent discoveries propose an
important role for miRNAs in hypoxic adaptation. Whilst HIF 1- alpha causes
metabolic adaptations by transcriptional regulation, miRNA work at the post-
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transcriptional level. The two systems may work in tandem to accomplish hypoxic
adaptation. The miRNA may be particularly helpful in transient and local hy-
poxic challenges. [44] miR-210 is a hypoxia-regulated miRNA that is expressed
in all cell types. [45] It targets specific proteins needed for the functioning of the
mitochondrial electron transport chain and the TCA cycle. Under hypoxic con-
ditions, miR-210 causes repression of protein function. This results in relatively
more ATP formation for the oxygen available through augmented glycolysis. [46]
Therefore future research in understanding the exact pathways by which miRNAs
act will help direct therapeutic strategies to perhaps augment their function.
3. One therapeutic strategy that might help hypoxic patients is the use of dexam-
ethasone. Prophylactic use of dexamethasone in mountaineers has ben observed
to reduce the risk of high altitude pulmonary edema. The mechanism of action
might be a direct augmentation of ventilatory acclimatisation to hypoxia. The
proposed mechanisms that might cause this are increased surfactant production
and an increase in the sodium transporters in the alveoli. [47] In addition, dexam-
ethasone may up regulate oxidative phosphorylation gene expression. [48] Finally,
dexamethasone probably acts on the HIF system and decreases the production of
erythropoietin. In turn, there is a reduction in haematocrit and viscousity aiding
in reduction of pulmonary vascular resistance. [49] In chronic hypoxic patients,
early utilisation of dexamethasone might reduce the risk of developing right heart
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failure secondary to pulmonary hypertension.
In subsequent sections, I will detail the oxygen cascade, the Doppler ultrasound
cardiac output measurement technique, the principles of near infra-red spectroscopy
and basic mitochondrial physiology.
1.7 The Oxygen Cascade
The cardiovascular and respiratory systems work in concert to deliver oxygen to
the tissues and to wash out metabolites from the tissues. The delivery and con-
sumption of oxygen by the body are in series. The oxygen pathway starts with the
inspired air (21% at sea level). With inspiration, oxygen travels to alveoli. From
alveoli, a step-wise cascade transports it to the tissues. Figure 1.2 illustrates this
cascade. [50] The main determinants of oxygen delivery to tissues are the Alveolar-
arterial oxygen (A-a) gradient, the cardiac index, haemoglobin concentration and
arterial oxygen saturation. We will now consider the measurement of oxygen de-
livery by incorporating these parameters into a single model.
Page 21
1.7. THE OXYGEN CASCADE
Figure 1.3: The Oxygen Cascade
The x-axis denotes the steps an oxygen molecule takes leading from the atmosphere
to the mitochondria. The y-axis depicts the gradual drop in the partial pressure
of oxygen at the various sites. Amended from Raman et al. [50]
1.7.1 Oxygen Delivery
Oxygen delivery (DO2) can be calculated by measuring the various components
necessary for transfer to the tissues. The formula incorporates haemoglobin (Hb),
haemoglobin oxygen saturation (HbO2), cardiac output (CO) and the partial pres-
sure of arterial oxygen in blood (PaO2). The formula is as follows:
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DO2 = CO ⇥ CaO2 (1.1)
where
DO2 is measured in mls of O2/min
CO denotes cardiac output measured in L/min and
CaO2 denotes oxygen content of arterial blood.
The oxygen content can be calculated by the formula:
CaO2 = (1.36⇥Hb⇥ SaO2) + (0.0031⇥ PaO2) (1.2)
where
Arterial oxygen content is measured in ml of O2/100ml of blood,
Hb denotes haemoglobin measured in grams/decilitre,
SaO2 denotes saturations from arterial blood gas measured as percentage,
PaO2 denotes arterial oxygen tension measured in mm Hg
the constant 1.36 is the amount of oxygen bound to each gram of hemoglobin
the constant 0.0031 is the amount of oxygen dissolved in plasma
A major determinant of oxygen delivery is the cardiac output. I will discuss the
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measurement of cardiac output in further detail now.
1.7.2 Cardiac Output
Cardiac output (CO) is the amount of blood pumped out of the heart in a minute.
This is a product of the heart rate per minute and the stroke volume (blood volume
per heart beat). Cardiac output is usually expressed as cardiac index (CI) (CO per
unit body surface area). Cardiac index is crucial to ensure oxygenation of tissues.
The normal range of CI in humans is between 3.5-6 L/min/m2. Clinicians consider
cardiac output as a marker of the global oxygen demand-supply relationship. [51]
In a study in septic adult patients, low cardiac output (set at <4.5 L/min/m2)
was demonstrated to have worse outcome (74% vs. 40%, p <0.05). [52] In the
landmark study from Rivers, patients’ central venous oxygen saturation was op-
timised by measuring and supporting their cardiac output. [53] The association
between measuring/ supporting CO and influencing outcome is unclear. A patient
may have a cardiac output in the normal range, but still be in a negative oxy-
gen demand-supply relationship. LeDoux et al proved, in their septic model, that
augmenting perfusion pressure does not improve tissue perfusion or outcome. [54]
This finding may be due to the varying relationship of oxygen delivery (DO2) and
consumption (V O2). I will explore this relationship later in chapter 6.
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Methods of Measurement of Cardiac Output
The clinical signs used to assess cardiovascular function are useful, but inaccurate
at times. A recent study substantiates this view. [55] Adolf Fick was the first to
devise a solution to measure cardiac output. He described the measurement of
cardiac output by using the universal principle of law of mass di↵usion. [56] His
technique has been advanced further in the last century. In the present day, some
of the following techniques are used to measure cardiac output:
A. Thermodilution technique
B. Lithium dilution techniques
C. Arterial pressure wave / contour analysis techniques
D. Technique using ultrasound and Doppler
I have used the ultrasound doppler techinque in my thesis. This is discussed in
more detail here.
Ultrasound Doppler Cardiac Output Measurement
The Doppler principle in conjunction with ultrasound has enabled the non-invasive
measurement of cardiac output. Two methods use this principle: 2 D Echocar-
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diography and Ultrasound Cardiac Output Monitor (USCOM). Echocardiography
provides a more in-depth analysis of the cardiovascular status. However, it is im-
practical in an intensive care unit. This is partly due to the prolonged training
needed to become proficient in echocardiography. In addition, it is time-consuming
and resource intensive. Most intensivists prefer a non-invasive bedside tool. Con-
sequently, USCOM becomes appealing.
USCOM has a major inherent assumption. It assumes that the aortic valve acts
as a fixed circular outlet. There are some reservations to this assumption, as ex-
plored later. If we were to consider a circular tube - akin to the aortic outflow -
the formula to measure the mass is:
Mass = V olume⇥Density (1.3)
We can assume the density of blood coming out of the heart is constant and hence
can be treated as ’1’. Therefore, the formula can e↵ectively be considered to be:
Mass = V olume (1.4)
At the aortic valve, this volume will be a measurement of the stroke volume. The
next stage is to measure the volume.
According to fluid dynamics,
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V olume = A⇥ v ⇥ t (1.5)
where
A denotes Area,
v denotes Velocity and
t denotes Time.
As the cardiac output is measured at the aortic valve, the area of the tube con-
sidered in our model is known. This is the area of aortic valve annulus. By the
use of echocardiography measurements and body surface area, nomograms of the
aortic valve annulus have been created for both adults and children of all ages.
The main reservation is the lack of standards for measurement of the aortic valve
diameter (distance between outer edges or inner edges) and also whether the mea-
surement should be made during systole or diastole (the annulus width is not
constant throughout the cardiac cycle). [57] [58] [59]
The measurement of Velocity Time Integral (VTI) is feasible by directing the ul-
trasound wave at the aortic valve. This is possible because we can measure the
flow and the time it takes for the Doppler wave to hit the blood outflow from the
heart and return to the probe. Some authors have suggested using nomograms of
the aortic flow velocity integral instead of aortic valve area for more accurate and
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individualised measurement of the cardiac output. However, these need further
exploration. [60] Despite its limitations, USCOM has nevertheless found clinical
utility due to the simplicity and non-invasive nature of this method.
Researchers have proven the validity of USCOM in several settings. An animal
study measured cardiac output by USCOM and ultrasonic flow probe placed di-
rectly over the ascending aorta in 6 anaesthetised dogs. The mean bias (Bland-
Altman method) was  0.01 L/min and the limits of agreement were  0.34 to
0.31 L/min. In 5 of the 6 dogs, Lin’s coe cient of concordance was >0.9. [61] A
study on children (<12 years old) who underwent elective surgery similarly showed
a high concordance correlation coe cient of 0.87 for inter-observer variability. It
also showed a small intra-observer variability. [62] A validation study in adults
comparing USCOM to the thermodilution technique using a PAC showed a rea-
sonable correlation at 0.8. [63]
Although there are reports of the validity of USCOM in the theatre setting it will
be ideal to show this in the emergency department or the intensive care unit. A
study in children presenting to an emergency department has addressed one of
these issues. This study included the examination of 41 children. The procedure
was successful in 94.7 % of the children and yielded acceptable records in 75.9 % of
these. However, the kappa value for clinical correlation of USCOM measurements
was low between two raters. [64] Most operators believe USCOM to give reason-
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ably reliable values in children and adults despite the issues surrounding intra and
inter-observer variability.
A study in premature neonates showed poor correlation and reliability. [65] A
meta-analysis including 10 studies in children and adults in a variety of clini-
cal settings reported 42.7 % (95 % CI: 38.5-46.9 %) error. This is similar to
other minimally invasive techniques of cardiac output measurement. Of note the
mean weighted bias between USCOM and thermodilution techniques was low at
 0.39L/min (95%CI :  0.25 to  0.53 L/min). [66] Normal ranges of USCOM
measurements are available both for children and adults. [67] [68]
A recent study, set in a tertiary paediatric intensive care unit, supports the use of
USCOM in children in shock. The investigators demonstrated the ability to moni-
tor progress and titrate vasopressor and inotrope therapy using the cardiac output
and systemic vascular resistance index (SVRI) measurements from USCOM. [69]
Figure 1.1 shows a representative recording from USCOM. [70]
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Figure 1.4: Example Ultrasound Cardiac Output Monitor (USCOM) Waveform
The x-axis denotes time and the y-axis depicts the flow noted by the probe. Each
triangular wave represents one heartbeat. The cardiac output is measured by
calculating the area within the triangular waveform. Reproduced from USCOM
product guide. [70]
1.7.3 Oxygen Consumption
Oxygen consumption depends on cellular respiration. The amount of oxygen
utilised by the cells to generate adenosine triphosphate (ATP) - by oxidative phos-
phorylation system in the mitochondria - is a major determinant of consumption.
Non-mitochondrial oxygen consumption accounts for a small proportion of the to-
tal oxygen consumed. Therefore, the oxygen consumption might potentially act
as a marker of mitochondrial function and the functional status of cells.
The oxygen extraction rate (OER) is the ratio of oxygen consumption to oxygen
delivery. The OER is can be employed to analyse oxygenation of tissues.
OER =
V O2
DO2
(1.6)
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where
OER denotes oxygen extraction rate,
V O2 denotes oxygen consumption and
DO2 denotes oxygen delivery.
1.8 Surrogate Measures of V O2  DO2 Balance
Some surrogate measures such as lactate anad mixed venous saturations have been
employed to analyse the V O2  DO2 balance.
A. Lactate
Normal arterial serum lactate ranges between 0 and 2 mmol/L. The production of
lactate occurs when the tissues have an insu cient supply of oxygen. Glycolysis
for energy production is not optimal in these low perfusion / low oxygen states.
The body is forced to produce ATP (albeit ine ciently) by anaerobic pathways.
The end product of this anaerobic reaction is lactate. Hence, an increase in lactate
can be a marker of low perfusion or low oxygen states. However, the interpretation
of high levels must be made with caution. Not all scenarios of high lactate are
low perfusion states. For example, in the setting of acute severe asthma one of
the common therapeutic interventions is to administer nebulised or intravenous
salbutamol. Despite the peripheral oxygen saturation being in the high 90s, ma-
Page 31
1.8. SURROGATE MEASURES OF V O2  DO2 BALANCE
jority of the patients display high lactate levels. Salbutamol causes the generation
of lactate by an as yet unexplained mechanism. [71]
B. Mixed venous oxygen saturation
The ‘true’ mixed venous oxygen saturation is measured from a pulmonary artery
catheter placed in the main pulmonary arterial trunk. Blood returning to the
right side of the heart contains the residual oxygen after utilisation by the tissues.
This makes the MxV enO2 an indirect measure of whole body tissue oxygen con-
sumption. Acute changes in basal metabolic rate and the cardiovascular support
needed can be determined fromMxV enO2. As noted earlier the pulmonary artery
catheter has fallen out of favour.
The next best available site of measure for the venous oxygen content is from
the superior vena cava (SVC). One can get as close to the ‘true’ value as safely
possible by positioning the central line tip at the SVC and the right atrial junc-
tion. A reasonable correlation exists between the mixed venous oxygen saturation
measured from SVC and pulmonary artery. [72] This technique is widely used in
the adult emergency medicine and intensive care setting. However, placement of
central venous lines, especially in the internal jugular vein, is uncommon as part of
routine management of a critically ill child on a paediatric intensive care unit. This
measure loses its significance when the blood is sampled from a femoral venous line.
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Both lactate and mixed venous saturations are from the vascular compartment.
Each tissue receives blood in proportion to its metabolic rate. For example, brain
receives three times as much oxygen delivery as its consumption. [73] Therefore,
using surrogate markers of oxygen extraction ratio from the vascular compartment
may not be an appropriate method to measure oxygen consumption. The ‘ideal’
way to analyse the V O2   DO2 balance would be to delineate this at a regional
organ system level and at the whole body level. Unfortunately, there are some
practical issues in the search for such a technique. Foremost, it has to be of use
in a clinical setting. Further, the technique should be able to analyse tissues from
di↵erent compartments and compare the results. Unfortunately, these complexities
make it impossible for any one technique to be the answer. Therefore, selected
a lab-based method for oxygen consumption measurement from peripheral blood
mononuclear cells.
1.9 Measurement of Oxygen Consumption
All reliable methods to measure oxygen consumption are invasive. One non-
invasive technique that might be a surrogate for regional oxygen consumption
measurement is near infrared spectroscopy.
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1.9.1 Invasive Methods of Measurement of Oxygen Con-
sumption
Direct laboratory measurements:
Leland Clark was the first to measure oxygen consumption (1953) in a solution
using an oxygen electrode after suspending the tissue in a closed chamber with
an oxygen restricted medium. He created a platinum electrode coated with silver
chloride. A Teflon membrane separated it from the reacting solution. Reduction
occurs at the tip of the electrode when oxygen molecules di↵use through the mem-
brane. The flow of electrons due to this chemical reaction generates an electrical
current. A potential di↵erence measures this current. He was then able to plot
this potential di↵erence as a curve. [74] [75] This technique has evolved in the last
half-century.
Two commercially available analysers perform measurement of oxygen consump-
tion from di↵erent types of tissues. These are the Seahorse analyser and the
Oxygraph-2K high resolution respirometry analyser.
A. Seahorse analyser :
The Seahorse analyser works by creating a micro-environment around sensor probes
in the micro-chamber. It analyses the medium surrounding a single layer of cells.
It measures the rate of oxygen consumption (OCR) and the rate of acid e✏ux
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(ECAR). The measurement of proton leak and the concentration of dissolved oxy-
gen produces these results. The OCR is a marker of the mitochondrial respiration.
The ECAR is a marker of the glycolytic metabolism. [76] [77]
B. Oxygraph-2k analyser :
The Oxygraph-2K works on a similar principle as the Sea horse analyser. It anal-
yses two samples at one time (two chambers). Researchers have reported analysis
of nearly all human tissues with this analyser. The most common tissues in use
are muscle and skin samples. Peripheral polymorphonuclear cells (lymphocytes)
and platelets have also been used for analysis. [78] The Oxygraph-2K analyser will
be discussed in further detail in the methods chapter (section2.3) and under the
‘Variation in oxygen consumption during paediatric critical illness’ chapter (Chap-
ter 6).
Oxygen consumption in the mitochondria is proportional to intra-mitochondrial
ATP levels. ATP levels are linked to oxidative phosphorylation (OXPHOS) activ-
ity. [79] An association between OXPHOS activity and gene expression has been
noted in patients with mitochondrial myopathies. [80] Therefore, analysing the
expression of OXPHOS genes is a way of assessing mitochondrial function. I have
utilised this method to analyse children admitted to the intensive care unit. This
will be discussed in further detail in chapter 6.
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As already noted, mitochondrial function can be estimated by measuring the oxy-
gen consumption of a tissue. I will now investigate the ways to measure oxygen
consumption in di↵erent tissues.
1. Blood - The measurement of oxygen extraction from the blood is complex.
Firstly, the di↵erent components of blood extract oxygen at di↵erent rates. Sec-
ondly, the mitochondrial content is variable. The idea that one can measure the
oxygen extraction from whole blood with an oxygen analyser may be simplistic
and probably partly erroneous. Researchers have grappled with this issue for more
than a decade. The search was for a biomarker that can quantify the mitochon-
drial content. Following testing of numerous markers, cardiolipin content followed
by citrate synthase activity has shown the greatest promise. [81]
Citrate synthase activity is used widely for two main reasons: (a) It gives a reason-
ably accurate measure of the mitochondrial content and (b) there is no published
report to date of an isolated citrate synthase deficiency being compatible with
life. Therefore, by separating whole blood into its components and measuring the
citrate synthase activity (hence the mitochondrial content) we can quantify the
oxygen extraction more accurately.
2. Muscle and other tissues - By utilising the same principle as used for analysis
of blood one can analyse any tissue sample. The only additional step needed is
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the permeabilisation of the tissue. [82] However, di↵erent tissues of the body have
di↵erent OXPHOS activity. [83]
1.9.2 Non-invasive Surrogate Measure of Oxygen Consump-
tion
The invasive technique detailed above are the ‘gold standard’ for analysis of oxygen
consumption blood, muscle and other tissues. In the paediatric intensive care non-
invasive techniques are preferred. Nuclear magnetic resonance spectroscopy is a
popular method used in large research units. Another variant is the functional
MRI (fMRI) with blood oxygen level dependent e↵ect (BOLD). This technique
has been widely used in neuroscience. [84] Scientists have also measured oxygen
consumption in the brain in animal models by using fluorescence microscopy. [85]
The only available technique for use as a bedside non-invasive surrogate measure
in the paediatric intensive care setting is Near Infra Red Spectroscopy (NIRS).
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1.10 Near Infrared Spectroscopy (NIRS)
1.10.1 The Physics of Near Infrared Spectroscopy
Two key parameters of human tissues make NIRS feasible. Firstly, human tissue
is translucent to light. Secondly, these tissues contain proteins that are variable
absorbers of light depending on their oxygenation state. [86]. Near infrared (NIR)
light has a wavelength between 780 and 2500 nanometres. Most commercially
available NIRS machines use NIR light in the region of 700 to 1000 nanometres.
In this range the attenuation of light, whilst passing through tissue, is low. This
creates an ideal region of the electromagnetic spectrum in which to investigate
tissues.
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Figure 1.5: Near Infrared Region of the Electromagnetic Spectrum
The electromagnetic radiations are separated into di↵erent components depending
on their wavelength. This ranges from ultraviolet to far infrared regions.
The Beer-Lambert law describes the e↵ect of a dissolved compound on the light
passing through a solution. Accordingly, the attenuation of incident light is pro-
portional to the wavelength and the concentration of the compound dissolved in
solution (where the solution itself does not have any e↵ect on the light).
A = ✏⇥ C ⇥ d (1.7)
where
A is the attenuation of incident light,
✏ is the extinction coe cient,
C is the concentration of the absorbing compound in solution and
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d is the distance between the point of entry of the light and the point where it
leaves the solution.
If there were to be more than one absorbing compound in the solution the atten-
uation will then be proportional to the sum of the individual e↵ects of each of the
compounds on the incident light. In the human tissue there are certain compounds
that attenuate light, but have a fixed e↵ect with regards to time or oxygenation
state (melanin, water and lipids). These compounds are ‘fixed absorbers’ and can
be safely ignored for the final analysis of tissue oxygenation. The importance of
these compounds, especially water, is that they absorb more of the incident light
at certain wavelengths. Therefore, it will be prudent to select the wavelengths for
our investigation in a region not concomitant with this range. The above scenario
works well in a non-biological medium. However, human tissues create inherent
complexities. [86]
In human tissues there is absorption, scatter, and reflection of light. The reflected
and the scattered component of the incident light is finally received by the optode.
The standard Beer-Lambert law is inapplicable in this setting. The modified Beer-
Lambert law explains this scenario. It incorporates two di↵erences in the tissue.
The first is to account for the loss of incident light due to scattering. The second
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is to incorporate the extra distance travelled by the incident light due to scatter
within the tissue.
A = (✏⇥ C ⇥ d⇥ B) +G (1.8)
where
A denotes attenuation of the incident light,
✏ is the extinction coe cient,
C denotes the concentration of the absorber,
d denotes the geometrical pathlength,
B denotes the pathlength correction factor and
G is the additive term for scattering losses
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Figure 1.6: The Modified Beer-Lambert Law
The figure depicts a container with a solution. The solution has an absorber
dissolved in it. The incident light with an intensity of I0 is absorbed, scattered
and reflected as it passes through the solution and exits with an intensity I. d
stands for the absolute path length.
The scattering losses (G) are not measurable. To overcome this limitation the
formula has to be slightly modified. If we were to measure the change in the con-
centration of the absorber instead of the actual concentration, then the absolute
value of G is no longer needed. Let us say we measure the attenuation for absorber
C1 (A1) and then add another absorber C2 with a di↵erent attenuation (A2). The
equation 1.8 changes to:
  A =  C ⇥ ✏⇥ d⇥ B (1.9)
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where
  A denotes the di↵erential attenuation
  C denotes change in the concentration of the absorber
It is evident that ‘d’ and ‘B’ are still necessary to solve the equation. It is easy to
measure ‘d’. It is the absolute distance between the point of entry of light into the
medium and the point of exit. But ‘B’ (the di↵erential pathlength factor) depends
on the amount of scatter which in turn is specific to each tissue. One can use
di↵erent techniques to measure ‘B’. This can be by measuring the change in time
of flight of light, change in frequency or measuring the tissue absorption with a
known quantity of water. [87] [88] [89]
Several studies furnish values for ‘B’ for cerebral and forearm measurements in
adults. But the values for neonates and children are limited. We have extrapolated
from adult and neonatal studies. [88] [90] [91] [92] We will explore the absorbers
that NIRO-NX measures.
1.10.2 History of Near Infrared Spectroscopy
The first report utilising NIRS to investigate tissue oxygenation was by Jobsis. [93]
The studies exploring cerebral oxygenation in neonates and patients undergoing
surgery yielded promising results. [94] [95] These were followed by investigation
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into skeletal muscle oxygenation. One of the first studies observed change in
forearm muscle oxygenation with venous occlusion (occlusion of venous drainage
whilst arterial flow is preserved) for 8 minutes. Near infrared spectroscopy was
able to measure dynamic changes in tissue oxygenation. [96]
Blasi et al suggest a measurement of forearm blood flow with venous occlusion.
[97] The next step in the advance of NIRS in clinical practice was to use it in
conjunction with a vascular occlusion test. [98] There seems to be a correlation
between organ failure scores and rate of deoxygenation after vascular occlusion
in septic adults. [99] This also extends to a correlation with outcome. Septic
patients with lower rates of increase in tissue oxygen after arterial occlusion (slope)
had a higher mortality. The baseline slope was 3.3 ± 1.4 %/sec compared to
nonsurvivors’ slope of 2.4 ± 1.5 %/sec. This di↵erence was persistent until 48
hours after admission. [100] These and numerous other studies have led clinicians
to believe that NIRS can be a measure of cardiovascular status. [101] NIRS has also
been widely used in children with critical illness secondary to infective aetiology,
trauma, and post cardiac surgery. [102] The physics behind NIRS technique will
be reviewed now.
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1.10.3 Parameters Measured by Near Infrared Spectroscopy
The NIRO-NX machine (Hamamatsu, figure 1.8) was employed for my NIRS mea-
surements. [103] The chromophores (absorbers in a biological tissue) in the human
body can be di↵erentiated into static and non-static absorbers. The ‘static ab-
sorbers’ (such as bilirubin) can be ignored as their absorption does not change
with occlusion of blood flow. From the non-static measures NIRO-NX gives four
outputs: Oxygenated Haemoglobin (O2Hb), Deoxygenated Haemoglobin (HHb),
Tissue Oxygen Index (TOI), and net Total Haemoglobin Index (nTHI). The NIRO
measures oxygenated and deoxygenated haemoglobin and calculates the others.
NIRO is able to give a continuous measure of TOI by utilising the varied absorp-
tion spectra of haemoglobin depending on the oxygenation state.
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Figure 1.7: The NIRO-NX 200 Machine
Reproduced from the product leaflet from the Hamamatsu inc. [103]
The total haemoglobin index (THI) is calculated by the formula:
THI = O2Hb+HHb (1.10)
From the O2Hb and THI the NIRO calculated the tissue oxygen index (TOI) by
the formula:
TOI =
O2Hb
THI
(1.11)
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Another parameter of note is the 3:1 representation of venous and arterial com-
partments during NIRS TOI measurement. A study of cerebral oxygenation val-
idated this ratio. [104] In keeping with this, one can consider TOI as a closer
measure of mixed venous saturations.
1.10.4 Limitations of NIRS
NIRS technology has been in use in clinical practice for more than 3 decades, but
lacks robust trial data to support its routine use. In addition, there are some
technical limitations as outlined below.
1. Adipose tissue under the skin can a↵ect the NIRS measurements from skeletal
muscle. [105]
2. Pathlength of light changes during and after arterial occlusion. This change
will be nearly consistent across all subjects. This will have a negligible e↵ect as
the change is possibly less than 8 %. [106]
3. I used a fixed di↵erential pathlength factor for all ages. This is an assumption
based on literature as no report exists for the exact values for various ages. This
assumption only a↵ects the  oxyhaemoglobin ( O2Hb) and  deoxyhaemoglobin
( HHb) values. The TOI and THI use the spatially resolved spectroscopy (SRS)
principle. Spatially resolved spectroscopy measures the change in absorption at
several wavelengths and at several pathlengths (emitter-receiver distances). The
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TOI is then calculated from the relative absorption coe cients of oxygenated and
deoxygenated haemoglobin. By using several pathlengths SRS is able to account
for some of the constraints of the modified Beer-Lambert law.
4. Haemoglobin (Hb) and Myoglobin (Mb) have similar absorption spectra. De-
lineating each of their contributions to TOI values is not possible. As desaturation
of Mb is minimal at 3 minutes of vascular occlusion, one can assume that the TOI
values will represent changes in oxygenation of Hb. [107]
The measurement of oxygen consumption acts as a surrogate marker of mitochon-
drial function. Having considered the parameters of the oxygen cascade and the
cardiovascular physiology in health (section 1.4), I will discuss how this knowledge
can be translated to the critically ill patient.
1.10.5 Oxygen Delivery - Oxygen Consumption Relation-
ship During Critical Illness
Shoemacker investigated the cardiovascular physiology during critical illness. He
studied the changes in haemodynamic variables in 180 patients with a mixture
of aetiologies (haemorrhagic shock, sepsis and trauma) leading to critical illness.
Oxygen consumption was measured as the product of arterio-venous oxygen con-
tent di↵erence and cardiac index. Oxygen delivery was measured as the product
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of cardiac index and arterial oxygen content. He described a changing pattern of
cardiovascular response with time during illness by investigating the link between
oxygen consumption and oxygen delivery. [108] This led to a comparison study
of survivors and non-survivors with critical illness. Outcomes of post-operative
patients with circulatory shock were compared by analysing 26 variables in 67
survivors and 31 non-survivors. The period of illness was divided into early, mid-
dle and late stages. A clear distinction in the cardio-respiratory pattern between
survivors and non-survivors was demonstrated. Survivors had a higher cardiac
output, left ventricular stroke work, oxygen availability and consumption. [109]
In a further study, investigating 113 critically ill postoperative patients, Shoemacker
et al used the predictive model from the previous study. They reported that ef-
ficiency of tissue oxygen extraction (ETOE) correctly predicted outcome in 91%
of cases. The e ciency of tissue oxygen extraction was calculated by dividing
arterial-venous oxygen content and red cell mass. This had a high predictive co-
e cient through all the stages of critical illness. [110] Hence, oxygen extraction
seems to be an important parameter during the evolution of critical illness. Clinical
states such as hyperthermia and certain toxins may increase the oxygen extraction
in the tissues. Aggressive normalisation of haemodynamic targets may be helpful
in only a subset of patients. [111] Oxygen consumption is a surrogate for OXPHOS
activity. Further, OXPHOS activity is linked to OXPHOS gene expression. There-
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fore, oxygen consumption is modulated by OXPHOS gene expression (described
earlier under section 1.9.1.B). An increased oxygen extraction in the critically ill
patient might suggest an e cient mitochondrial function. I have investigated the
change in drop TOI (as a marker of oxygen consumption) during critical illness to
investigate this hypothesis (chapter 6). I will now discuss the OXPHOS system in
more detail.
1.11 Mitochondria: The Site of Oxygen Utilisa-
tion
Mitochondria are structures present in almost every cell of the body (except mature
red blood cells). Their main function is the production of energy-rich ATP com-
pounds and utilisation of breakdown products from carbohydrate, fat and protein
metabolism. In addition, mitochondria have roles in cell apoptosis, in balancing
the cellular reactive oxygen species and anti-oxidant status. [112]
The number of mitochondria within each cell varies considerably between tissues.
The tissues that have a high energy demand such as the heart, brain and mus-
cles have a proportionally higher number. [83] The structure and morphology of
mitochondria are also variable. After the advent of the electron microscope this
aspect of the mitochondrion was described. It is formed of an outer membrane,
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an intermembrane space, an inner membrane, and an internal matrix. The inner
membrane forms ba✏e-shaped structures called cristae. [113] Recent evidence from
yeast and human cells suggests that mitochondria are dynamic structures. They
are in a continuous dance of fission and fusion, forming a reticulum. [114] [115] [116]
This dynamic nature of the mitochondrion is also implicated in the pathophysi-
ology of diseases. [117] Fission and fusion events within the mitochondrion help
to balance the electrochemical milieu and create the right environment for the
e cient functioning of the OXPHOS system. The whole structure of the mito-
chondrion is also dynamic. Mitochondria elongate in times of increased oxidative
stress or nutritive deficiency. [118] [119] Conversely, they fragement and uncouple
the phosphorylation and electron transport chain during nutritive excess. [120]
Figure 1.8: The Structure of Mitochondrion
The mitochondrion has two membranes, a inter-membrane space, and a matrix
inclosed by the inner membrane. The oxidative phosphorylation system is situated
on the inner membrane.
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1.11.1 The Oxidative Phosphorylation System
The ‘Chemiosmotic theory’ hypothesised (1966) that the electron transport chain is
coupled to phosphorylation. [121] [122] [123] The OXPHOS system is composed of
two parts: the electron transport chain and the ATP synthase. [124] It is situated
on the inner mitochondrial membrane. It is made up of five multiple subunit
enzyme complexes (complex I to IV and the ATP synthase) that participate in
the production of energy. The complexes I, II, III, IV and V (ATP synthase) each
have 44, 4, 11, 14 and 16 subunits respectively. [125] [126]
Complex I
This (NADH:Ubiquinone oxidoreductase) is the largest of the 5 enzyme complexes.
It was first isolated in 1962 from bovine heart. [127] Seven of the subunits in this
complex are coded by mitochondrial DNA. It has a hydrophilic arm which pro-
trudes into the matrix and a hydrophobic arm (mitochondrially coded) that is
embedded in the inner mitochondrial membrane. [128] It has been divided into
three functional components: an electron input module (N module), an electron
output module (Q module) and a proton translocation module (P module). [129]
Rotenone is the most commonly utilised complex I inhibitor. It causes an increase
in ROS production. [130] Complex I is also involved in cell apoptosis. [131]
Complex II
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Complex II (succinate: ubiquinone oxidoreductase) is a membrane protein com-
plex. The crystal structure of this complex has been delineated from porcine heart.
Similar to complex I, it has a hydrophobic membrane component and a hydrophilic
membrane component. [132] It is part of the Krebs cycle and links it to the elec-
tron transport chain. Malonate and oxaloacetate are inhibitors of complex II. [133]
Complex III
Complex III (ubiquinol-cytochrome c oxidoreductase) is made of 10 nuclear coded
subunits of the total 11 subunits. [124] Like complex I, it is both an electron
and proton transporter. It is also called cytochrome bc1 complex. It contain 3
protein subunits, one di-haem cytochrome b, a cytochrome c1 and a iron-sulphur
protein. [134] Cytochrome b is the only component coded by mitchondrial DNA.
The inhibitors of this complex are classed into those acting on site N or site P.
Antimycin A (used in this thesis, see chapter 2 and 6) works on site N. [135]
Complex IV
Complex IV (Cytochrome c oxidase) is the site of production of water from two
protons and half a molecule of oxygen. It is the final acceptor of electrons. In
addition, it is a site of proton transfer across the inner mitochondrial membrane.
It belongs to a family of haem-copper complexes. [135] Cyanide is an inhibitor of
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complex IV and acts on the oxygen binding site. [136]
Complex V
Complex V has two domains. One (F1) is in the mitochondrial matrix and another
(F0) is in the inner mitochondrial membrane. [137] F1 comprises of 5 subunits. F0
is made of 6 subunits that include a c-ring and an oligomycin sensitivity conferring
protein (OSCP). [138] This is the site of ATP production. The OSCP is the site
of action of Oligomycin, a complex V inhibitor (used in this thesis, see chapter 2
and 6).
The functional organisation of the OXPHOS system formed by these complexes is
under debate. The presence of supercomplexes have been noted in yeasts as well
as mammalian cells. [139] A ‘plasticity model’ has been suggested as their mech-
anism of action. According to this theory, the supercomplexes take part in ATP
production with di↵erent individual component complexes. [140] Supercomplexes
are thought to make the electron transport chain more e cient. In addition, they
may have a role in controlling the ROS production. [139]
The mitochondrial electron transport chain is the most important source of ROS
production. [141] The primary ROS produced by mitochondria are superoxide rad-
ical and hydroxyl radical. The hydroxyl radical is the more reactive ROS. Most
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of the ROS is formed in complex I. This is due to reverse electron transfer and
inhibition of electron transport chain downstream. A small proportion is from
complex III. [22]
The overall function of the OXPHOS system is the transfer of electrons from nicoti-
namide adenine dinucleotide (NAD reduced form) and flavin adenine dinucleotide
(FAD reduced form) to oxygen. During this process protons are extruded into the
intermembrane space (through complex I, III and IV) from the matrix. Ubiquinone
is the intermediate carrier of protons between complex I / complex II and com-
plex III while cytochrome C interacts between complex III and complex IV. This
results is an electrochemical gradient across the inner mitochondrial membrane.
This proton motive force is utilised when there is a need for ATP production. The
protons return to the matrix through the F1   F0 rotary mechanism of the ATP
synthase causing the phosphorylation of ADP to ATP. [140] [142] (Figure 1.9)The
substrates of OXPHOS sytem (NADH and FADH2) are formed in the Krebs cycle.
This cycle utilises acetyl Co-A. Most of the primary substrates (pyruvate and fatty
acids) are converted to acetyl Co-A in the mitochondrial matrix to facilitate the
Krebs cycle. [143]
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Figure 1.9: The Oxidative Phosphorylation System
The electrons move along the chain and protons move across the membrane at
complex I, III and IV. ATP is formed at complex V. The oxidative phosphorylation
system is situated on the inner mitochondrial membrane. Adapted from the Acin-
Perez article. [140]
1.12 Mitochondrial Diseases
Mitochondrial diseases are a group of inherited disorders characterised by an im-
pairment in energy production secondary to a genetic mutation leading to a bio-
chemical defect a↵ecting the oxidative phosphorylation pathway. [144] These dis-
eases are rare with an estimated combined incidence of about 1 in 5000 births. [145]
The first reported case of mitochondrial disease was a patient with hyperme-
tabolism. [146] This complex heterogeneous group of diseases are di cult to diag-
nose and no cure exists for the majority of cases. Diagnosis is often challenging
because of a lack of specific clinical features. The treatment options available are
also limited. Therapeutic strategies are directed at the augmentation of mitochon-
drial biogenesis, removal of toxic metabolites and to boost the electron transport
chain. [147] Riboflavin and Coenzyme Q10 are supplements that have been tried
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to date. These work in specific subgroups. The vast majority of patient groups
derives minimal improvement from these drugs. A recently updated cochrane sys-
tematic review noted the lack of convincing evidence for any of the treatment
modalities. [148] Currently, these conditions are diagnosed by performing invasive
blood, skin and muscle biopsy tests. The ‘gold standard’ for diagnosis is muscle
enzymology studies. Gene mutation analysis is proving useful in diagnosis.
1.12.1 Genetics of Mitochondrial Diseases
Mitochondrial genetics has been defined in detail only in the last 15 years. The
‘serial endosymbiont theory’ postulates that the mitochondrion was formed after
the first eukaryote organism engulfed a prokaryote and formed a symbiotic rela-
tionship. The discovery of two genomes (nuclear and mitochondrial) lends support
to the above theory. [149]
Both nuclear genes and mitochondrial DNA code for mitochondrial proteins. Chil-
dren inherit the nuclear genes ( 20,000 genes) from both parents and it is estimated
that about 1500 of these are needed for mitochondrial function. Mitochondrial
DNA (37 genes), however, are inherited wholly from the mother. They were dis-
covered in the 1960s. They code for 13 of the >90 proteins in the OXPHOS
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system. [150] [151] Mitochondrial DNA (mtDNA) are prone for mutations and re-
active oxygen species damage. [152] Mutations in nuclear and mitochondrial genes
can cause mitochondrial diseases. About 75-90% of the diseased patients express
a mendelian pattern of inheritance due to a mutation in the nuclear genes. The re-
minder 10-25% are due to mitochondrial mutations. [153] [154] The mitochondrial
mutations are either mutations in the genes encoding for mitochondrial synthe-
sis of Ribonucleaic acids, in the electron transport chain proteins or others such
as gene deletions (Kearns-Sayre syndome). [155] [156] A very small proportion of
mitochondrial diseases are drug induced or due to sporadic mutations. [157] Het-
eroplasmy adds further complexity. This is the condition wherein within a cell
both mutated mtDNA and normal mtDNA are present. The proportion of mu-
tated mtDNA determines the severity of the disease. More than 250 mutations in
the mitochondrial DNA have been reported. In addition, over 200 nuclear disease
genes have been described. [112] [158]
1.13 My Hypotheses
In conclusion, the available evidence to date suggests that hypoxia is harmful.
There is some early evidence that suggests harm from hyperoxia too. However,
the safe range for arterial PaO2 is unclear. The risk and benefits of many ICU
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interventions is unknown. As most therapeutic strategies in intensive care try to
achieve normal physiology, there is an onus to understand the oxygen delivery -
consumption balance better during critical illness.
Null hypotheses of my thesis:
Hypoxia and hyperoxia do not cause harm in paediatric critical illness.
Hypoxic adaptation does not occur during paediatric critical illness.
The questions that will need to be answered to disprove the null hypothesis are:
1. Is there evidence that hypoxia or hyperoxia do not have the expected detrimen-
tal e↵ect in paediatric critical illness?
2. Does hypoxic adaptation occur in children in hypobaric hypoxic conditions?
3. Is there any evidence of hypoxic adaptation in critically ill children?
In each of the results chapters, I have investigated one step towards my attempt
at disproving the null hypothesis.
Chapter 3: Systematic review and two observational studies.
These projects investigate:
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1. The evidence of harm from hypoxia and hyperoxia in acutely ill children and
2. Test the hypothesis that there is no relationship between PaO2 and mortality
in critically ill children. Both these hypotheses would look for any pattern which
might indicate that hypoxic adaptation is at play.
Chapter 4: Utility of NIRS VOT.
I have tested two hypotheses. They are:
1. NIRS VOT is unable to measure oxygen consumption from forearm muscle.
2. NIRS VOT is unable to diagnose mitochondrial disease.
Chapter 5: Oxygen consumption and delivery in hypobaric hypoxic conditions.
The hypotheses tested in this chapter were:
1. Whether or not children can demonstrate adaptation to hypoxic conditions
induced by low partial pressure of atmospheric oxygen.
2. Children will have similar cardiorespiratory response as adults when exposed
to hypobaric hypoxic conditions.
3. It is safe for children to trek to moderately high altitude (3525 meters).
4. There will not be a change in oxygen consumption during the short time period
(4 days) of exposure to hypobaric hypoxic conditions.
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Chapter 6: Oxygen consumption and delivery in critically ill children.
The hypotheses tested in this chapter were:
1. Serial measurements of drop Tissue Oxygen Index (TOI) during the vascular
occlusion test will not alter during the time course of critical illness in children.
2. Serial measurements of peripheral blood mononuclear cell mitochondrial oxygen
consumption will not alter during the time course of critical illness in children.
3. Gene expression of oxidative phosphorylation genes will not change in the first
48 hours of paediatric critical illness.
Page 61
Chapter 2
Methods
2.1 Near Infrared Spectroscopy with a Vascular
Occlusion Test
The Near infrared spectroscopy with a vascular occlusion test (NIRS VOT) has
been proposed as a tool to estimate dynamic changes in oxygen consumption in
forearm muscle. The test involves a continuous measure of tissue oxygen in-
dex (TOI) and incorporates a period of arterial occlusion followed by recovery.
The post occlusion phase reflects post ischaemic reperfusion / hypereamia. The
technique has been utilised in septic shock patients and patients under anaesthe-
sia. [159] The NIRS VOT technique has been employed in two formats: a ‘time-
targeted’ VOT and a ‘TOI-targeted’ VOT. The former format involves inflating
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the blood pressure cu↵ for 3 minutes whilst the later format continues the cu↵
inflation until the TOI value decreases to 40%. I chose the time-targeted format,
as this was considered more tolerable for children. [160] [161] The phases of NIRS
VOT are: baseline, downslope (from the start of arterial occlusion to release),
upslope (immediately follows release of occlusion) and recovery. (Figure 2.1)
Figure 2.1 is an example recording of a vascular occlusion test showing baseline,
downslope, upslope and recovery phases. The blood pressure cu↵ was inflated at
the end of baseline phase. The deflation of the blood pressure cu↵ denoted the
end of downslope and the start of upslope. The NIRS VOT measures the Tissue
Oxygen Index (TOI). The DropTOI is the di↵erence between the lowest TOI (at
the end of cu↵ inflation) and baseline TOI.
The baseline TOI is a marker of the forearm oxygen saturation at rest. The
downslope is a surrogate for forearm oxygen consumption. The DropTOI is the
di↵erence between lowest TOI and baseline TOI. The DropTOI is of particular
relevance to my hypothesis of hypoxic adaptation. A lower DropTOI (i.e. downs-
lope with a less steep gradient) indicates reduced oxygen utilisation. This change
would be expected in the event of successful hypoxic adaptation. The upslope is
due to post occlusive hyperaemia from reactive vasodilation. This phase has been
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used as to assess microcirculation. When the upslope is has a slower gradient,
it might suggest delayed vasodilation. This can be due to pre-existing maximal
vasoconstriction (high sympathetic activity) or vasoplegia. Recovery phase is the
final normalisation phase. The downslope and recovery phase vary with di↵erent
clinical states such as sepsis and post-trauma. [162]
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Figure 2.1: The Near Infrared Spectroscopy Vascular Occlusion Test Curve
The x-axis denotes time in a compressed scale. The y-axis shows the tissue oxygen
index as recorded by the near infrared spectroscopy machine. The horizontal black
lines separate the recording into 4 phases. The inflation of the blood pressure cu↵
denotes the end of baseline (1) and start of the downslope (2). The downslope
ends at the deflation of the cu↵. This is followed by upslope (3) and then recovery
phase (4).
Several adult studies have indicated that NIRS VOT may be suitable methodol-
ogy for use in critically ill patients. This technique is able to di↵erentiate between
patients with and without a high lactate. Patients with poor perfusion and a
high lactate were observed to have a lower downslope with a vascular occlusion
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test. This finding suggests that in the setting of decreased oxygen delivery (lack of
oxygen), tissues have decreased oxygen consumption and anaerobic pathways that
produce ATP are active. [163] Patients in septic shock showed a similar decrease
in downslope. This finding could be attributed to a mechanism similar to the
above study i.e. decreased oxygen consumption. [164] In post-trauma patients,
the upslope was noted to be lower. As this study had a heterogeneous trauma
population, it is di cult to draw firm conclusions from this finding. One might
hypothesise that there was an element of vasoplegia in these patients. It would
be interesting to explore how many of these were spinal injury patients. This
was not reported. [165] In a systematic review that included 20 studies, drop TOI
(di↵erence between lowest TOI and baseline TOI) was observed to be lower in sep-
tic patients compared to healthy controls (7.8% vs. 12.5%, p = 0.01) suggesting
lower oxygen consumption. [166] In a recent adult study, serial NIRS VOT was
performed in critically ill patients (n= 89) and healthy controls (n=27). They
demonstrated slower desaturation in the last phase of downslope in patients. The
drop TOI was higher in non-survivors everyday until day 3 of ICU admission. The
lower baseline TOI was observed with sepsis, high lactate, use of noradrenaline
and hypotension. A few points are worth discussing further regarding these find-
ings. First, there was slower desaturation in patients. This suggests lower oxygen
consumption. Interestingly, the desaturation was slower in the last phase of the
Page 66
2.1. NEAR INFRARED SPECTROSCOPY WITH A VASCULAR
OCCLUSION TEST
downslope. This might be due to an impaired microcirculatory autoregulation and
inability to redirect blood flow (augment oxygen delivery) during ischaemic chal-
lenge. The second finding was that non-survivors seemed to have higher oxygen
consumption. This might be interpreted as an inability to adapt adequately to
hypoxic conditions. Finally, the lower baseline probably demonstrates the exist-
ing haemodynamic instability and decrease in oxygen delivery in this critically ill
population. [167]
The above studies suggest that NIRS VOT measures the decreased oxygen con-
sumption in critically ill patients. Further, in some populations (trauma), NIRS
VOT enables assessment of the microcirculatory autoregulation. In addition, there
maybe an association between drop TOI and ICU outcome. These findings indi-
cate that NIRS VOT might be a suitable technique to assess dynamic oxygen
consumption in critical illness.
The vascular occlusion test (VOT) acts as an internal calibration within each pa-
tient. This is because both oxygenated Hb and deoxygenated Hb reach near zero
values at di↵erent points of the test. The NIRO-NX 200 manufacturers’ guide also
suggests that calibration is not necessary. [168]
Page 67
2.1. NEAR INFRARED SPECTROSCOPY WITH A VASCULAR
OCCLUSION TEST
One part of basic physiology that might impact the results is the e↵ect of vasocon-
striction. Lima showed significant variation of TOI with peripheral vasoconstric-
tion due to surface cooling in healthy volunteers. [169] The same group assessed
the variation of TOI in critically ill patients. They demonstrated an influence
of vasopressors and the status of peripheral circulation on the recovery phase of
NIRS VOT. Interestingly, they were unable to detect an impact of any of these
on the downslope of NIRS VOT. [170] This finding is particularly relevant for my
thesis. The limitation of NIRS VOT in this context might the lack of specificity of
drop TOI. The drop TOI may be a↵ected by mitochondrial changes or microvascu-
lar dysfunction (secondary to pathophysiology or therapeutic vasoactive drug use).
The NIRS VOT was part of three projects within this thesis: Young Everest Study
2 (healthy children who trekked to Namche Bazaar - 3525 metres), children with a
suspected mitochondrial disease, and children admitted to the intensive care unit.
The test lasted for 13 minutes. Subjects lay down on a comfortable bed. They
rested their forearms on pillows. On each forearm, two 2 cm probes were placed on
the skin overlying the Brachioradialis muscle (upper lateral aspect of the forearm).
To secure the probes to the forearm, probes were wrapped with a bandage. The
bandage also reduced interference from ambient light. The data were displayed
as a continuous graph and represented a change in the tissue oxygen index. This
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was the baseline tissue oxygen index measurement. An appropriately sized blood
pressure cu↵ was then placed on the non-dominant arm. After a 5 minute record-
ing of the baseline tissue oxygen index, the blood pressure cu↵ was inflated. This
was maintained at 30 mm Hg above systolic blood pressure for 3 minutes and then
deflated. A further 5 minutes of recording were measured. This concluded the
test. Figure 2.1 shows a healthy volunteer undergoing a VOT.
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Figure 2.2: Healthy Volunteer Undergoing a Vascular Occlusion Test
The volunteer lay down comfortably. The probes were placed on the forearm
and wrapped with a bandage. The volunteer also had a saturation probe on the
index finger and a blood pressure cu↵ on the arm. After a 5-minute baseline
measurement, the blood pressure cu↵ was inflated for 3 minutes. A further 5-
minute recording was made after deflating the cu↵.
2.2 Cardiac Output Monitoring
Cardiac index was measured in all subjects using an Ultrasound Cardiac Output
Monitor (USCOM). The height, weight, systolic and diastolic blood pressure were
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also collected for calculating this measure. The subject lay down comfortably on
the bed. A small quantity of ultrasound gel was applied to the lower part of the
neck. The USCOM probe was placed on the suprasternal notch and directed to-
wards the apex of the heart. The aim was to achieve a waveform with a triangular
apex. Calculation of the cardiac index was from the sum of a group of waves. The
recording was saved over a 2 minute period. This was repeated three times. The
average gave a measure of cardiac index.
Physiological parameters that might have an impact on the cardiac index measure-
ment such as heart rate, temperature, inotropes being administered, fluid resus-
citation, and the aetiology of illness were also recorded where available. Some of
these measurements were only possible for the children in the intensive care unit.
Figures 2.3 and 2.4 illustrate the direction of probe placement and measurement
in a volunteer. [70]
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Figure 2.3: Direction of Probe Placement for Aortic Flow Measurement
The tip of the probe is directed towards the apex of the heart. The aortic valve lies
in this direction. The Doppler wave hits the blood exiting the valve and returns
to the probe. Reproduced from the USCOM product literature by Phillips. [70]
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Figure 2.4: Healthy Volunteer Undergoing USCOM Measurement
The volunteer is lying flat on the bed with head in midline. The probe is placed
on the sternal notch and directed towards the left nipple. Reproduced from the
USCOM product literature by Phillips. [70]
2.3 Oxygen Consumption in Peripheral Blood
Mononuclear Cells
2.3.1 Oroboros High Resolution Respirometry
The Oxygraph-2K high resolution respirometry analyser (O2K, Oroboros instru-
ments, Innsbruck, Austria) measures the rate of oxygen consumption in cell sus-
pensions. The O2K analyser has an airtight chamber with an oxygen electrode in
a solution. The oxygen consumption is deduced from the change in concentration
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of oxygen in the chamber after instilling permeabilized or intact cells and reagents.
The analyser was first developed in the late 1990s. [171] A step-wise titration of
reagents can be performed with this analyser. In addition, each step of the electron
transport chain can be interrogated.
This analyser was selected since it has been shown to give reproducible results.
Furthermore, it enables interrogation of oxygen consumption from several tissues.
Tissues that may be interrogated with this analyser include muscle fibers, periph-
eral blood mononuclear cells and platelets. [172] [173] [174] [175] It was utilised
in the adult Xtreme Everest studies. The O2K machines were transported to the
Everest base camp to analyse skeletal muscle oxygen consumption. This proved
its robustness. [176]
I undertook a 5-day on-site training in Schroeken, Austria to learn the O2K
methodology. For my experiment, I hired the O2K machine situated in Starling
lab, UCL. The daily machine calibration was run by Dr Kotiadis (post doctoral
research associate). An air calibration was performed before each run of the ex-
periment by me.
The following reagents were used in my experiment.
1. Oligomycin - This is a complex V inhibitor (ATP synthase of the oxidative
phosphorylation system). This causes leak respiration.
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2. FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone) - This is a
protonophore and acts as an uncoupler. It dissociates the proton concentration
outside the mitochondrial membrane and electron transport and oxygen uptake.
In turn it separated the ATP synthase from the electron transport chain. There-
fore, it causes maximal respiration (not associated with ATP production) that is
termed Electron Transport System capacity (ETS).
3. Antimycin A - This is a complex III inhibitor. It causes residual oxygen con-
sumption by fully inhibiting the oxidative phosphorylation system.
The reagents were sourced from Sigma-Aldrich industries. Oligomycin was in the
powdered form of ‘Oligomycin from Streptomyces diastatochromogenes’. FCCP
was in the powdered form. Antimycin was in the powdered form of ‘Antimycin
A from Streptomyces species’. All three reagents were reconstituted as detailed
below.
Preparation of reagents
1. Oligomycin: To make 5mM solution.
a. Weigh 4 mg Oligomycin in 2 ml glass vial.
b. Dissolve in 0.975 ml 99.9% Ethanol.
c. Divide into 0.2 ml portions and store at  20  C.
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2. Antimycin-A: To make 5mM solution.
a. Weigh 5.4 mg of Antimycin A into a glass vial.
b. Dissolve in 1.85 ml 99.9% Ethanol.
c. Divide into 0.2 ml vials and store at  20  C.
3. 4-(trifluoromethoxy)phenylhydrazone (FCCP): To make 1mM solution.
a. Weigh 1.27 mg of FCCP into a glass vial.
b. Dissolve in 5 ml 99.9% Ethanol.
c. Divide into 0.2 ml portions and store at  20  C.
Table 2.1: Final concentration of the stock solution of the reagents
Reagent Titration volume Final concentration
Oligomycin 1 µL 2 µmolar
Antimycin-A 1 µL 2.5 µmolar
FCCP 1 µL 0.5 µmolar
Key: FCCP - 4-(trifluoromethoxy) phenylhydrazone
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2.3.2 Phases of Respiration
The di↵erent phases of respiration that I assessed as part of my experiment were
(Figure 2.6):
1. Routine respiration (R) - This is the respiration (molecules of oxygen utilised)
by the peripheral blood mononuclear cells without the addition of any reagents.
It represents the aerobic metabolic activity under routine culture conditions with
the physiological substrates in the RPMI medium. It depends on cellular energy
demand, energy turnover and the degree of coupling to phosphorylation.
2. Leak respiration (L) - Under normal conditions, electrons flow along the electron
transport chain and protons are extruded across the inner mitochondrial membrane
from the matrix to the inter-membrane space. When ATP synthase is inhibited,
by adding Oligomycin to the solution, no ATP is produced. However, as the flow
of electrons and protons continue to occur, a proton gradient is generated across
the inner mitochondrial membrane. This is called the proton motive force. At
maximal proton motive force, some protons passively leak back into the matrix of
the mitochondria. This is called proton leak. It is the dissipative component of
respiration and is not available for basal metabolic requirements. This is repre-
sented as leak respiration in O2K high resolution respirometry.
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3. Residual oxygen consumption (Rox) - Some oxygen is utilised by cell pathways
other than the electron transport chain. This is estimated by assessing oxygen
utilization after inhibition of oxidative phosphorylation by inhibition of complex
III by Antimycin A.
All of the above values (routine, leak and residual oxygen consumption) are mea-
sured in picomols.sec 1.10 6cells. Figure 2.5 shows the steps of oxidative phos-
phorylation with the sites of action of the three reagents utilised in my experiment.
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Figure 2.6: Example of a Typical Output from Oroboros Analyser
The primary y-axis denotes oxygen concentration in the chamber. The blue curve
represents decreasing oxygen concentration. The secondary y-axis denotes oxy-
gen flow per cell. This is presented as the red curve, which depicts the oxygen
consumption during the experiment. The x-axis denotes time (minutes). The
vertical boxes with red borders represent the periods that were utilised for sum-
mative measurement. The first box is for basal respiration. Oligomycin A (ATP
synthase inhibitor) was added which leads to leak respiration. Carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP - Mitochondrial uncoupler) is added
as sequential titrations. This gives the Electron Transfer System capacity value
(ETS). The last reagent added is Antimycin-A (Complex III inhibitor) which abol-
ishes respiratory chain function completely, leaving what is known as the Residual
Oxygen Consumption (ROX)
Before discussing the control ratios I employed in my experiments, let me briefly
discuss coupling and uncoupling in mitochondrial physiology. Under normal con-
ditions, the electron transport chain and ATP synthase are coupled forming the
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oxidative phosphorylation system. The ATP is formed as an end product due to
the coupling of the electrochemical system (transfer of electron and formation of
a proton gradient) to phosphorylation system (ADP to ATP). Despite the leak of
some protons back into the inter-membrane space, coupling ensures e cient utili-
sation of substrates and oxygen to produce energy.
Uncoupling of the electron transport chain and ATP synthase can occur in cer-
tain situations such as membrane damage and activation of uncoupling proteins
(UCP). When UCPs are activated, protons leak back into the inter-membrane
space without the production of ATP. The main role of UCPs is to control ex-
cessive production of reactive oxygen species (ROS). The UCP2 and UCP3 are
stimulated by ROS. These in turn, cause a negative feedback loop and limit ROS
production. [177] They are also involved in thermogenesis (UCP1) and insulin
secretion (UCP2). Their gene expression is tightly linked to the need for heat
production or regulation of ROS production. [18]
2.3.3 Flux Control Ratios
Both routine and leak respiration vary according to the mitochondrial content.
In addition, di↵erent tissues from the same individual may also show varying
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respirometry measurements due to mitochondrial heterogeneity. Consequently,
the respiration data have to be normalised for the mitochondrial content to enable
inter and intra-subject comparison. Surrogate markers such as cardiolipin and
citrate synthase have been used to derive the mitochondrial content. [81] Ideally I
would have used a citrate synthase assay to normalize for mitochondrial content:
unfortunately this was restricted by time/resource availability.
In the absence of a measure of mitochondrial content, Flux Control Ratios (FCR)
are the standard way to express oxygen consumption independent of mitochondrial
content (total volume of mitochondria). [178] This normalization procedure calcu-
lates the oxygen consumption during leak and routine respiration as a proportion
of the maximal oxygen consumption. The maximal oxygen consumption can be
elicited in intact cells by administering FCCP. This is termed Electron Transport
System (ETS) capacity. By normalizing for ETS, the ratios enabled like-for-like
comparisons between sequential daily measurements of respiration states within
the same subject. These were particularly relevant in my study in order to nor-
malise for the mitochondrial heterogeneity.
The FCR includes routine control ratio, net routine control ratio, leak control ra-
tio and coupling e ciency. These are defined as the oxygen flux or consumption
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during di↵erent respiratory states - such as routine or leak respiration - normalized
for maximum oxygen consumption after administration of FCCP (ETS capacity).
The lower and upper limits of the ratios are 0.0 and 1.0. [179]
Figure 2.6 depicts the periods of routine respiration (R), leak respiration (L), ETS
capacity and residual oxygen consumption (Rox). I will be utilising the following
measures to analyse the results of my O2K experiments.
1. Leak control ratio (LCR - L/E): This is the ratio of leak respiration (L)
and ETS capacity (E - maximum FCCP stimulated oxygen consumption). The
L/E ranges from 0.09 to 0.14 in human cells. [179]
The L/E ratio could be a measure of uncoupling. Uncoupling increases the L/E
ratio by increasing the leak respiration. The L/E ratio can also increase if the
ETS capacity is reduced. Ideally, therefore, defects of ETS capacity should be
ruled out by measuring ETS capacity per mitochondrial marker (such as citrate
synthase). [180]
It has been hypothesised that during hypoxic adaptation, uncoupling is reduced
in preference to a more e cient coupled respiration. [181] In-vivo studies have
demonstrated a decrease in LCR in human islet cells exposed to hypoxia. [182]
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In addition, hypoxic mice were observed to have a decrease in mitochondrial bio-
genesis and uncoupling protein levels. [183] Finally, human skeletal muscle after
exposure to hypobaric hypoxic conditions were noted to have decreased mitochon-
drial biogenesis. [176] Following on from the above studies, in my O2K study, a
drop in L/E ratio during recovery from critical illness might be a sign of hypoxic
adaptation.
2. Net Routine Control Ratio [net RCR - (R  L)/E]: Net RCR is the dif-
ference between routine (R) and leak (L) respiration as a proportion of maximal
FCCP stimulated oxygen consumption (E- ETS capacity). In other words, it is the
oxygen consumption due to phosphorylation after normalizing for leak respiration
and ETS capacity. Under normal conditions, 0.1 to 0.3 of ETS capacity is used
for oxidative phosphorylation. [184]
In a septic child with an increased ATP demand, this ratio increases showing that
the ATP formation increases due to an increase in routine respiration. When the
child is in a stable compensated state, this ratio remains steady. When there is
full uncoupling, this ratio becomes zero. [179] [185]
For the purpose of my O2K study, net RCR gives an indication of the proportion
of oxygen utililsed to produce ATP. With hypoxic adaptation, I hypothesise that
the net RCR increases.
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3. Coupling e ciency [(E L)/E]: Coupling e ciency is the di↵erence between
maximal FCCP stimulated respiration (E-ETS capacity) and leak respiration (L)
as a proportion of maximal FCCP stimulated respiration (E-ETS capacity). In
other words, it is the amount of coupling occurring when normalised for leak res-
piration. [184]
As mitochondria become more e cient with hypoxic adaptation, leak respiration
decreases. This results in an increase in coupling e ciency. This has been demon-
strated in healthy volunteers after acclimatisation to hypobaric hypoxic condi-
tions. [186]
In my O2K study, if hypoxic adaptation were to occur, I would expect an increase
in coupling e ciency with recovery from critical illness.
With the limitations of the O2K technique, the ratios detailed above might be the
best method available to investigate the mechanism of hypoxic adaptation. For
example, L/E ratio decreases with increasing duration in hypoxic conditions whilst
coupling e ciency increases under these conditions. As this is a novel methodol-
ogy, no other ratios have been investigated for hypoxic adaptation assessment. [187]
Therefore, if I were to demonstrate these changes in critically ill children it might
support my hypothesis that hypoxic adaptation occurs during recovery from crit-
ical illness.
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2.3.4 Protocol
The Oxygraph-2K analyser measures oxygen consumption from cells suspended in
a solution. The analysis involved two steps: isolation of peripheral blood mononu-
clear cells from whole blood and analysis.
Peripheral Blood Mono-nuclear Cells (PBMC) separation protocol:
Blood sample collection:
1. 5 µL heparin was pippetted into a 20 ml Falcon tube. The tube was inverted
to ensure heparin coated the sides of the tube.
2. 5 ml of blood was collected in a syringe and transferred immediately into the
Falcon tube precoated with heparin (Falcon tube 1). The sample was mixed well.
A blood sample was collected every day whilst the patient was in the intensive
care unit.
Ficoll-Paque density gradient cell separation of PBMCs:
1. The Falcon tube 1 was topped up with plain RPMI medium (Roswell Park
Memorial Institute) in a 1:1 proportion (5 mls).
2. In new 2 ml Falcon tube 5 ml of Lymphoprep was collected. This was carefully
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overlaid with the contents of Falcon tube 1 (diluted blood with RPMI) at an angle
(Falcon tube 2).
3. The contents of Falcon tube 2 were spun at 2400 RPM for 20 minutes without
brakes or acceleration at room temperature (Temperature set at 25  C).
4. The PBMCs were harvested with a sterile 3 ml Pasteur pipette into a new 20
ml Falcon tube (Falcon tube 3). Three mls of the separated serum was collected
and stored in  80  C freezer.
5. The Falcon tube 3 contents were topped up with plain RPMI. This was spun
at 1800 RPM for 10 min without brakes.
6. The supernatant was discarded. The pellet was re-suspended in 2.6 mls of the
plain RPMI medium. A 0.2 ml aliquot of this cell suspension was collected in an
Eppendorf tube and stored in  80  C freezer for later citrate synthase assay. A
further 0.2 mls of the suspension was taken to the haematology lab in another
Eppendorf tube for Fluorescence Activated Cell Sorting (FACS) analysis.
The final volume of 2.2 mls of cell suspension containing PBMCs was transported
to the Starling lab.
Previously employed O2K techniques were utilised to measure the oxygen con-
sumption in peripheral blood mononuclear cells. [172] This included daily sampling
of blood (5 mls) soon after the NIRS VOT for the recruited patients.
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Oxygraph-2k experiment protocol
Set up:
Temperature 37  C
Volume 2.2 ml / chamber
Stirrer speed 750 rpm
Data sampling interval 2 s
Concentration: 1 million cells / ml. No viability check was performed as ratios
were employed.
Sensor calibration and Instrumental calibration:
The chamber was filled with 70% Ethanol for 20 mins for sterilization. The cham-
ber was then washed three times with distilled water and filled with plain RPMI
medium.
Air calibration:
a. Ensure gas phase above the medium
b. Wait for signal stabilisation
c. Mark R1 as the period of stable signal
d. Open datlab calibration window. Input temperature (37  C) and solubility of
medium (RPMI 0.89)
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e. Click calibrate and copy to clipboard
f. Save file on calibration excel sheet for both chambers separately
Instrumental background calibration would have been done in the morning.
Experiment:
1. Ensure stirrer is on and the laptop is connected to the machine
2. Add 2.2 mls of cell suspension into the chamber
3. Stir cell suspension for 2 minutes in contact with air for oxygenation
4. Close chamber. Wait for 5 minutes for signal stabilisation
5. Start titrations:
a. Record 10 mins of Basal respiration (B)
b. Add Oligomycin A (1 microL; 2 microg/ml = 2 microMolar). Record Leak
respiration (L) for 5 mins
c. Add Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (Each
titration: 2 microL; 1 microMolar). Record maximal respiratory capacity (ETS).
Add 1 -2 more titrations of the same volume of FCCP. Notice the inhibition of
respiration with excess uncoupler. This recording takes about 10 minutes.
d. Add Antimycin A (1 microL; 2.5 microM). Record the residual oxygen con-
sumption for 10 minutes.
The experiment ended and the recording was saved in my folder. Finally, the
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chamber was washed three times with 100% ethanol, three times with distilled
water and then left with 70% Ethanol in the chamber for the night.
2.4 Data Handling
The USCOM, NIRO-NX monitor and Oxygraph-2K give outputs in an excel for-
mat. All recordings and the excel outputs were saved in an University College
London computer and Great Ormond Street Hospital computer. Serial study num-
bers were used for anonymisation of the data. This followed format: Subject 1
(Metabolic disorder group)- GM101, Subject 1 (Intensive care group) - GICS101,
Subject 1 (Young Everest Study 2) - Y01, SOCK101 - Serial oxygen consumption
study.
A Great Ormond Street Hospital computer holds a master file with codes for the
specific patients. This linked anonymisation is necessary to correlate the NIRS
data with the results of all clinical investigations performed as part of the patients
management.
Physiological data were recorded in the REDCAP database. REDCAP is a secure
database created by the Vanderbilt University. [188]
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Prevalence and Outcome of
Hypoxia and Hyperoxia in
Critically Ill Children: A Cohort
Study
This chapter addresses the relationship between arterial oxygenation and mortality
in critically ill children. First, I set out to study the PaO2-Mortality relationship
internationally. To achieve this, I completed a systematic review that investigated
the association of admission arterial oxygenation with survival in children.
Next, I set out to describe the incidence of hypoxia and the relationship between
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admission PaO2 and mortality in the paediatric intensive care unit (PICU) in
Great Ormond Street Hospital (GOSH). I performed this observational study in
two parts: a threshold study (‘extreme hypoxia’) and an association study assess-
ing relationship of PaO2 (as a continuous variable) to mortality.
Finally, I aimed to ascertain if practice on the PICU in GOSH is representative of
that which is followed in other units across the United Kingdom. To this end, I
conducted a national survey exploring the decisions in administering supplemen-
tal oxygen in all PICUs in the country. This survey was conducted to explore if a
clinical trial of ’restrictive’ to ’liberal’ oxygen strategy was justified.
3.1 Introduction
The administration of supplemental oxygen is widespread in the management of
critically ill children. The aim of this therapy is to augment oxygen delivery to the
tissues (DO2). An increase in partial pressure of arterial oxygen (PaO2) should in
the normal physiological state increase DO2. The eventual e↵ect of the increase
in DO2 on tissues is unclear. As alluded to in chapter 1 (section1.3), high oxygen
concentration in the cells can lead to the production of reactive oxygen species
(ROS). Reactive oxygen species, in turn, have a potential to cause cell injury.
Conversely, low oxygen levels (hypoxia) cause cell death. Therefore, the risks and
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benefits of oxygen therapy need to be evaluated by the clinician.
Do clinicians consider oxygen toxicity when devising management strategies in the
intensive care setting? Eastwood et al surveyed the practice of a large cohort of
intensivists in Australia and New Zealand. Of a total of 99 respondents, 77%
reported prescribing oxygen saturation targets. Clinicians working in a regional
centre were less concerned with oxygen toxicity. Further, only 26.5% of the re-
spondents considered oxygen related lung injury to be a major concern. [189]
A Dutch study explored the response of clinicians to arterial blood gas values with
a retrospective database analysis over a 5-year period in tertiary intensive care
units. They interrogated 126,778 arterial blood gas values by setting PaO2 >16
kPa as the threshold for hyperoxia. Although 28,222 PaO2 values (22%) were
higher than the threshold, clinicians reduced the FiO2 in only 25% of these sit-
uations. [190] Other than individual clinician’s practices, a recent survey reports
that three-quarters of adult intensive care units do not have a strategy for the
management of refractory hypoxaemia. [191] This is evidence in adults. Children
have important physiological di↵erences.
Multi-organ failure (MOF) is noted in a majority of patients preceding death. [192]
In adults, MOF is usually seen by day 3-4 after admission to the intensive care unit.
The risk of developing MOF in adults increases with pre-existing chronic disease
and lifestyle-related conditions such as obesity, atherosclerosis, malnutrition or al-
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coholism. [193] In contrast, MOF occurs earlier (2-3 days) in children. [194] [195]
The risks for developing MOF are also not clearly defined in children. This di↵er-
ence in MOF epidemiology extrapolates to survival. Children have better survival
compared to adults. The co-morbidities observed in adults only explain this vari-
ation in part. The growth and regenerative potential of organs probably present
a survival advantage in children. [196]
These di↵erences necessitate a systematic review, one observational study (with
two parts) and a national survey.
3.2 Systematic Review
Impact of hypoxia and hyperoxia on survival in unwell children
Harm from both hypoxia and hyperoxia in adult critical illness has been re-
ported. [17] This perceived harm has not yet been investigated in children. There
is no consensus for the ‘ideal arterial oxygen tension’ target in the critically ill
child.
The aim was to explore the e↵ect of hypoxia and hyperoxia on mortality in un-
well children. The Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines was abided by for the following report. [197]
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3.2.1 Inclusion Criteria
1. Patient: Children from 4 weeks to less than 18 years of age
2. Intervention - Observational cohort:
Hypoxia was defined as peripheral oxygen saturations <90% or PaO2 <60 mmHg
(8 kPa) and
Hyperoxia was defined as PaO2 >300 mmHg (40 kPa)
For the alternative threshold: Hyperoxia was defined as PaO2 >200 mmHg (26.6
kPa) and hypoxia was defined as peripheral oxygen saturations <92%.
3. Comparison cohort: Normoxia was defined as PaO2 between 60-300 mmHg
(8.1-40 kPa) or peripheral oxygen saturations >90%.
4. Outcome: In-hospital mortality
5. Study design: Randomised controlled trials and cohort studies
Hypoxia is prevalent in unwell children presenting to resource-limited settings.
[198] Inclusion of the hypoxia group in this review enabled comparison of the
e↵ect of hypoxia with and without aggressive intensive care practices.
Studies in pre-term infants and neonates with hypoxic-ischemic encephalopathy
were excluded because the transition during the perinatal period from a hypoxic
to an oxygen rich environment is complex and di↵ers from the pathophysiology of
hypoxic injury in older infants and children. [199]
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3.2.2 Search Strategy
Randomised controlled trials, cohort studies and observational studies were iden-
tified by using predefined search terms in MEDLINE (1950 - Jan 2015), EMBASE
(1980 - Jan 2015), Cochrane systematic reviews and DARE databases.
The search terms used in the MEDLINE database were hyperoxia, hypoxia, sur-
vival and critically ill children or pediatric intensive care and mortality. The search
was conducted in April 2015. The full search strategy in MEDLINE and a snapshot
of the EMBASE search is included as appendix2.
3.2.3 Selection Criteria
The principal summary measure was the odds ratio for survival. After initial
search and discarding duplicate publications, studies were ascertained by perusing
the titles and abstracts.
The risk of bias within individual studies was ascertained by using the Newcastle
Ottawa Scale at the study level. [200] A meta-analysis and meta-regression was
performed using the OpenMeta[Analyst] software. [201] Meta-regression enabled
us to determine the e↵ect of co-variate (Newcastle Ottawa Scale) on the e↵ect
estimate (Odds ratio of survival with hyperoxia). For heterogeneity analysis, I2
was used as the measure of consistency. A priori subgroup analysis with aetiology
as the moderator was planned. Creating a funnel plot aided in assessing the risk
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of bias across studies. R software was utilised to draw these plots.
3.2.4 Meta-analysis
Ameta-analysis was performed using a random e↵ects model with OpenMeta[Analyst]
software. I2 was used as the measure of consistency for heterogeneity analysis. For
subgroup analysis, the studies were divided into patients admitted with lower res-
piratory tract infection (LRTI) or CA or TBI.
3.2.5 Results
The initial search strategy resulted in 1749 articles. Duplicate publications (155)
were discarded. From the remaining 1594 articles, 1513 were excluded as not being
relevant to the current review. For the full review, 81 full-text articles were chosen.
Finally, 20 articles and a conference abstract were included for review. The review
of the impact of hyperoxia included 6 studies and the hypoxia review consisted of
11 articles. There were 2 further hyperoxia and 2 hypoxia articles deemed relevant
when the alternative threshold was employed. The flowchart describes exclusions
at each stage. All the articles were cohort studies apart from one with a single
centre unmatched case-control design. Experts in the field were contacted to dis-
cover any unpublished work.
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Figure 3.1: Flow Chart Showing the Selection of the Studies for the Systematic
Review
Studies selected after employing an alternate threshold were included in the
flowchart.
The hyperoxia studies analysed were: 5 cohort studies of CA and 1 study in
children with TBI. The hypoxia studies analysed were: 4 cohort studies in CA
survivors, 3 in children with LRTI, 2 studies in children with TBI and one each of
children with malaria and diarrhoea.
With the alternative threshold, hyperoxia studies included 6 in CA survivors and
2 in TBI group. The hypoxia studies consist of 4 each in the CA and LRTI groups,
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3 with TBI and one each with malaria and diarrhoea.
Analysis of Bias
Publication bias might be present as the range of PaO2 explored in all the studies
were <8 kPa or >40 kPa. The investigators may have considered PaO2 between 8
and 40 kPa as an extended normal range. Therefore, there are no publications of
studies where the relationship to mortality for this range has been assessed. This
might suggest a bias in establishing the inclusion criteria for the cohorts. Selection
bias was ascertained by reviewing the methodology of studies. As most of them
are cohort studies, there was a high probability of selection bias. The risk of bias
was only assessed at the study level and not at the outcome level.
The funnel plots were created with the x-axis as log odds ratio and the y-axis
as 1/standard error. There might be publication bias in the hyperoxia studies
suggested by one of the studies lying outside the 95% confidence interval limits.
Even within the plot, there were more studies on the left, suggesting a negative
bias.(Figure 3.10) For the hypoxia studies, a single study was outside the 95%
confidence interval limits suggesting some bias.(Figure 3.11)
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Figure 3.2: Funnel Plot of Hyperoxia Studies Suggesting Publication Bias
The odds ratio and standard error for each of the studies was calculated. The
x-axis represents log of the odds ratio (OR). The y-axis denotes one over the
standard error (SE). Un-shaded circles represent individual studies. The vertical
dashed central line depicts the mean log odds ratio. The solid vertical curved lines
on each side of the dashed lines represent 95% confidence intervals. The plot was
generated using R software.
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Figure 3.3: Funnel Plot of Hypoxia Studies
The odds ratio and standard error for each of the studies was calculated. The
x-axis represents the log of the odds ratio (OR). The y-axis denotes one over the
standard error (SE). Un-shaded circles represent individual studies. The vertical
dashed central line depicts the mean log odds ratio. The solid vertical curved lines
on each side of the dashed lines represent 95% confidence intervals. The plot was
generated using R software.
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Figure 3.4: Studies Analysed for Bias According to the Newcastle Ottawa Scale.
[200]
The studies were scored a maximum four stars for the selection of studies according
to predefined criteria, two stars for the comparability of groups and three stars for
the studies having the same outcome.
Hypoxia
The crude mortality from all the hypoxia studies was 26.2% for the hypoxia group
and 19.9% in the normoxia group.
Eleven studies of 5280 children revealed a higher combined odds ratio of mortality
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with hypoxia (PaO2 <60 mmHg (8 kPa) or peripheral oxygen saturations <90%)
compared to normoxia (OR: 3.13, 95%CI: 1.79-5.48, p <0.001). The I2 was 86%
indicating a high level of heterogeneity.
The analysis of hypoxia studies (14) with alternative threshold (n=5549) also
showed a higher combined odds ratio of mortality with hypoxia (PaO2 <60 mmHg
(8 kPa) or peripheral oxygen saturations <92%) compared to normoxia (OR 2.82,
95%:1.76-4.52). A summary of all published studies is shown in a forest plots.
(Figure 3.16)
For subgroup analysis, the studies were divided into patients admitted with LRTI
or CA or TBI. The single studies in children with malaria and diarrhoea were
excluded from the subgroup analysis.
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Table 3.1: Hypoxia analysis - Weights of individual studies
Study name Weight
Del Castillo [202] 10.67%
Ferguson [203] 12.00%
Van Zellem [204] 7.46%
Onyango [205] 6.56%
Orimadegun 2013 [206] 11.66%
Orimadegun 2014 [207] 9.88%
Chisti 2012 [208] 8.37%
Chisti 2013 [209] 7.73%
Ramaiah [210] 8.37%
Pigula [211] 10.90%
Guerra-Wallace [212] 6.38%
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Figure 3.5: Forest Plot of all Atudies Exploring the Impact of Hypoxia on Mortality
The estimate assessed is the odds ratio of mortality. I2 is the measure of het-
erogeneity. The width of the horizontal line for each study represents the 95%
confidence interval (CI). The red vertical dashed line represents the overall odds
of mortality. The blue rhomboid represents the 95% CI of the overall odds ratio.
Subgroup Analysis of Hypoxia Studies
Children admitted following cardiac arrest
The crude mortality of the CA subgroup was 42.0% in the hypoxia group and 38.6%
in the normoxia group. The CA subgroup (3 studies, n=2025) showed a signif-
icantly higher mortality with hypoxia compared to normoxia (OR: 2.03, 95%CI:
0.61-6.77, p = 0.352). The measure of heterogeneity (I2) was 83% (p <0.001).
Children admitted with lower respiratory tract infection
The crude mortality of LRTI subgroup was 12.7% in the hypoxia group and 6.4%
in the normoxia group. The subgroup analysis shows higher odds of mortality with
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hypoxia compared to normoxia (OR: 3.99, 95%CI: 1.23-12.97, p = 0.021). The I2
was high (79%, p = 0.008). There were di↵erences in the selection criteria within
this subgroup (3 studies, n=2083) that make interpretation of the results di cult.
Children admitted following traumatic brain injury
The crude mortality of the TBI subgroup was 40.5% in the hypoxia group and
17.7% in the normoxia group. The TBI subgroup (2 studies, n=546) displayed
higher mortality with hypoxia (OR: 3.12, 95%CI: 1.9-5.14, p <0.001). However,
the oxygen thresholds were di↵erent between the studies. Despite this I2 was
0% (p = 0.914) suggesting no heterogeneity. Tables 3.11-3.18 give a summary of
the characteristics recorded from the studies including odds ratios and outcome
measures.
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Table 3.2: Subgroup analysis of hypoxia studies
Subgroup Estimate Lower
bound
Upper
bound
Std.err p-value
CA subgroup 2.03 0.61 6.77 0.61 0.25
(4 studies)
LRTI subgroup 3.99 1.23 12.96 0.60 0.02
(3 studies)
TBI subgroup 3.13 1.78 5.47 0.28 <0.001
(2 studies)
Key: CA - Cardiac arrest, LRTI - Lower respiratory tract infection, TBI - Trau-
matic brain injury
Table 3.3: Heterogeneity analysis of hypoxia studies
Studies Het. p-value I2
CA subgroup <0.001 83%
LRTI subgroup 0.008 79%
TBI subgroup 0.914 0%
Key: CA - Cardiac arrest, LRTI - Lower respiratory tract infection, TBI - Trau-
matic brain injury
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Figure 3.6: Forest Plot Showing Subgroup Analysis of Hypoxia Studies
The estimate assessed is the odds ratio of mortality. I2 is the measure of het-
erogeneity. The width of the horizontal line for each study represents the 95%
confidence interval (CI). The red vertical dashed line represents the overall odds
of mortality. The blue rhomboid represents the 95% CI of the overall odds ra-
tio. The yellow rhomboid represents the 95% CI of the odds ratio of the three
subgroups odds. CA - Cardiac arrest subgroup, TBI - Traumatic brain injury
subgroup, LRTI - Lower respiratory tract infection subgroup.
Hyperoxia
The crude mortality from all the hyperoxia studies was 37.5% for the hyperoxia
group and 38.4% in the normoxia group.
Six studies of 2012 children revealed no e↵ect on mortality. The combined odds
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ratio of death with hyperoxia (PaO2 >300 mmHg (40 kPa)) compared to nor-
moxia was 1.15 (95%CI: 0.42-3.17, p = 0.77). The I2 was 82% indicating a high
level of heterogeneity. For subgroup analysis, the studies were divided into pa-
tients admitted following CA or TBI. The analysis of all eight hyperoxia studies
(alternative threshold, n= 2244) also showed no e↵ect on mortality (OR 1.31,
95%CI:0.54-2.36, p = 0.74). (Tables 1.4 and Figure 3.18)
Table 3.4: Hyperoxia analysis - Weights of individual studies
Study name Weight
Del Castillo [202] 16.69%
Puiman [213] 16.69%
Ferguson [203] 19.33%
Ramaiah [210] 16.59%
Van Zellem [204] 14.90%
Guerra-Wallace [212] 15.78%
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Figure 3.7: Forest Plot of Hyperoxia Studies
The estimate assessed is the odds ratio of mortality. I2 is the measure of het-
erogeneity. The width of the horizontal line for each study represents the 95%
confidence interval. The red vertical dashed line represents the overall odds of
mortality. The blue rhomboid represents the 95% confidence interval of the over-
all odds ratio.
Subgroup Analysis of Hyperoxia Studies
Children admitted following cardaic arrest
The crude mortality of the CA subgroup was 47.2% in the hyperoxia group and
39.2% in the normoxia group. The CA subgroup (5 studies, n=1832) displayed
higher odds of mortality with hyperoxia compared to normoxia (OR: 1.59, 95%CI:
0.64-3.91, p = 0.313). The studies were retrospective except the Del Castillos
prospective multicenter study.(19) The measure of heterogeneity (I2) was 73% (p
= 0.005).
The leave-out-one-study analysis showed that the e↵ect estimate (odds ratio of
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mortality) was una↵ected by the variation in outcome measure between studies.
Children admitted following traumatic brain injury
No subgroup analysis was possible since only a single study investigated children
with TBI. With an alternative threshold, 2 studies were included. The crude mor-
tality of the TBI subgroup was 12.1% in the hyperoxia group and 24.4% in the
normoxia group. The TBI subgroup (2 studies, n=239) revealed lower mortality
with hyperoxia compared to normoxia (OR: 0.34, 95%CI: 0.10-1.08, p = 0.06).
The heterogeneity measure was 48% (p=0.16).
Table 3.5: Subgroup analysis of hyperoxia studies
Subgroup Estimate Lower
bound
Upper
bound
Std.err p-value
Cardiac arrest
(5 studies)
1.59 0.64 3.91 0.46 0.31
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Table 3.6: Heterogeneity analysis of hyperoxia studies
Studies Het. p-value I2
Cardiac arrest subgroup 0.005 73%
Figure 3.8: Forest Plot for Subgroup Analysis of Hyperoxia Studies
The estimate assessed is the odds ratio of mortality. I2 is the measure of het-
erogeneity. The width of the horizontal line for each study represents the 95%
confidence interval (CI). The red vertical dashed line represents the overall odds
of mortality. The blue rhomboid represents the 95% CI of the overall odds ratio.
The yellow rhomboid represents the 95% CI of the odds ratio of the two subgroups
odds. CA cardiac arrest subgroup, TBI Traumatic brain injury subgroup.
Results of the Meta-regression
Further analysis was performed using meta-regression using the Newcastle Ottawa
Scale as a moderator. The beta-coe cient for the Newcastle Ottawa Scale was
-0.106 (95%CI: - 0.367-0.154, p = 0.424). (Figure 3.15)
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Figure 3.9: Meta-Regression analysis of hyperoxia studies using the Newcastle
Ottawa Scale as a moderator
This analysis included the Newcastle Ottawa Scale (NOS) as the independent
variable and log odds ratio of each of the studies as the outcome variable. The
odds ratio represents the odds of death with hyperoxia compared to normoxia.
The diameter of the circles are proportional to the sample size. There were 8
studies included in this analysis. The blue line is the regression line denoting the
relationship between NOS and log odds ratio.
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Table 3.7: Characteristics of hyperoxia studies - 1
Author Study design Hyperoxia
threshold
Hypoxia
threshold
Post cardiac arrest
Del Castillo [202] Prospective cohort
study
>300 mmHg
(40 kPa)
<60 mmHg
(8 kPa)
Ferguson [203] Retrospective obser-
vational study
>600 mmHg
(40 kPa)
<60 mmHg
(8 kPa)
Guerra-Wallace [212] Retrospective co-
hort study
>300 mmHg
(40 kPa)
<60 mmHg
(8 kPa)
Puiman [213] Retrospective co-
hort study
>300 mmHg
(40 kPa)
None
Bennett [214] Retrospective co-
hort study
>200 mmHg
(26.7kPa)
<50 mmHg
(4 kPa)
Van Zellem [204] Retrospective co-
hort study
> 300 mmHg
(40 kPa)
<60 mmHg
(8 kPa)
Traumatic brain
injury
Michaud [215] Retrospective co-
hort study
>350 mmHg
(46 kPa)
<105 mmHg
(13.8 kPa)
Ramaiah [210] Retrospective co-
hort study
>300 mmHg
(40 kPa)
<60 mmHg
(8 kPa)
Legend: The control population included normoxic children for all the studies.
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Table 3.8: Characteristics of hyperoxia studies - 2
Author Age Sample
size
Outcome
Post cardiac arrest
Del Castillo [202] 1 month to 18 years 223 In-hospital mortality
Ferguson [203] <16 years 1875 In-PICU mortality
Guerra-Wallace [212] <18 years 74 Mortality at 6
months
Puiman [213] Unclear 67 In-hospital mortality
Bennett [214] >24 hrs to 18 years 195 In-hospital mortality
Van Zellem [204] >28 days to 18 years 200 In-hospital mortality
Traumatic brain
injury
Michaud [215] <16 years 75 In-hospital mortality
Ramaiah [210] <14 years 194 In-hospital mortality
Key: PICU - Paediatric intensive care unit
Page 115
3.2. SYSTEMATIC REVIEW
Table 3.9: Characteristics of hyperoxia studies - Actual numbers
Author Hyperoxia Normoxia Hypoxia
Total
exposed
Survived Total
exposed
Survived Total
exposed
Survived
Post cardiac arrest
Del Castillo [202] 19 9 145 86 59 34
Ferguson [203] 207 115 1220 743 448 282
Guerra-Wallace [212] 38 26 10
Puiman [213] 32 16 37 14
Bennett [214] 107 36 66 29 22 8
Van Zellem [204] 83 31 25 22 92 31
Traumatic brain
injury
Michaud [215] 47 35 12 8 11 3
Ramaiah [210] 99 93 78 60 17 9
Page 116
3.2. SYSTEMATIC REVIEW
Table 3.10: Characteristics of hyperoxia studies - Odds ratios
Author Unadjusted
OR
(95%CI)
Adjusted
OR
(95%CI)
Co-variates
Post cardiac arrest
Del Castillo [202] 0.61 N/A N/A
(0.24-1.61)
Ferguson [203] N/A 0.8 Age, sex, ethnicity,
CHD,
(0.73-0.87) OOHCA, year, PIM2,
organ support
Guerra-Wallace [212] N/A 1.19 PaO2 <60 mmHg and
(0.19-7.38) PaO2 >200 mmHg
Puiman [213] 1.64 N/A N/A
(0.63-4.29)
Bennett [214] N/A 1.02 Age, arrest location,
(0.46-2.27) arrest rhythm,
epinephrine doses
Van Zellem [204] 1.38 0.905 Age, gender, BLS or
(0.782.47) (0.46-1.76) APLS, rhythm, lowest
pH and highest lactate
Traumatic brain
injury
Michaud [215] 1.46 N/A N/A
(0.37-5.72)
Ramaiah [210] N/A 8.02 Older age, lower injury
(1.73-37.18) severity score, paCO2
36-45 mmHg
Key: OR - Odds ratio, CI - Confidence interval, PaO2 - Arterial oxygen tension,
PaCO2 - Arterial carbon dioxide tension, BLS - Basic life support, APLS - Ad-
vanced paediatric life support, CHD - Congenital heart disease, OOHCA - out of
hospital cardiac arrest, PIM2 - Paediatric index of mortality 2,
N/A - Not applicable
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Table 3.11: Characteristics of hypoxia studies - 1
Author Study design Hypoxia
threshold
Control Age
Smyth [216] Prospective observa-
tional cohort
<92%  92% <5 yrs
Onyango [205] Prospective observa-
tional cohort
<90%  90% <3 yrs
Orimadegun
(2013) [206]
Prospective cohort 90% >90% <15 yrs
Orimadegun
(2014) [207]
Prospective cohort <90%  90% <5 yrs
Chisti (2012)
[208]
Prospective cohort <90%  90% <5 yrs
Chisti (2013)
[209]
Prospective case-control
(unmatched)
<90%  90% <5 yrs
Pigula [211] Prospective cohort PaO2 >60 <17 yrs
<60 mmHg mmHg
Key: PaO2 - arterial partial pressure of oxygen
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Table 3.12: Characteristics of hypoxia studies - 2
Author Age Sample
size
Outcome
Smyth [216] LRTI 158 Survival to
hospital dis-
charge
Onyango [205] LRTI 256 Survival on
day 5
Orimadegun (2013)
[206]
LRTI 1726 Survival to
hospital dis-
charge
Orimadegun (2014)
[207]
Malaria 369 Survival to
hospital dis-
charge
Chisti (2012) [208] Diarrhoea 258 Survival to
hospital dis-
charge
Chisti (2013) [209] LRTI 148 Survival to
hospital dis-
charge
Pigula [211] TBI 451 Survival to
hospital dis-
charge
Key: LRTI - Lower respiratory tract infection, TBI Traumatic brain injury, PaO2
- arterial oxygen tension
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Table 3.13: Characteristics of hypoxia studies - Actual numbers
Author Normoxia Normoxia Hypoxia Hypoxia
Total exposed Survived Total exposed Survived
Post cardiac arrest
Del Castillo [202] 145 86 59 34
Ferguson [203]
Bennett [214] 66 29 22 8
Van Zellem [204] 25 22 92 31
LRTI, Diarrhoea or
Malaria
Smyth [216] 103 90 55 45
Onyango [205] 65 63 144 125
Orimadegun (2013)
[206]
1232 1147 494 438
Orimadegun (2014)
[207]
Chisti (2012) [208] 138 134 119 94
Chisti (2013) [209] 111 107 37 26
Traumatic brain
injury
Michaud [215] 12 8 11 3
Ramaiah [210] 78 60 17 9
Pigula [211] 384 320 67 41
Page 120
3.2. SYSTEMATIC REVIEW
Table 3.14: Characteristics of hypoxia studies - Odds ratios
Author Unadjusted
OR
(95%CI)
Adjusted
OR
(95%CI)
Co-variates
Post cardiac arrest
Del Castillo [202] 0.933 N/A N/A
(0.505-1.723)
Ferguson [203] 0.52 N/A N/A
(0.487-0.555)
Bennett [214] 0.729 N/A N/A
(0.269-1.973)
Van Zellem [204] 0.069 N/A N/A
(0.019-0.25)
LRTI, Diarrhoea or
Malaria
Smyth [216] 0.65 N/A N/A
(0.265-1.597)
Onyango [205] 0.209 N/A N/A
(0.047-0.925)
Orimadegun (2013) [206] 0.58 N/A N/A
(0.406-0.827)
Orimadegun (2014) [207] N/A 0.133 Metabolic
(0.05-0.357) acidosis,hypoxaemia,
hypoglycemia
Chisti (2012) [208] 0.112 N/A N/A
(0.038-0.333)
Chisti (2013) [209] 0.088 N/A N/A
(0.026-0.3)
Traumatic brain injury
Michaud [215] 0.188 N/A N/A
(0.031-1.122)
Ramaiah [210] 0.337 N/A N/A
(0.114-1.002)
Pigula [211] 0.315 N/A N/A
(0.180-0.552)
Key: OR - Odds ratio, CI Confidence interval, N/A Not applicable, LRTI - Lower
respiratory tract infection
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In summary, the systematic review shows an increased odds of mortality with
hypoxia (OR-3.13). The evidence from hyperoxia is unclear. I will now detail the
observational studies followed by the national survey.
3.3 Observational Studies
3.3.1 Methods
3.3.2 Extreme Hypoxia Threshold Study
The null hypothesis of this study was that ‘extreme hypoxaemia’ is not survivable.
‘Extreme hypoxaemia’ was defined as an admission arterial partial pressure of
oxygen (PaO2) <2.67 kPa (20 mmHg). This cut o↵ was chosen as per the Gray
paper. Historically patients with values below this threshold were expected to die.
However the Gray study from 1970 showed that some patients survived to hospital
discharge with values below this limit. [9] More recently, Grocott observed a PaO2
of 19.1 mmHg in a healthy adult mountaineer. [10] Therefore, I aimed to disprove
the null hypothesis and explore the theory that adaptative mechanisms might be
active even during acute hypoxia.
This retrospective observational study was performed in GOSH. All admissions
to critical care services over an 11-year period (Jan 2004 - December 2014) were
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included for analysis. Repeat admissions were excluded. The incidence of ‘extreme
hypoxaemia’ was explored.
3.3.3 PaO2 - Mortality Continuous Variable Study
For this part of the observational study PaO2 was employed as a continuous vari-
able. The relationship between admission arterial PaO2 ranging from 1 to the
maximum recorded value of 147 kPa and mortality at intensive care unit discharge
was investigated. All admissions to critical care services over 11-years (Jan 2004
- December 2014) were utilised for this analysis. Children with no documented
admission PaO2 or FiO2 were excluded. Further analysis was performed with
thresholds. Hypoxia was defined as PaO2 <8 kPa, normoxia as PaO2 between
8.1-40 kPa and hyperoxia as PaO2 >40 kPa. These cut-o↵s were selected in ac-
cordance with the paper by Kilgannon. [11]
3.4 Statistical Analysis
3.4.1 Extreme Hypoxia Threshold Study
The incidence of ‘extreme hypoxia’ was presented as absolute numbers with the
denominator as total admissions to the critical care services over the study period
with a full dataset. Children with a cardiac pathology were analysed separately
Page 123
3.4. STATISTICAL ANALYSIS
since some of them may have been hypoxic for a longer period (cyanotic condi-
tions). I wished to investigate if being hypoxic for a longer duration conferred a
beneficial e↵ect on eventual survival. Therefore within the ‘extreme hypoxaemia’
group, Fishers exact test of significance was used to compare survivors with and
without cardiac aetiology.
3.4.2 PaO2 - Mortality Continuous Variable Study
A logistic regression model was employed to assess the admission arterial PaO2
and mortality relationship. Following this, a regression curve estimation technique
in SPSS (IBM software, V21.0) was utilised to explore the relationship between
admission PaO2 and probability of death. The most parsimonious model was
chosen as the final best fit using goodness of fit method (Bayesian Information
Criterion). A model is considered more parsimonious if it is of a lower complexity.
For example, the hierarchy might be linear, logarithmic, quadratic, cubic, logistic
and so on. This was the quadratic function in my case. The equation was as
follows:
Predicted mortality = Constant + (b1 * PaO2) + (b2 * (PaO2)2)
Patients were empirically categorised into 6 groups according to their admission
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PaO2 (<8, 8.1-10, 10.1-13, 13.1-25, 25.1-40 and >40 kPa).
The Paediatric Index of Mortality 2 (PIM2) is a risk prediction score. It enables
the comparison of care delivered by intensive care units by creating a score from
specifically chosen admission variables. Admission PaO2 is one of the variables in-
cluded in the model. [217] In order to delineate the e↵ect of PaO2 on the outcome,
the logit equation for the Paediatric index of mortality 2 (PIM2) was amended.
The coe cient of FiO2/PaO2 was removed from the PIM2 equation to create a
modified PIM2 (mPIM2). Non-linear regression analysis was employed to analyse
the e↵ect of co-variates (admission PaO2, age, ethnicity and mPIM2) on mortality.
In addition, the PIM2 and Paediatric Index of Mortality 3 (PIM3) risk of mor-
tality vs PaO2 curves were analysed. The aim was to analyse the contribution
and impact of PaO2 to the prediction model. All variables in the model were
kept constant (using the values quoted for ‘model patient’ described in the PIM3
article). [218] Then when PaO2 was varied the curve represented univariate rela-
tionship to the predicted mortality.
The Standardised Mortality Ratio (SMR) was calculated as per the equation:
SMR = Observed deaths / Expected deaths
The expected deaths were calculated from the PIM2 value. A modified SMR
Page 125
3.5. RESULTS
(mSMR) was determined by using the mPIM2 in place of PIM2. The relation-
ship between mSMR, SMR and admission PaO2 was investigated. Standardised
mortality ratio, mSMR and 95% confidence intervals were plotted for each of the
pre-defined groups.
3.5 Results
3.5.1 Extreme Hypoxia Threshold Study
A total of 14,308 children were admitted to the critical care services during the
study period. On average, there were 1635 admissions per year to the critical care
services at GOSH over the study period. Complete datasets were available for
7751 patients.
The admission PaO2 was <20 mmHg in 40 children (0.5%). The median weight
in this group was 3.21 kgs (LCI 3.1, UCI 4.02). Twenty seven of them were
admitted to the cardiac intensive care unit, 7 to the neonatal intensive care unit
and 6 to the paediatric intensive care unit. The etiology was a cardiac pathology
in 19 children. The rest were: 13 respiratory, 2 neurological, 1 general surgical
post-op and 5 miscellaneous disorders. Nearly 57% (23) patients had previous
ICU admissions.
Of the 40 children, 33 (82.5%) were alive at intensive care unit discharge. There
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were 3382 (43.6%) patients with a cardiac aetiology. Children with and without
a cardiac aetiology did not have a statistically significant di↵erence in mortality
(Fishers exact p = 0.68). Table 3.1 shows the number of children according to
cardiac aetiology and survival.
Table 3.15: Extreme hypoxaemia: Survival to intensive care unit discharge vs.
Aetiology
Aetiology Cardiac disease Others Total
Survival to
ICU discharge
Yes 15 18 33
No 4 3 7
Legend: Extreme hypoxia was defined as admission PaO2 of <20 mmHg. The
total number of children with ‘extreme hypoxia’ was 40. The table displays the
outcome of children separated as either having a cardiac aetiology or other. The
outcome is similar between the groups (Fishers exact - p = 0.68). ICU - Intensive
care unit.
3.5.2 PaO2 - Mortality Continuous Variable Study
Data from all admissions to critical care services in Great Ormond Street Hospital
over an 11-year time interval was reviewed. Of 14,321 total admissions during the
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study period, 7410 patients had a documented admission PaO2 in the first hour.
In all, 1324 (17.8%) of these patients were hypoxic, 5385 (72.6%) were normoxic
and 701 (9.4%) were hyperoxic on admission. The crude mortality was 204 (15.4%)
in the hypoxic group, 287 (5.3%) in the normoxic group and 64 (9.1%) in the hyper-
oxic group. PaO2 and crude mortality was found to have a quadratic (U-shaped)
relationship.(Figure 3.1) The table shows the coe cients for non-linear regression
analysis with PaO2, age, gender and mPIM as co-variates.(Table 3.2) On the ba-
sis of the primary diagnosis on admission, the patients with cyanotic congenital
heart disease were identified and separately analysed. The U-shaped relationship
between PaO2 and crude mortality was preserved even in this subgroup of children
with cyanotic cardiac disorders.
The ‘U-shaped’ relationship suggests that probability of death increases both at
low and high PaO2 level.
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Figure 3.10: Relationship between admission PaO2 (kPa) and probability of death
Relationship between arterial partial pressure of oxygen on admission and un-
adjusted mortality in 7410 critically ill children admitted to Great Ormond St
Hospital Intensive Care 2004-2014. The regression curve estimation shows that
PaO2 mortality relationship is a quadratic function (U-shaped curve).
The PIM2 and PIM3 mortality risk prediction score had an inverse power law
relationship to admission PaO2. This relationship was consistent across all risk
categories of patients. (Figures 3.2 and 3.3)
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The equation for PIM2 is:
PIM2 = (0.016*absolute (systolic blood pressure)-120)) + (4.0767 * pupillary reac-
tion) + (0.2074*100*(FiO2/PaO2)) + (0.0671* absolute base excess)) + (0.6999*(me-
chanical ventilation)) - (0.6496*(elective admission)) - (1.1876*(surgical recov-
ery))+ (0.0866*(cardiac bypass)) + (1.408*(high risk diagnosis)) - (1.8624*(low
risk diagnosis)) - 4.4585
The equation for PIM3 is:
PIM3 = (3.8233*pupillary reaction) + (0.5378*elective admission) + (0.9763*me-
chanical ventilation) + (0.0671*absolute base excess) + (0.0431*systolic blood
pressure) + (0.1716*(systolic blood pressure /1000) + (0.4214*(FiO2/PaO2)*100)
+ (1.2246*cardiac bypass) + (0.8762* surgical recovery - non-bypass) + (1.5164*
surgical recovery - non-cardiac) + (1.6225*very high risk diagnosis) + (1.0725*high
risk diagnosis) + (2.1766 * low risk diagnosis) 1.7928
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Figure 3.11: Relationship between admission PaO2 (kPa) and PIM2 predicted risk
of mortality
Relationship between arterial partial pressure of oxygen on admission and risk of
mortality as predicted by the PIM2 score. The clinical variables of the ‘model
patient’ described in the PIM3 article were inputted into the PIM2 equation with
varying PaO2. An inverse power law relationship was noted. [218]
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Figure 3.12: Relationship between admission PaO2 (kPa) and PIM3 predicted risk
of mortality
Relationship between arterial partial pressure of oxygen on admission and risk of
mortality as predicted by the PIM3 score. The clinical variables of the ‘model
patient’ described in the PIM3 article were inputted into the PIM3 equation with
varying PaO2. A inverse power law relationship was noted. [218]
The standardized mortality ratio (SMR) and modified standardized mortality ratio
(mSMR) were 0.93 and 1.34 respectively for the hypoxic group (PaO2 <8 kPa),
0.75 and 0.83 for the normoxic group (8-40 kPa) and 0.82 and 0.85 for the hy-
peroxic group (>40 kPa).The mSMR was higher compared to SMR when PaO2
was less than 13 kPa. This relationship persisted even when the patients were
separated into subgroups of cardiac and non-cardiac.
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Figure 3.13: Relationship between admission PaO2 (kPa) and the standardized
mortality ratio / modified standardized mortality ratio in all patients
Panel A and B. The relationship between the partial pressure of oxygen (PaO2)
and the modified standardized mortality ratio and standardized mortality ratio.
The modified standardised mortality ratio was calculated by excluding the FiO2
/ PaO2 coe cient from the PIM2 calculation. The standardised mortality ratio
was calculated using the paediatric index of mortality 2 (PIM2) score. The grey
dashed lines represent 95% upper and lower confidence intervals.
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The non-linear regression analysis shows that PaO2 has a statistically significant
association to the outcome (death) in the overall group and less so in the cyanotic
cardiac disease subgroup. Of note, the coe cients for PaO2 are small. The modi-
fied SMR, unsurprisingly, also has a statistically significant e↵ect on the outcome.
Table 3.2 and table 3.3 show the non-linear regression coe cients.
Table 3.16: Nonlinear regression - Death as outcome - All admissions
Co-variates Estimate Std.err p-value
(PaO2)2 3.99⇥ 10 5 7.38⇥ 10 6 <0.0001
PaO2  3.63⇥ 10 3 5.26⇥ 10 4 <0.0001
Age 6.23⇥ 10 5 4.96⇥ 10 5 0.21
Sex  9.11⇥ 10 3 5.60⇥ 10 3 0.10
Modified PIM2 0.82 0.02 <0.0001
Legend: Coe cients of non-linear regression model. The model includes all pa-
tients with valid data. Death is the outcome. Age and sex do not have a statis-
tically significant e↵ect on the outcome. Modified PIM2 has the largest e↵ect on
the outcome. PaO2 has a small but statistically significant e↵ect on the outcome.
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Table 3.17: Nonlinear regression - Death as outcome - Cyanotic cardiac disease
subgroup
Co-variates Estimate Std.err p-value
(PaO2)2 4.53⇥ 10 5 2.39⇥ 10 5 0.06
PaO2  2.91⇥ 10 3 1.09⇥ 10 3 0.007
Age  5.17⇥ 10 5 7.47⇥ 10 5 0.488
Sex -0.013 0.007 0.073
Modified PIM2 0.52 0.05 <0.0001
Legend: Coe cients of non-linear regression model. The model includes patients
with cyanotic cardiac disease with valid data. Death is the outcome. Age, sex
and PaO2 do not have a statistically significant e↵ect on the outcome. Modified
PIM2 has the largest e↵ect on the outcome. PaO2 has a small but statistically
significant e↵ect on the outcome.
3.6 Survey
The survey was designed to describe the UK clinical practice in respect of sup-
plemental oxygen therapy in ventilated critically ill children. Similar surveys have
proved to be valid tools for describing true variability in clinical practice and
feasibility steps to randomized clinical trials. [219] [220] A web-based tool was
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employed to facilitate data collection using a University College London website
(opino.ucl.ac.uk.).
All members of the Paediatric Intensive Care Society (PICS), UK, were requested
by email to complete the survey via a weblink that would only permit a single con-
tribution from each email. Paediatric Intensive Care Society membership consists
of approximately 800 nursing, medical and allied health professionals working in
paediatric intensive care units. Clinical sta↵ from neonatal intensive care units in
the UK were not approached, as their patient profile was considered to be signifi-
cantly di↵erent.
Demographic data, including age, intensive care unit type, their seniority and years
of practice were sought. After discussion of this study with the chair of Blooms-
bury Research and Ethics Committee (London, UK), I was advised that a formal
ethics review was not required.
The survey outlined the following clinical scenario:
A 1-year-old with no premorbid conditions is ventilated with peak inspiratory pres-
sure of 28 cm H2O, positive end expiratory pressure of 6 cm H2O, respiratory rate
of 20 breaths per min and FiO2 of 0.8. His peripheral oxygen saturation (pulse
oximetry), heart rate, blood pressure and mean blood pressure are 94%, 125 beats
per min, 85/56 mmHg and 66 mmHg respectively. He has bilaterally equal and
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reactive pupils measuring 3 mm. He is sedated on intravenous morphine and mi-
dazolam. He is not paralysed. Latest arterial blood gas values are - pH: 7.32,
PCO2: 6.2 kPa, PaO2: 10 kPa, BE: -ve 4 and Lactate: 1.5 mmol/L. The PIM2
predicted risk of mortality is 8.8 %. He has been ventilated for 2 days.
With the same clinical history, clinicians were asked to decide on the oxygenation
targets when the potential diagnosis is acute respiratory distress syndrome, post-
cardiac arrest, sepsis, traumatic brain injury (TBI) or pulmonary hypertension.
A further question examined weaning protocols in their units. Interest in a poten-
tial randomised control trial with oxygenation targets was explored (Appendix 1).
3.6.1 Statistical Analysis
Survey results are presented in tables and figures. The characteristics of the re-
spondents are presented as absolute numbers with percentages. The responses to
scenarios are reported as histograms.
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3.6.2 Results
Only 53 of those who were invited to participate in the online survey responded.
The total number invited to participate was unclear as the PICS membership was
not well defined. This number was suspected to be about 400. Hence, the response
rate was 13%. The majority of respondents worked in moderate sized ICUs, with
admission rates between 500-1000 patients per annum. The characteristics of re-
spondents are presented in table 3.4.
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Table 3.18: Demographic characteristics of respondents
The table gives number of respondents (percentage within brackets) and their
characteristics.
Number of admissions to intensive care
unit
Number(%)
<500 9 (17)
501 1000 24 (47)
1001 1500 13 (25)
>1500 5 (10)
No response 2
Cardio-surgical center 33 (66)
Neuro-surgical center 35 (67)
Age
20 - 30 years 1 (2)
31 - 40 years 24 (46)
41 - 50 years 19 (36)
>50 years 8 (15)
No response 1
Grade of person filling survey
Consultant 25 (48)
Senior nurse 10 (19)
Senior fellow 12 (23)
Junior fellow 5 (10)
No response 1
Number of years of practice in intensive
care
2 - 5 years 13 (25)
5 - 6 years 13 (25)
>10 years 25 (49)
No response 2
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The majority of responders (96%) reported having an alarm target on the oxy-
gen saturation monitors in their unit. Thirty-eight respondents (73%) worked in
units that did not have an oxygen weaning protocol for mechanically ventilated
patients. The units with more than 1500 admissions were less likely to have a wean-
ing protocol compared to those with between 500 and 1500 admissions.(Figure 3.5)
Figure 3.14: Relationship between Volume of Admissions and Presence of an Oxy-
gen Weaning Protocol
The result was normalised for the units with an admission volume of fewer than
500 cases a year. The largest units were more likely not to have a weaning protocol.
For the given clinical scenario, 21 respondents (42%) did not follow PaO2 targets.
Of the reminder, 21 clinicians (42%) targeted between 8.1 and 10 kPa. Only 8
(16%) aimed for the normal range (10.1-13 kPa).(Figure 3.6)
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Figure 3.15: Target of PaO2
Respondents were classified into three groups according to their PaO2 target prac-
tice. The respondents were requested to choose the range of PaO2 they would
target for the patient with the illustrated clinical scenario. Nearly half the respon-
dents do not follow PaO2 targets. Of the rest, the majority claim to target slightly
lower targets than the normal range.
In acute respiratory distress syndrome, cardiac arrest (CA) and sepsis, there was
a tendency to aim for lower PaO2 (<10 kPa) as the FiO2 increased. This was no-
ticeable when the FiO2 was more than 0.4 (45%) which equates to a PaO2 / FiO2
ratio of less than 200. Following TBI and in pulmonary hypertension, there was a
propensity to aim for normal PaO2 (10.1-13 kPa) even as the FiO2 rose (28-33%
when FiO2 >0.4). In TBI, the proportion of respondents targeting a lower PaO2
increased when the FiO2 was more than 0.8 (8%). A proportion of respondents
targeted PaO2 ranges above normal (15%). In pulmonary hypertension, normal
range remained the preferred choice throughout the range of FiO2.(Figure 3.7)
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Figure 3.16: Target PaO2 and FiO2 Profile in Various Clinical Scenarios
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in 5 clinical scenarios in
a child with moderate ventilatory requirements. The PaO2 ranged from <8 kPa
in the top panel to >13 kPa in the bottom panel within each scenario. FiO2
ranged from 0.21 (blue) through to 0.81-1 (purple). The three scenarios in the top
panel show a pattern of more restrictive PaO2 targets with increasing FiO2. The
2 scenarios in the lower panel show that higher normal PaO2 ranges are targeted
irrespective of increasing FiO2.
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Figure 3.17: Target PaO2 and FiO2 Profile in Acute Respiratory Distress Syn-
drome
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in a child with ARDS
and moderate ventilatory requirements. The PaO2 ranged from <8 kPa in the top
panel to >13 kPa in the bottom panel. FiO2 ranged from 0.21 (blue) through to
0.81-1 (purple). The pattern is of more restrictive PaO2 targets with increasing
FiO2.
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Figure 3.18: Target PaO2 and FiO2 Profile in Cardiac Arrest
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in a child following cardiac
arrest and moderate ventilatory requirements. The PaO2 ranged from <8 kPa in
the top panel to >13 kPa in the bottom panel. FiO2 ranged from 0.21 (blue)
through to 0.81-1 (purple). The pattern is of more restrictive PaO2 targets with
increasing FiO2.
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Figure 3.19: Target PaO2 and FiO2 Profile in Sepsis
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in a child with sepsis and
moderate ventilatory requirements. The PaO2 ranged from <8 kPa in the top
panel to >13 kPa in the bottom panel. FiO2 ranged from 0.21 (blue) through to
0.81-1 (purple). The pattern is of more restrictive PaO2 targets with increasing
FiO2.
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Figure 3.20: Target PaO2 and FiO2 Profile in Traumatic Brain Injury
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in a child following trau-
matic brain injury and moderate ventilatory requirements. The PaO2 ranged from
<8 kPa in the top panel to >13 kPa in the bottom panel. FiO2 ranged from 0.21
(blue) through to 0.81-1 (purple). The pattern is of liberal PaO2 targets despite
increasing FiO2.
Page 146
3.6. SURVEY
Figure 3.21: Target PaO2 and FiO2 Profile in Pulmonary Hypertension
The profile of PaO2 (y-axis) and FiO2 (x-axis) targeted in a child with pulmonary
hypertension and moderate ventilatory requirements. The PaO2 ranged from <8
kPa in the top panel to >13 kPa in the bottom panel. FiO2 ranged from 0.21
(blue) through to 0.81-1 (purple). The pattern is of liberal PaO2 targets despite
increasing FiO2.
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The response to no improvement after 24 hours of intensive care followed a simi-
lar trend as the initial management. A larger proportion of respondents targeted
higher PaO2 in children who su↵ered from pulmonary hypertension and TBI. The
majority of respondents were permissive with PaO2 targets for the children suf-
fering from acute respiratory distress syndrome. Almost 58% of the respondents
aimed for a FiO2 of 0.4-0.6 to the amended PaO2 targets.
An equal number of respondents felt there was a need for a randomised control
trial with tight arterial oxygenation targets. A large number were not fully con-
vinced of the need for a trial.(Figure 3.8) This suggests that clinicians are not
yet convinced by the evidence of harm from hyperoxia in critical illness. A small
proportion of the respondents felt it was not ethical to perform such a trial (11%).
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Figure 3.22: Randomised Control Trial with Tight Arterial Oxygenation
The respondents answered the question: ‘Is there a need for a randomised con-
trolled trial exploring the restrictive oxygenation targets to normal targets?’ The
opinion is nearly equally split between the groups.
3.7 Conclusions
Despite the universal use of supplemental oxygen therapy in intensive care, its
e↵ect on the PaO2 and the eventual outcome is unclear. Results of the systematic
review suggest that hyperoxia may not have a significant e↵ect on mortality in the
overall group of critically ill children. The odds of death with hyperoxia seemed to
increase (not statistically significant) in children admitted following cardiac arrest.
This is consistent with the reports from adult studies. [11] The review suggests
that avoiding hypoxia may be beneficial in all critically ill children, particularly in
the TBI subgroup.
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According to the review, hypoxia is harmful. This contradicts the hypoxic adap-
tation hypothesis. However, there was significant heterogeneity in the studies.
Children admitted following a TBI seem to fair worse when hypoxic. Ong re-
ports poor outcome in children <15 years of age following TBI (OR: 7.48, 95%CI:
1.27-21.76) in the presence of hypoxia. The composite outcome measure (poor out-
come) was severe disability, persistent vegetative state or death at discharge and
6 months adjusted for Glasgow Coma Scale, subarachnoid haemorrhage, di↵use
axonal injury and brain swelling. [221] Mayer performed a prospective observa-
tional study of 200 children with severe TBI. They observed a significantly higher
mortality (55% vs. 7.7%) in those children with any of the following: hypotension,
hypercarbia or hypoxia, compared to those without any of these signs. [222] The
review findings seem to lend support to the international recommendations on the
management of TBI in children. [223] The high heterogeneity in CA and the LRTI
subgroups makes the interpretation of these results di cult.
Several limitations restrict the scope of this review. The number of studies in-
cluded is small. Furthermore most were retrospective. The characteristics of the
studies vary and the possibility of selection bias within each study is high. The
funnel plot of the hyperoxia studies suggests some reporting bias.
However, the leave-one-study-out analysis suggests that the di↵erent outcome mea-
sures used in the studies do not a↵ect the overall result of the meta-analysis. In
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addition, the subgroup analysis accounts for some of the heterogeneity. The thresh-
old of PaO2 >200 mmHg (26.7 kPa) does not seem to be di↵erent to PaO2 >300
mmHg (40 kPa).
Nearly all the studies explore the relationship of PaO2 either <60 mmHg (8 kPa)
or >300 mmHg (40 kPa) on mortality. This suggests an inherent bias in the set-
ting of the PaO2 thresholds for the cohorts. In addition, none of the studies have
addressed the range in between 60 and 300 mmHg (8-40 kPa) as a continuous
variable. Most of the studies included in this review have a small sample size.
This further limits the generalizability of the results.
The extreme hypoxia observational study shows that extreme hypoxia is not a
good predictor of mortality. This is in keeping with a case report from more than
40 years ago. [9] Even though I observed survival in the extreme hypoxia group,
the functional outcome of these children was not investigated. With the small
number of patients and incomplete assessment of outcome, it would be prudent
not to draw firm conclusions from this finding. There was no di↵erence in sur-
vival between children with and without a cardiac disease (combined cyanotic and
acyanotic heart disease data). Unfortunately, the specific data on cyanotic car-
diac disease patients were not available. It would be interesting to investigate if of
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the cardiac children who survived, what proportion had a cyanotic cardiac disease.
The PaO2 - mortality continuous variable study shows a ‘U-shaped’ relationship
between PaO2 and mortality in critically ill children. The risk of death predicted
by the PIM2 and PIM3 models has an inverse law link to PaO2. As the PaO2
increased, the di↵erence between SMR and mSMR ceased to exist. Thus, the in-
fluence of PaO2 on PIM2 predicted risk of death is higher in the hypoxic range
than the hyperoxic range.
The U-shaped relationship between PaO2 and mortality observed in my study dif-
fers from the inverse relationship between PaO2 and mortality in the PIM2 model.
There may be two explanations to this apparent discrepancy. Although hyperoxic
children seem to have a higher crude mortality, the relationship may not be causal.
They are hyperoxic because clinicians recognise them as being sick and are reluc-
tant to wean oxygen. Alternatively, PIM2 may need to have a modified coe cient
for hypoxia and hyperoxia. There might be several reasons for the higher predicted
mortality in the patients with hyperoxia such as brain death or other high risk di-
agnoses. These seem to be associated with death despite adequate oxygenation.
The survey results suggest variations in oxygen delivery practices. The higher re-
sponse rate from the consultants is perhaps linked to their experiential knowledge.
Of particular note, no oxygen weaning protocol exists in nearly three-quarters of
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the PICUs.
The review suggests that a strategy that aims for normoxia and avoids hyperoxia
in the CA subgroup may be better for survival. The variability in the TBI group
is too great to allow firm conclusions to be drawn with respect to hyperoxia.
Limitations of the systematic review:
1. The literature search was conducted by a single author. Formal Cochrane re-
views are reviewed by two independent authors. To account for this limitation, the
search strategy was reviewed and ratified by an Institute of Child Health librarian.
2. There were no randomised control trials in the area of interest. Of the cohort
studies that were included, risk of a selection bias was high. A thorough assess-
ment of bias was performed with the Newcastle Ottawa Scale and funnel plots.
3. The co-variates included in the individual studies vary. This limits the signifi-
cance of the odds ratio of the overall population. Where available, adjusted odds
ratio was utilised for the meta-analysis.
4. The retrospective design and heterogeneous patient population with di↵erent
mechanisms for hypoxia or hyperoxia make interpretation of the results di cult.
The focus was on the relationship between PaO2 and mortality. While PaO2 is
a marker of alveolar gas exchange, tissue oxygen delivery is influenced by various
factors, including haematocrit and vasomotor tone. The e↵ect of ventilatory strat-
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egy on PaO2 was not explored. The mode of death and withdrawal of care due
to ongoing hypoxia may introduce bias to the association. However, despite these
limitations, my study would inform future studies in this area.
Limitations of the observational studies:
The data for the two retrospective observational studies was sought from the PI-
CANet team in Great Ormond Street Hospital. The team collect a large admission
dataset, check for errors in data input data at the bedside and submit it to PI-
CANet. Despite this process, there is a risk of incorrect data being sourced from
the PICU clinical database.
Limitations of the survey:
1. As with any survey, the respondents are a self-selecting population. They in-
clude motivated individuals or people who already hold a strong opinion - both
positive and negative - on the subject.
2. There were more doctors in the respondents. This may be partly due to the
membership of the PICS. The ideal would be to sample a larger population with
an equal proportion of professionals.
3. Unfortunately, I did not survey practitioners from neonatal intensive care units
in the UK. As they have a di↵erent patient profile, it will be a valuable review that
could be undertaken in the future. This is particularly pertinent in view of the
reports from the Boost 2 and COT trials. These have shown that the restrictive
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oxygenation targets cause worse outcom in premature infants. [224] [225]
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Chapter 4
Oxygen Consumption in Children
With a Suspected Mitochondrial
Disorder
This chapter investigates the use of a novel biomarker - Near infra-red spectroscopy
with a vascular occlusion test (NIRS VOT) to estimate oxygen consumption from
forearm muscle. The NIRS VOT method has been described in detail in chapter
2 (section 2.1). Children with suspected mitochondrial disease and other neuroge-
netic disease were chosen to test the usefulness of this technique.
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4.0.1 Rationale for Choosing Mitochondrial Disease Pa-
tients
With advances in science, numerous health conditions have been attributed to mi-
tochondrial dysfunction. The majority of these are due to defects in the respiratory
electron transport chain. [226] These manifest as an inability to utilise oxygen.
Phenotypically they demonstrate exercise intolerance, collapse in the neonatal pe-
riod with lactic acidosis, seizure disorders, neurodevelopmental regression or as a
neuromyopathy. [227]
Taivassalo et al demonstrated an increase in the partial pressure of oxygen in ve-
nous blood in patients with mitochondrial myopathy following a forearm exercise.
Furthermore, they found a linear correlation between the rise in partial pressure
of venous oxygen and severity of oxidative impairment (peak systemic a vO2 dif-
ference) as assessed during exercise. [228] By extrapolating from this inability to
extract oxygen, researchers have devised a test to assess the severity of mitochon-
drial myopathy. The modified exercise test (MET) aids in the screening of these
patients by measuring the rise in lactate following a sub-anaerobic exercise test.
The MET showed a sensitivity of 78% and a specificity of 100% when compared
to healthy controls. [229] In another set of experiments, Taivassalo et al showed
that the oxygen delivery during exercise is increased in quadriceps muscle in mi-
tochondrial myopathy patients. In addition, the capillary density is increased,
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suggesting a localised response to ine cient oxygen utilisation at the respiratory
electron transport chain. [230] The concept of mitochondrial disease physiology
is that the impact of the deficiencies of respiratory chain enzymes is a reduced
oxygen metabolism and energy production. These studies support this concept
and the reduced oxygen metabolism seems to match the clinical picture.
In this thesis, I wished to investigate the utility of NIRS in critical illness and, as
defended above, congenital mitochondrial disease group provided a valuable po-
tential positive control of reduced oxygen utilisation. However, I have not made
a direct comparison between mitochondrial disease and critically ill children. I
looked at the mitochondrial disease children when well so that critical illness was
not a confounding factor. The aim was to look at a pure mitochondrial disease
state.
4.1 Introduction
Mitochondrial disease is a term used to describe a heterogeneous group of inherited
conditions with a defective oxidative phosphorylation as the central process. They
are rare. The birth prevalence of mitochondrial disease in the western world is
estimated at 1 in 5000. [231] [232] The most common mitochondrial diseases (both
clinical and biochemical phenotypes) are leigh syndrome, Kearns-Sayre disease and
complex IV disorders (Respiratory electron transport chain protein - discussed in
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section 1.8.1). [112]
Typical presentations of severe mitochondrial disease include a delay in reaching
developmental milestones or an acute admission to the emergency department with
metabolic acidosis (typically associated with hyperlactatemia) and some combina-
tion of encephalopathy, myopathy or a multi-system disorder. The family history
may include consanguinity, early miscarriages, sudden unexpected deaths or an
a↵ected relative. Making a diagnosis usually requires several invasive blood, urine
and cerebrospinal fluid tests, muscle and skin biopsies. A final diagnosis may take
months or, in a significant proportion of cases, may not be confirmed.
The varying symptomatology makes applying strict criteria for diagnosis di cult.
Some clinicians employ a set of major and minor criteria to assist in the diagnosis
of mitochondrial disease. These incorporate the clinical phenotype with the his-
tology, functional characteristics, molecular and enzymology studies from muscle
and skin biopsies. [233]
Mitochondrial diseases are rarely treatable. The few reported exceptions include
the riboflavin transporter defect, in which riboflavin supplementation can slow
disease progression and occasionally improve the clinical condition. [234] Coen-
zyme Q10 (CoQ) acts as an electron carrier between Complex I/II and substrates
from fatty acid beta oxidation and Complex III. When given as a supplement, it
is beneficial in patients with primary CoQ deficiency but probably not helpful in
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Complex IV disorders (Cytochrome C Oxidase - COX). [235]
The follow-up of a mitochondrial disease patient ideally should include objective
serial measurements of their functional status. However, there are no universally
agreed validated scoring systems and those that have been proposed are com-
plicated and cumbersome and di cult to complete in a busy outpatient clinic
setting. [236] [237] There is no bedside ‘gold standard’ test to diagnose and moni-
tor mitochondrial disease either. In summary, the diagnosis, prognostication and
objective measure of treatment e↵ect are all challenging in mitochondrial disease
management.
The predominant site of oxygen metabolism in a cell is the mitochondrion. [238]
Therefore, a measure of the oxygen consumption could provide insight into mito-
chondrial function. NIRS VOT is a candidate for estimating oxygen consumption
and may aid in quantifying this function. The principle of NIRS has been detailed
previously in section 1.11. Wilson utilised NIRS with arterial occlusion to measure
oxygen consumption in patients with heart failure. [239] Other investigators were
able to di↵erentiate between normal subjects and mitochondrial myopathy (MM)
patients using NIRS with a treadmill exercise protocol. [240] Van Beekvelt studied
5 adult patients with MM with a vascular occlusion test (VOT) at rest. They
recorded a V O2 of 0.063± 0.027 ml/min/100 grams (mean±SE) in patients with
MM as compared to 0.106± 0.006 ml/min/100 grams in normal adult volunteers
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(p=0.02). [241] Grassi performed NIRS VOT in a similar group of patients. They
demonstrated a statistically significant di↵erence in the mean ± SE peak V O2
between the MM patients and controls. [242] These results support the utility of
NIRS VOT as a possible tool in the diagnosis of mitochondrial disease. More re-
cently, in a randomised controlled trial, Glover used NIRS as a tool to measure
the change in oxygen consumption with supplementation of Coenzyme Q10. They
found no di↵erence in the oxygen saturation at rest, average saturation and maxi-
mal desaturation between the treatment groups after a 90-s exercise protocol. [243]
Magnetic resonance spectroscopy (MRS) is another technique that is employed in
the assessment of mitochondrial disease. It is a non-invasive method that aids in
screening of patients. Furthermore, it is able to assess mitochondrial function in-
vivo. The principle is to use a radiofrequency pulse to excite nuclei placed under
high power magnetic conditions. The nuclei absorb energy and are displaced from
their thermal equilibrium. The nuclei release this energy when they relax back to
equilibrium. Each chemical in the tissue (brain or muscle) has an identifying signa-
ture response in the MR spectrum. For example, abnormal oxidative metabolism
in the mitochondrial present as a change in the high-energy phosphate levels in
the MR spectrum. This can be extrapolated to tissue oxidative function [244]
Matthews et al performed resting muscle MRS in mitochondrial myopathy pa-
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tients (n=17, age range 1-73 years) with mild clinical signs. They chose other
myopathy patients (no-mitochondrial) as controls. They were able to complete
the test in 30 minutes. They noted altered phosphorus metabolite concentrations
suggestive of impaired cellular energy metabolism. In addition, results correlated
well with clinical signs. [245] I was unable to employ this technique as it is not a
bedside measure, more expensive and needs an established experimental MRI re-
search service. In addition, previous studies suggest that my patient group would
have had similar results as the NIRS VOT with a MRS technique. Therefore, for
this thesis I worked with NIRS VOT.
Tissue oxygen index (TOI) was measured with Near infrared spectroscopy vas-
cular occlusion test (NIRS VOT) as described in chapter 2.1. The di↵erence in
tissue oxygen index between the lowest value of tissue oxygen index (at the end of
blood pressure cu↵ inflation) to the baseline is termed Drop TOI. This may be an
indirect measure of tissue oxygen consumption.
The similarity between the mitochondrial disease patient and the patient on inten-
sive care is the reduced oxygen consumption. [246] The discussion above supports
the theory that mitochondrial disease patients have restricted oxygen utilisation.
In comparison, despite adequate oxygen delivery, the intensive care patient might
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be limited in his capacity to consume oxygen. This limitation could result in
physiological responses as described in chapter 1 (section 1.5). By investigating
the mitochondrial disease patients, not only am I able to validate the NIRS VOT
technique, but also start understanding the adaptive mechanisms that might act
in the chronic hypoxic setting. Further, this project augments my understanding
of the mitochondrial respiratory chain and its function. I was able to utilise this
knowledge in my gene expression study detailed in chapter 6. It focuses on the
electron transport chain and explores mitochondrial dysfunction in the intensive
care patient.
The work described in this chapter is set out to assess if NIRS VOT values di↵er
between mitochondrial disease children and healthy controls. Furthermore, the
utility of this technique as a diagnostic tool in children with suspected mitochon-
drial disease was explored by comparing them to children with other neurogenetic
diseases (non-mitochondrial disease).
4.2 Methods
General objectives:
1. To assess the utility of NIRS VOT for detecting di↵erences in forearm muscle
tissue oxygen consumption in children with a known mitochondrial disease and
2. To assess the potential of NIRS VOT as a screening tool to identify patients
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with a higher probability of having a mitochondrial disease.
Hypothesis 1: Mean Drop TOI in cases of confirmed mitochondrial disease will be
equivalent to controls (neurogenetic disease and healthy children).[Null hypothesis]
Hypothesis 2: Cases with a suspected mitochondrial disease with mean Drop TOI
below a threshold value have an increased risk of having confirmed mitochondrial
disease (by either muscle enzymology or genotype). [Alternative hypothesis 1]
Hypothesis 3: NIRS VOT results will not change the probability of a diagnosis in
children with suspected mitochondrial disease. [Alternative hypothesis 2]
Design: Prospective observational study.
Ethics approval:
The project was registered with the R&D o ce in Institute of Child Health (R&D
ref: 13AR09). The Camden and Islington Research Ethics Committee (REC
ref:13/LO/1259) approved the study on 4th October 2013. The final R&D ap-
proval was gained on 28th November 2013.
Page 164
4.2. METHODS
The tests were performed after informed written consent was obtained from the
parents. Children, where able, signed an ‘Assent form’. A signed copy of the
consent form, parent information sheet along with the age-specific child informa-
tion sheet was given to parents. The original copy of the signed consent form was
stored in the research o ce in the paediatric intensive care unit.
Inclusion criteria:
All patients with a suspected mitochondrial disease who were referred to Prof
Shamima Rahman were eligible for inclusion. Both inpatients and outpatients
were considered for recruitment. The inpatient cohort was limited to elective ad-
missions because of the potential e↵ect of acute illness on mitochondrial function.
Disease controls with non-mitochondrial neurogenetic diseases were recruited from
Dr DeVile’s paediatric neurology outpatient clinic. These patients do not have a
primary mitochondrial disease. The prevalence of secondary mitochondrial dys-
function in this group is unknown.
The procedure was discussed with all eligible patients including those who su↵er
from dystonic movements and muscle pain. The decision to undergo the test (after
formal consent) was made if the parents anticipated that the test would not cause
an increase in dystonia or cause undue pain.
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Exclusion criteria:
1. Children admitted to the ward following unexpected deterioration
3. Children with a cyanotic congenital heart disease
4. Ex-premature infants (<30 weeks gestation at birth)
Inpatients:
In-patients with a suspected mitochondrial disease are usually admitted to the
neurology and metabolic wards in Great Ormond Street Hospital (GOSH). When
a child’s admission was planned, either the nurse in-charge of the ward or the
clinicians informed me. Permission to approach the family was obtained from the
lead clinician.
Following this, an invitation letter, information sheets and a consent form were sent
to the family. The documents were sent at least 1 week before the planned date of
admission. The family was approached on the day of admission and any questions
about the study answered. The families were free to withdraw consent at any time.
Outpatients:
Eligible out-patients:
Children (<16 years) with a follow-up in the outpatient department at Great Or-
mond Street Hospital.
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A list was created of patients meeting inclusion criteria 2 weeks prior to the outpa-
tient appointment. Families received an invitation letter, information sheets and a
consent form at least 1 week in advance. They were informed that they would be
approached on the day of clinic. If they were unwilling to participate, the family
had no further involvement in the study.
Participants were classified as outlined in Table 4.1.
Table 4.1: Classification of children recruited in this study
Group Diganosis
Controls Neurogenetic disease:
Non-mitochondiral
Non-biochemical abnormality
Neurological abnormality
Healthy controls:
Healthy children
Mitochondrial
diease group
Genetically confirmed (and/or)
Biochemically confirmed with good clinical phe-
notype (and/or)
Non-mitochondiral genetic abnormality and pos-
sible secondary mitochondrial dysfunction
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The ‘textbook’ mitochondrial disease patient would have a strong clinical pheno-
type, a biochemical defect (as measured from muscle biopsy) and a known genetic
mutation. But methods and technology for genetic analyses are still evolving and
nearly 50% of the patients with the phenotype and biochemical defect do not cur-
rently have a genetic diagnosis. Less frequently, patients have normal biochemistry
in the setting of a strong clinical phenotype and/or a known mutation. The Venn
diagram (Figure 4.1) represents the subsets: Patients with a strong clinical phe-
notype, patients with a genetically confirmed and/or a biochemically confirmed
diagnosis. The aim of this project was to investigate if the NIRS VOT di↵erenti-
ates between patients within the Venn diagram and those outside it.
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Figure 4.1: Venn Diagram Showing Inter-relationship of the Subsets Within the
Suspected Mitochondrial Disease Group
The children recruited into the mitochondrial disease group all were suspected to
have mitochondrial disease. They could be further subdivided into four subsets:
1. Children with a strong clinical phenotype (C) in addition to a genetic mutation
(G) (pastel green shaded area), 2. Children with a strong clinical phenotype (C)
and biochemical abnormality (B) (blue shaded area), 3. Children with a strong
clinical phenotype (C), a genetic mutation (G) and a biochemical abnormality (B)
(pink shaded area) and 4. Children who do not fall into any of the preceding
categories (grey shaded area).
The recruits underwent two tests - the NIRS VOT and a cardiac output measure-
ment (with Ultrasound cardiac output monitor). The full details of the techniques
are described in chapter 2 (section 2.1 and 2.2).
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4.3 Statistical Analysis
The sample size was calculated using two methods:
1. Previous work with NIRS in a study of adults with one clinical syndrome of a
mitochondrial disease (Chronic Progressive External Ophthalmoplegia) observed
a mean fall in the tissue oxygen index of 0.106 (se=0.006) in controls and 0.063
(se=0.027) in chronic progressive external ophthalmoplegia patients.[12] If this
same percentage di↵erence (37%) were to be reproduced in this study, then with
an alpha set at 0.05 and power at 80%, 16 patients would be required in each
group.
2. To distinguish a case of mitochondrial disease from non-mitochondrial dis-
ease cases, one requires estimates of the mean and variance of TOI from non-
mitochondrial disease cases. These have not been reported in the literature pre-
viously. We, therefore, made an assumption that the neurogenetic disease (non-
mitochondrial disease) group may behave in a similar fashion to normal children.
Therefore for the sample size calculation, pilot data from children with mitochon-
drial disease and data from normal children in the Young Everest Study 2 (chapter
5) were used. The pilot data from mitochondrial disease children has been included
in the final data analysis.
The sample size calculation using two means (mitochondrial disease group and
healthy children) from the pilot study yielded a sample size of 28 per group. The
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mean for group 1 (mitochondrial disease) was 13.2 and that for group 2 (healthy
children) was 21.1. A second method was used to calculated sample size using
a two-sample two-sided equality analysis. The power was set at 80, alpha set at
5, standard deviation of the mitochondrial disease group was 7.61 and standard
deviation was healthy children of 7.09. The formula includes the ratio between
sample sizes of two groups. In my case, this is equal to 1. The result is 13 per
group. I chose to recruit a larger sample size as per the first calculation.
Numerous additional factors introduce imprecisions into NIRS estimations of mus-
cle oxygen index. These include variability in patient size, muscle mass and severity
of underlying mitochondrial disease. The aim was to recruit 30 patients in each
group to account for these factors.
The Drop TOI (di↵erence between baseline and lowest Tissue Oxygen Index) of
the mitochondrial disease group was compared to healthy controls and then to the
neurogenetic disease group. The recordings in children with suspected mitochon-
drial disease had significant movement artefact. Therefore, summary measures
were utilised for analysis. The reference measurement to confirm mitochondrial
disease was either genetic or biochemical results.
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The following were addressed:
1. To test the null hypothesis i.e the mean DropTOI is not di↵erent between chil-
dren with mitochondrial disease and controls (neurogenetic disease and healthy
children), a ‘t-test’ was used to compare the groups.
2. To test alternative hypothesis 1: A 2x2 table was created. Proven mitochon-
drial disease (yes or no) was tabulated against DropTOI threshold value (e.g.,
 14 or <14). Thresholds were selected by interrogating the TOI values of controls
and mitochondrial disease patients and choosing a level that had no or minimal
crossover. Fisher’s exact test was used to compare those with mitochondrial dis-
ease to those without.
3. To test alternative hypothesis 2 i.e. NIRS VOT results will not increase the
probability of a diagnosis of mitochondrial disease: Bayesian inference with a Fa-
gan’s nomogram was employed.
Bayesian statistics involve applying previous theoretical and empirical knowledge
to formulate hypotheses, rank them on the basis of observed data and update prior
probability estimates and hypotheses using observed data. [247] The prior proba-
bility of mitochondrial disease or ‘prior’ was determined from previous knowledge
of the epidemiology of mitochondrial disease and referral patterns to the outpa-
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tient clinic.
In the general population, the incidence of mitochondrial disease is 1 in 5000
(0.02%). However, children presenting to the outpatient clinic with clinical signs
suggestive of a neuromuscular, neurogenetic or mitochondrial disorder are expected
to have a higher probability than the general population. In addition, Prof Rah-
man’s outpatient clinic is a specialist clinic for children with suspected mitochon-
drial disease. Other clinicians from within GOSH and the district general hospitals
in the region refer patients to her when they suspect mitochondrial disease or have
ruled out other more common diagnoses. This increases the ‘prior’ further.
After consideration of these parameters, a prior probability of mitochondrial dis-
ease was chosen from the proportion of children with mitochondrial disease and
all children tested with NIRS VOT within this thesis. This yielded a ‘prior’ of
0.4. Expert opinion from other clinicians in the metabolic medicine and neurology
department in GOSH were sought. The general consensus was that this ‘prior’ was
a reasonable estimate. A Fagan Nomogram was employed with the agreed ‘prior’
to calculate the posterior probability or ‘posterior’.
4.4 Results
Demographics:
The total number of children recruited was: 43 children in the mitochondrial dis-
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ease group and 32 controls (12 healthy children from the sea level tests within the
Young Everest Study 2, one healthy sibling of a patient with suspected mitochon-
drial disease and 19 children in the neurogenetic disease group).
The results are presented in two sections - Comparison of children with mito-
chondrial disease to controls and a further exploratory comparative analysis of the
mitochondrial disease to neurogenetic disease group.
4.4.1 Section 1: Comparison of Mitochondrial Disease to
Controls
The age, weight and height were not normally distributed (Table 4.2). Mitochon-
drial disease children were shorter than healthy controls. The median age, weight
and mean/median cardiac index were not statistically di↵erent between mitochon-
drial disease group and controls.
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Table 4.2: Characteristics of children with mitochondrial disease and controls
The values presented are median with interquartile range within brackets. CI -
Cardiac index.
Characteristics Mitochondrial dis-
ease (n=43)
Controls (n=32) p-value
Age (yrs) 10.4 (6.5  13.6, 43) 10.0 (7.8  13.8, 32) 0.39
Weight (kgs) 31 (21.7  47, 29) 40 (26.9  47, 29) 0.31
Height (cm) 135.1 (117.4  150.4, 28) 146 (126.2  160, 29) 0.23
CI (L/min/m2) 3.1 (2.5  4.3, 25) 3.0 (2.8  3.8, 28) 0.63
A linear regression with Drop TOI as the outcome measure with age and presence
of mitochondrial disease as independent variables was performed. Although there
was a decrease in Drop TOI by 0.05 for every year increase in age, this was not
statistically significant.
Testing of the null hypothesis
The baseline TOI was not di↵erent between groups. The Drop TOI was not dif-
ferent between the mitochondrial disease group to controls (t-test, p = 0.14). The
di↵erent sections of the NIRS VOT curve were also compared. Box plots were
created to assess normal distribution. Figures 4.2 show that the data is not nor-
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mally distributed. Therefore, a Mann-Whitney test was employed to compare the
groups. (Table 4.3) The highest TOI was statistically di↵erent between the groups
(p=0.02).
Table 4.3: Tissue oxygen index (TOI) values of children with mitochondrial disease
and controls
The values presented are median with interquartile range within brackets
Characteristics Mitochondrial
disease (n=43)
Controls
(n=32)
p-value
Baseline TOI 74.2 (69.8  76.3) 73.4 (71.5 77.6) 0.42
Drop TOI 14.0 (11.1  25.1) 17.6 (13.1 23.5) 0.44
Highest TOI 81.2 (79.4  83.2) 83.4 (81.4 85.1) 0.02
Recovery TOI 21.7 (17.7  33.0) 28.1 (18.6 34.1) 0.42
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Figure 4.2: Box Plots of Various Sections of Tissue Oxygen Index Comparing
Mitochondrial Disease Group to Controls
Panel A - Baseline Tissue Oxygen Index, Panel B - Drop Tissue Oxygen Index,
Panel C - Recovery Tissue Oxygen Index and Panel D - Highest Tissue Oxygen
Index. Blue box represents data from controls while yellow box is from the mi-
tochondrial disease group. The dark black line in the middle of the box depicts
the median value. The error bars represent 1st and 3rd quartile values. The small
circles denote outlier values.
Testing of the alternative hypothesis 1
A Drop TOI value of 14 was noted to have the least crossover between the mito-
chondrial disease group and controls. This was set as the cuto↵ for the 2x2 table
(Table 4.4).
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Table 4.4: Comparison of children with mitochondrial disease to controls
Test Mitochondrial
disease present
Mitochondrial
disease absent
Total
NIRS VOT Positive 19 9 28
NIRS VOT Negative 24 23 47
Total 43 32 75
The Fisher exact test statistic was 0.22 and showed that NIRS VOT is unable to
di↵erentiate between mitochondrial disease and controls.
Testing of the alternative hypothesis 2
The Fagan nomogram was employed to include the prior probability of mitochon-
drial disease. As described earlier, 0.4 was chosen as the ‘prior’.
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Table 4.5: Fagan nomogram posterior probabilities
Test Positive likelihood Posterior Description
ratio probability
Positive test 1.57 (95%CI:0.84-
2.92)
51% (95%CI:36-
66%)
⇠ 1 in 2 children
with positive test
have the disease
Test Negative likelihood Posterior Description
ratio probability
Negative
test
0.78 (95%CI:0.54-
1.12)
34% (95%CI:26-
43%)
⇠ 1 in 1.5 children
with negative test
are well
Both the positive and negative posterior probability had wide confidence intervals.
Therefore, NIRS VOT is unable to discriminate between mitochondrial disease and
the control population.
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Figure 4.3: Change in Probability of Diagnosis of a Mitochondrial Disease After
Near Infrared Spectroscopy Vascular Occlusion Test (NIRS VOT) Compared to
Healthy Children.
The blue line represents the change in posterior probability following a positive
NIRS VOT. The red line shows the change in the posterior probability after the
NIRS VOT is negative. Prior probability is set at 0.4.
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4.4.2 Section 2: Comparison of Mitochondrial Disease to
Neurogenetic Disease
This section explores the ability of NIRS VOT to di↵erentiate between children
with mitochondrial disease and other neurogenetic disease. Patient demographics
- age, weight, height and cardiac index - were not di↵erent between the groups.
Although the mitochondrial disease group were shorter and weighed less, these
di↵erences were not statistically significant.
Table 4.6: Characteristics of children with mitochondrial disease and neurogenetic
disease group
The values presented are median with interquartile range within brackets. CI -
cardiac index.
Characteristics Mitochondrial Neurological p-value
disease (n=43) disease (n=19)
Age (yrs) 10.4 (6.5  13.6, 43) 12.1 (7  14, 19) 0.48
Weight (kgs) 31 (21.7  47, 29) 41.1 (25.2  51.6, 16) 0.35
Height (cm) 135.1 (117.5  150, 28) 147.7 (122  161.2, 16) 0.58
CI (L/min/m2) 3.1 (2.5  4.3, 25) 3.2 (2.9  4.1, 15) 0.64
Testing of Null hypothesis
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Figures 4.4 show that the data is not normally distributed. Therefore a Mann-
Whitney test was employed to compare the groups. The baseline TOI between
mitochondrial disease and neurogenetic disease group trends towards significance.
The highest TOI was di↵erent between the groups (p = 0.03). This result is similar
to the comparison of mitochondrial disease to controls. (Table 4.7).
Table 4.7: TOI values of children in mitochondrial and neurogenetic disease group
The values presented are median with interquartile range within brackets.
Characteristics Mitochondrial
disease (n=43)
Neurological
disease (n=19)
p-value
Baseline TOI 74.2 (69.8  76.3) 76.5 (72.7  79) 0.07
Drop TOI 14.0 (11.1  25.1) 14.1 (10.1 21.5) 0.77
Highest TOI 81.2 (79.4  83.2) 84.1 (81.2 85.6) 0.03
Recovery TOI 21.7 (17.7  33.0) 23.9 (14.3 31.0) 0.86
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Figure 4.4: Box Plots of Various Sections of Tissue Oxygen Index Comparing
Mitochondrial Disease Group to Neurogenetic Disease Group
Panel A - Baseline Tissue Oxygen Index, Panel B - Drop Tissue Oxygen Index,
Panel C - Recovery Tissue Oxygen Index and Panel D - Highest Tissue Oxygen
Index. Blue box represents data from mitochondrial disease group while yellow
box is from the neurogenetic disease group. The dark black line in the middle of
the box depicts the median value. The error bars represent 1st and 3rd quartile
values. The small circles denote outlier values.
Power recalculation:
The power was recalculated after collecting 48 patients (40 disease group - Mi-
tochondrial disease group and 8 disease controls - neurogenetic disease group).
With a median for neurogenetic disease group as 22.19, median for mitochondrial
disease group as 14.17 and a standard deviation of 8.76, a sample size of 40 and
alpha error set at 0.05, the power would be 0.98. With these values, a power of
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80% would be achieved with a sample size of 18. I recruited 11 more patients in
the neurogenetic disease group and 3 further patients in the mitochondrial disease
group.
The Drop TOI varies considerably within children with mitochondrial disease and
neurogenetic disease. This variation within groups is displayed in the bean plot.
(Figure 4.5) Group 1 was compared to group 0 and group 2. This presents the
problem of multiple comparisons. This is a small risk as there are only two compar-
isons. To account for this, I have included a Bonferroni correction. Accordingly,
the p value that would be needed to show significance would be 0.025 (0.05/2).
Both comparisons have non-significant p-values.
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Figure 4.5: Comparison of Drop TOI Between Groups
Bean plots of delta tissue oxygen index (Drop TOI). The plot shows the delta
tissue oxygen index (Drop TOI) with 95% CI. The subjects were classified into 3
groups healthy children (0), children with neurogenetic disease (1) and children
with mitochondrial disease (2). p-value (t-test) when comparing group 0 to 1
was 0.22 while that for group 1 to 2 was 0.84. The thick black horizontal line
within the yellow bean plot is the median. The red horizontal lines within the plot
represent individual patient values. The width of the bean plot is proportional to
the number of observations at that value.
Testing of alternative hypothesis 1
Fagan nomogram was employed to compare children with mitochondrial disease
and neurogenetic disease.
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Table 4.8: Comparison of children with mitochondrial disease to neurogenetic
disease
Test Mitochondrial
disease present
Neurogenetic
disease present
Total
NIRS VOT Positive 19 8 27
NIRS VOT Negative 24 11 35
Total 43 19 62
The Fisher exact test statistic was 0.98. This showed that NIRS VOT is not able
to di↵erentiate between children with mitochondrial disease and those with other
causes of neurogenetic disease. The clinical utility of NIRS VOT is expected to be
in a setting with varying prior probability. Hence, Fagan nomogram was employed
to test post-NIRS VOT probabilities.
Testing of alternative hypothesis 2
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Table 4.9: Fagan nomogram posterior probabilities
Test Positive likelihood Posterior Description
ratio probability
Positive test 1.05 (95%CI:0.60-
1.83)
41% (95%CI:29-
55%)
⇠ 1 in 2.4 children
with positive test
have the disease
Test Negative likelihood Posterior Description
ratio probability
Negative
test
0.96 (95%CI:0.60-
1.53)
39% (95%CI:29-
50%)
⇠ 1 in 1.6 children
with negative test
are well
Both positive and negative posterior probabilities are similar. This suggests that
NIRS VOT is not helpful to di↵erentiate between mitochondrial disease and other
causes of neurogenetic disease.
Page 187
4.4. RESULTS
Figure 4.6: Change in Probability of Disease After NIRS VOT Comparing Mito-
chondrial Disease and Neurogenetic Disease
The blue line represents the change in posterior probability following a positive
NIRS VOT. The red line shows the change in the posterior probability after the
NIRS VOT is negative.
In summary, the NIRS VOT derived measure of oxygen consumption (Drop TOI)
is not able to di↵erentiate between mitochondrial disease and other causes of neu-
rogenetic disease.
Although not clinically relevant, for the purposes of my thesis I explored if NIRS
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VOT is able to di↵erentiate between children with suspected mitochondrial dis-
ease and healthy children. Near infrared spectroscopy with vascular occlusion test
(NIRS VOT) was able to exclude mitochondrial disease in healthy children with
a high degree of certainty (positive LR - 5.74, 95%CI:0.85-39, negative LR - 0.60,
95%CI:0.44-0.82). This suggests that the technique is able to measure oxygen
consumption from the forearm muscle. This is particularly relevant for the other
studies discussed in chapter 5 (Young Everest Study 2) and chapter 6 (children
with critical illness).
4.5 Conclusions
This project suggests that NIRS VOT is unable to di↵erentiate mitochondrial
disease children from controls. The median Drop TOI in mitochondrial disease
children is 14 compared to 17.6 in the controls. These findings are in contrast to a
recent adult study comparing mitochondrial myopathy (MM) patients to healthy
controls. [248] However, a comparison to healthy controls is not useful in clinical
practice. The Fagan nomogram result shows that when the prior probability is
high NIRS VOT is not a clinically useful tool.
The children with neurogenetic abnormality may not be the ‘ideal’ control popula-
tion as they display a pattern of Drop TOI suggestive of secondary mitochondrial
dysfunction. The variability in baseline TOI and Drop TOI observed in the neu-
Page 189
4.5. CONCLUSIONS
rogenetic disease group is interesting and not previously reported. The utility of
NIRS VOT as a diagnostic tool in this population needs further investigation.
Mitochondrial disease children might have a degree of adaption to tissue hypoxia.
This may be seen as the absence of di↵erence in NIRS VOT between this group
and controls. If these tests were performed under conditions of higher oxidative
stress (eg. pre and post exercise), a di↵erence might become apparent.
Mitochondrial disease is a heterogeneous group of disorders with varied oxygen
consumption. Taivassalo has addressed this variation in adult patients with MM.
They performed cardiopulmonary exercise testing in 40 patients with MM and
compared the oxidative capacity to 32 healthy sedentary controls. Unsurprisingly,
the oxygen uptake (V O2) was di↵erent between the groups (MM patients had
lower V O2). The V O2 ranged from 6 to 47 ml/kg/min in MM patients. They
also noted a relative increase in cardiac output in MM patients during exercise
compared to controls. Furthermore, they observed a di↵erentiation between the
groups at V O2max. The range of V O2 is similar to the widespread of the Drop
TOI noted in the current study in children with mitochondrial disease. [249]
The variability in baseline TOI noted in my study is not surprising. Baseline TOI
is a marker of the resting oxygen consumption from forearm muscle. There are two
main reasons for this variability. The first is that oxygen consumption at rest is in-
versely proportional to the mitochondrial dysfunction. [228] [250] Therefore, when
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a patient has a severe disease their oxygen consumption will be lower compared
to a patient who has a milder form of the disease. The second reason is disease
penetrance and mitochondrial heterogeneity. Within the overall mitochondrial dis-
ease group, some diseases a↵ect muscles while others spare muscle function. [226]
In addition, even when muscle mitochondrial function is impaired there seems to
be a threshold e↵ect for this to translate to clinical signs. By extrapolation, this
threshold may present as normal baseline TOI in a patient with impaired muscle
oxygen consumption.
The highest TOI was statistically di↵erent between mitochondrial disease group
and both controls and neurogenetic disease group. There might be two explana-
tions for this:
1. The post occlusive reactive hyperaemia is lower in mitochondria disease chil-
dren. There is no documented literature on this physiology. However, with mito-
chondrial dysfunction, there may be an inherent vasomotor dysfunction.
2. There is an inability to further increase recruitment of capillaries in the mi-
tochondrial disease children in the normal state. This failure might be due to
impaired miR-210 (micro RNA) expression. [251] Therefore, when the arterial oc-
clusion is released there is a relatively lower vasomotor response.
As noted above, the cardiovascular response to NIRS VOT is dynamic in nature.
Consequently, the single point measure of cardiac output in this study is per-
Page 191
4.5. CONCLUSIONS
haps inadequate. Just the forearm occlusion during NIRS VOT might change the
cardiac index. I wanted to exclude any major change in oxygen delivery by a
continuous measure of the cardiac index. If this project were to be repeated, ide-
ally a continuous non-invasive measurement of cardiac output should be employed
whilst conducting the NIRS VOT. Unfortunately, no such validated non-invasive
technique is currently available.
During formal cardiopulmonary exercise testing, V O2max is achieved when further
work does not increase oxygen uptake (plateau in oxygen uptake). [252] It is a
measure of aerobic fitness. [253] The NIRS VOT with a 3-minute occlusion protocol
does not achieve V O2max. A longer occlusion protocol might result in achieving
this limit. As noted earlier, Taivassalo et al observed a di↵erence between MM
patients and healthy controls noted a di↵erentiation in at V O2max. Similarly,
the neurogenetic abnormality group might show di↵erent oxygen consumption at
V O2max.
One major presumption of the NIRS VOT is that the near infra-red light penetrates
to a depth appropriate to interrogate the forearm muscle. The circumference of
the forearm, the amount of subcutaneous fat and the muscle mass are all relevant
variables that impact the measurement. Unfortunately, these were not accounted
for in this project and limit the confidence in the interpretation of results.
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The thickness of adipose tissue impairs the measurement of oxygen consumption.
[254] This is not as relevant in children as in the adult population. Consequently,
for my study I have considered it to be a systematic error and not explored this
further.
Some of the children with mitochondrial disease su↵er from significant dystonia.
The Drop TOI will be artificially high if the child flexes their forearm during VOT.
The ideal would be to perform the test only in children without dystonia. This is
not feasible or pragmatic because many children with mitochondrial disease have
dystonia, particularly those with Leigh syndrome, the most common presentation
of mitochondrial disease in early childhood.
The children in this study had a wide age range. Furthermore, no study so far
has investigated the TOI with increasing age. This may be a relevant parameter.
However, my results do not show a statistically significnant relationship.
One of the potential future studies in this population might be to perform NIRS
VOT under conditions of higher oxidative stress (eg pre and post exercise). This
might display a reduced dro TOI. The increasing availability of whole exome and
whole genome next generation sequencing (NGS) has led to a reduction in the
number of muscle biopsies being performed for diagnosis of mitochondrial disease.
However, NGS is time consuming. NIRS VOT may have a role whilst awaiting
NGS results. NIRS VOT does not give any information about the biochemistry
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or genetic analysis. It could still be an adjunct in the diagnostic pathway.
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Chapter 5
Oxygen Consumption - Oxygen
Delivery Relationship at Altitude:
Young Everest Study 2
In chapter 3, NIRS VOT was shown as a potential bedside, non-invasive technique
that could estimate oxygen consumption from the forearm muscle. This chapter
explores the e↵ects of hypoxia on the oxygen delivery-consumption relationship in
healthy children. As a model of hypoxia, exposure to moderately high altitude was
investigated as part of the Young Everest Study 2. All the tests were performed
both at sea level and at Namche Bazaar (3525 metres).
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This study was conducted to test the following hypotheses:
1) Children will have a similar cardiorespiratory response to adults when exposed
to hypobaric hypoxic condtions
2) It is safe for children to trek to moderately high altitude (3525 metres) and
3) There will not be a change in oxygen consumption during the short time period
(4 days) of exposure to hypobaric hypoxic conditions.
The first hypothesis was tested in the initial part of the results. In this section, car-
diovascular changes at moderately high altitude are discussed - especially changes
in peripheral oxygen saturations (SpO2), heart rate (HR), respiratory rate (RR)
and cardiac index (CI). A 3-minute step test was incorporated to measure post-
exercise alterations in SpO2, HR and RR. These parameters enabled a non-invasive
measure of oxygen delivery and a comparison of adaptive responses noted in adult
studies.
The second hypothesis was tested by the results of the cardio-respiratory responses
and cerebral near infrared spectroscopy (NIRS). Cerebral NIRS (forehead) was
measured at both the altitudes as a simulation of static organ perfusion and oxy-
gen consumption.
The third hypothesis was tested by employing near infrared spectroscopy with a
vascular occlusion test (NIRS VOT). This estimated dynamic forearm muscle oxy-
gen consumption. The method of NIRS VOT was detailed in Chapter 2 (section
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2.1).
The next chapter (chapter 6) compares these results to children admitted with
critical illness to the paediatric intensive care unit.
I will start with a discussion on high altitude medicine research.
5.1 Introduction
5.1.1 High Altitude Medicine
High altitude medicine and the e↵ect of hypoxic conditions has interested moun-
taineers and physicians for centuries. [2] It was known for centuries that the par-
tial pressure of oxygen dropped with increasing altitude.(Figure 5.1) [255] Bert
first published evidence linking altitude sickness and low partial pressure of oxy-
gen. [256] Most humans do not show signs / symptoms of altitude sickness until
about 3000 meters. There seems to be an altitude theeshold above which the
symptoms occur and incrementally worsen. Therefore, the relationship between
the partial pressure of oxygen and symptoms of altitude sickness is linear above
certain altitude.
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Figure 5.1: Drop in Partial Pressure of Oxygen with Altitude
Reproduced and amended from a review article by Peacock 1998. [255] The plot
shows the decrease in atmospheric pressure and the partial pressure of oxygen with
increase in altitude. The primary x-axis denotes the atmospheric pressure in kilo-
pascals. The secondary x-axis shows the partial pressure of oxygen in kilopascals.
The y-axis shows the various altitudes where the measurements were recorded.
The red triangles denote well known high altitude destinations. The horizontal
red line denotes the altitude at Namche Bazaar. The vertical red line depicts the
partial pressure of inspired oxygen and the barometric pressure at Namche Bazaar.
Methodologies used in altitude research
Numerous expeditions to high altitude have studied acute physiological and evo-
lutionary responses such as changes in the haemoglobin concentration, the ven-
tilatory response and the shape of the chest. The main high altitude regions of
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interest are the Ethiopian highlands, the Andes and the Tibetan plateau. The
Ethiopian highlands are at an altitude of 3500 metres, the Andes are on average
4000 metres high while the Tibetan plateau ranges around 4000 metres above sea
level. The Ethiopians have been living in the region for about 5000 years, Andeans
for 11000 years and Tibetans in the Everest region for 20000 years. These pop-
ulations exhibit di↵erent physiological adaptations to altitude. Andeans increase
oxygen delivery by increasing their haemoglobin concentration whilst the Tibetans
achieve this by an increase in minute ventilation and vasodilation (secondary to
endogenous nitric oxide). The Ethiopians seem to have an adaptive physiology
which is a combination of the above two mechanisms. This variability in the phys-
iological responses can be explained by acclimatisation and natural selection. [257]
The formats employed to investigate the evolutionary response to altitude are:
1. Single population with multiple stresses (such as Quechua population studies).
For example, Quechua studies showed that children living in southern Peru at an
altitude of 4000-5500 metres had a slower and prolonged growth compared to chil-
dren at sea level in the United States and Peruvian lowlands. However, they had
relatively larger chest circumferences and forced vital capacities. [258]
2. Multiple populations with single stress - such as comparing Ethiopians to An-
deans and Sherpas i.e comparing highlanders living at similar altitudes.
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3. Quantitative genetics approach. [257]
Another method of investigating a single population would be the migrant study
design. The Muza study observed that resting and exercise oxygen saturations at
high altitude dropped initially on day 1 followed by a marginal stabilisation. A
reverse pattern was noted with the exercise heart rate. [259] This study is of par-
ticular interest as the Young Everest Study 2 explored these parameters in healthy
children.
Over a longer period the above-mentioned responses enable the understanding of
human evolutionary responses. For example, commonly measured cardio-respiratory
parameters such as heart rate and respiratory rate change in the acute phase whilst
the adaptive responses such as hypoxic ventilatory response take years to estab-
lish. [2] (Figure 1.2 and Figure 1.3).
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Figure 5.2: Acclimatization over a Long Period of Time
Adapted from the book by West, Schoene and Milledge 2007. [2] The acclimatisa-
tion is separated into acute (in minutes) and days (up to 100 days). Most of the
acclimatization responses revert to baseline values in a short span of time. Heart
rate, ventilation and haemoglobin would be expected to revert to baseline values
by 100 days. The long-term adaptations are trans-generational.
The figures 5.5 and 5.6 summarise the physiological changes with hypobaric hy-
poxia in healthy adult volunteers. The muscle fibre cross-sectional area, skeletal
muscle mass and muscle mitochondrial volume density are also reduced. [260] [261]
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Figure 5.3: Changes in the Cardiovascular Responses at High Altitude After a
Period of Acclimatization
Created from text in the article by Martin et al 2008. [261] The parameters on
the left hand side increase during acclimatisation while the ones on the right hand
side decrease.
Figure 5.4: Changes in the Respiratory System Responses at High Altitude After
a Period of Acclimatization
Created from text in the article by Martin et al 2008. [261] The parameters on
the left hand side increase during acclimatisation while the ones on the right hand
side decrease.PaO2 - Partial pressure of oxygen in arterial blood, SaO2 - Oxygen
saturation of arterial blood, PCO2 - Partial pressure of carbon dioxide, V O2 -
Oxygen consumption
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All the above-mentioned responses are with an eventual aim to optimise the oxygen
delivery-consumption relationship. Lets now discuss the oxygen cascade.
5.1.2 Oxygen Cascade at High Altitude
The oxygen cascade in a healthy human being at sea level (discussed in chapter
1.4) shows a sequential drop in the partial pressure of oxygen (PO2) from ambient
air through to the tissues. This decrease in PO2 is more gradual at high altitude
in adapted individuals. [262] [263] Consequently, although the PO2 in ambient
air is significantly lower at 4500 metres, the levels achieved in the mixed venous
blood are nearly the same. Figure 5.1 depicts this di↵erence in the rate of drop.
Several mechanisms may be at play here. In the lung, di↵usion of oxygen from
the inspired air into arterial blood may be more e cient at high altitude. In the
presence of pulmonary oedema, this is unlikely. In the tissues, there may be a
relative decrease in oxygen extraction from the arterial blood, perhaps due to a
more e cient utilisation of the available oxygen. Another mechanism in action at
high altitude is the relative drop in PCO2. In the healthy adult volunteer, there is
an inverse relationship between PaO2 and PCO2 at high altitude. Due to hypoxic
ventilatory response and hypercapnic ventilatory response the minute ventilation
increases and results in the drop in PCO2. Consequently, increasing the PaO2,
the arterial oxygen content and the oxygen delivery. An understanding of the dif-
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ference in slope of the oxygen cascade at high altitude under hypoxic conditions
could potentially be translated to the hypoxic patient on the intensive care unit.
Figure 5.5: Comparison of Oxygen Cascade Between Altitudes
Adapted from Torrance 1970. [263] The plot shows the decrease in the partial
pressure of oxygen down the oxygen cascade. The x-axis denotes points of mea-
surement - the oxygen molecule travels from ambient air through the alveolar gas,
arterial blood to the tissues. Mixed venous blood denotes the value after extrac-
tion of oxygen in the tissues. The y-axis shows the partial pressure of oxygen in
kilopascals.
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5.1.3 Relevance of Studying the E↵ects of Hypobaric Hy-
poxia to the Hypoxic Patient on the Intensive Care
Unit
Hypoxic patients in intensive care are in a normobaric environment. Although
most studies at high altitude investigate e↵ects of hypobaric hypoxia, some crossover
trials have compared hypobaric hypoxia and normobaric hypoxia. A review by
Coppel found that most of the physiological parameters compared were similar
between the groups. Several of the studies reported a di↵erence in minute ventila-
tion and exhaled nitric oxide (NO) (total - 13 cross-over trials). These di↵erences
have to be considered with caution. Not only did the studies include a small
number of participants, but also did not account for confounders such as duration
of exposure. Nonetheless, investigating response to hypobaric hypoxia may help
understand the clinical status in normobaric hypoxia patients. [264]
My YES2 expedition was conducted under the auspices of the Xtreme Ever-
est adult study. I will enumerate the salient studies conducted by the adult
team below. I will discuss studies investigating macrocirculation, microcirculation,
metabolic pathways, mitochondrial number and finally genetic polymorphisms.
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5.1.4 Results from the Xtreme Everest Study
I will discuss studies investigating macrocirculation, microcirculation, metabolic
pathways, mitochondrial number and finally genetic polymorphisms.
Maximal Oxygen Consumption
Formal cardiopulmonary exercise tests were performed in healthy volunteers at sea
level and Everest base camp by the Xtreme Everest team. They noted a significant
drop in maximal oxygen consumption from 43.8±5.4 mls/kg/min at sea level to
30.2±3.8 mls/kg/min in Everest Base Camp. [176] The relationship between oxy-
gen delivery and consumption is yet to be reported. However, preliminary results
seem to suggest a decrease in consumption that is not correlated with the delivery.
This might be a marker of alterations in mitochondrial function. The basic tenet
of goal-directed therapy (GDT) is to optimise oxygen delivery to match oxygen
consumption. These results would be crucial and might assist with targets for
GDT in the intensive care patient.
Skeletal Muscle Oxygen Consumption
Near infrared spectroscopy with a vascular occlusion test was employed by Martin
et al. They observed that baseline tissue oxygen measurement was reduced at
altitude compared to sea level. In addition, the rate of recovery post-arterial
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occlusion was significantly lower at high altitude. Of note, they did not find
a di↵erence in the rate of desaturation after arterial occlusion. [265] If the rate
of desaturation and the lowest TOI were unchanged during adaptation despite
hypoxic conditions, then the only explanation would be that body has become more
e cient at extracting oxygen. The hypoxic intensive care patient demonstrates
varying oxygen consumption profiles depending on the aetiology. For example,
patients with a cytotoxic tissue injury might utilise less oxygen whilst those in
a hyperdynamic warm shock state may need more oxygen. Hence it would be
di cult to extrapolate the Martin study findings without further research.
Alterations to Microcirculation
Martin et al investigated peripheral microcirculation using a sidestream darkfield
camera. In 24 healthy volunteers, they observed that microvascular capillary flow
reduced, while vessel density increased with ascent to 5300 meters. [266] In nor-
mal circumstances only a small proportion of the capillary bed is perfused. The
’unperfused’ vessels are perhaps recruited when there is a need for increased perfu-
sion. [267] The increased capillary density noted in hypobaric hypoxic conditions
suggests a reduction in di↵usion distance. This might account for a net augmen-
tation of perfusion despite a drop in flow. This might eventually lead to better
oxygen di↵usion from slowly moving red blood cells from numerous capillaries.
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Nitric oxide may be a potent mediator in the recruitment of capillaries. In ad-
dition to recruitment, neovascularisation may occur under hypoxic conditions by
the production of vascular endothelial growth factor by stimulating the hypoxia
inducible factor system. [268] Despite these theories, it is still unclear if these mi-
crocirculatory changes are adaptive or maladaptive.
Decreased microcirculatory flow is associated with poor outcome in adult patients
with septic shock. [269] If we explore the adaptive mechanisms in microcirculation
at altitude, this might then be translated to the directed management of the septic
intensive care patient.
Changes to Metabolic Pathways
Roberts et al investigated responses to exposure to altitude in 6 beta-blocked
adults and 5 healthy controls. They measured free fatty acid (FFA) and fatty acid
(FA) levels (at rest and after exercise) at sea level and after chronic exposure to an
altitude of 4300 meters. After acclimatization, resting FA consumption decreased
to zero. Following exercise, FA consumption increased but did not reach sea level
values (relative decrease). In addition, glucose uptake increased compared to sea
level. Therefore, exercise at altitude increases glucose uptake and decreases fat
utilisation. Beta-blockade seemed to potentiate these changes. [270] The increase
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in FFA levels might be due to lipolysis secondary to increased sympathetic neu-
ral activity. The enhanced glucose uptake is perhaps secondary to an increase
in basal metabolic rate. [271] With neutral energy and nitrogen balance in the
Roberts study, there is a suggestion that body transfers to a solely carbohydrate
based fuel consumption. This is an interesting result for the intensivist especially
as the ideal nutritional supplementation of the catabolic patient in intensive is
unclear.
Cooper et al investigated glucose utilisation during exercise in healthy volunteers
subject to hypoxic (FiO2 - 0.15) and hyperoxic (FiO2 - 0.8) environments. They
noted a significant increase in glucose uptake under hypoxic compared to hyperoxic
conditions. This finding is similar to the Roberts study results. [272] I did not
investigate these metabolic pathways as part of the YES2 study. However, they
may help explain my results from the investigation of oxygen consumption studies
on the paediatric intensive care population (Chapter 6).
Changes to Mitochondrial Density
With decrease in oxygen supply under hypoxic conditions (at high altitude), the
body needs to be more e cient and produce relatively similar amounts of ATP for
the available oxygen (lower). In order to reduce oxygen consumption, the body
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responds by decreasing the mitochondrial density. The exact mechanism by which
this reduction is achieved is unclear. Mitophagy might be one potential process.
Levitt et al performed muscle biopsies in 18 subjects in London and at Everest
Base Camp (5400 meters). They observed a 21% drop in mitochondrial volume
in Everest climbers and 14% drop in Base Camp climbers compared to sea level
values. Furthermore, the value of transcriptional protein peroxisome proliferator-
activated receptor coactivator-1 ↵ (PGC-1 ↵) decreased by 35% suggesting de-
creased mitochondrial biosynthesis. Therefore, there is a reduction in number of
mitochondria with a drop in production. [176] The explanation for this adaptive
response could be that mitochondria become more e cient in producing ATP.
However, to prove this we need to show that there is no deficit in energy produc-
tion.
Interventions to increase oxygen delivery could potentially be withheld if this adap-
tive mechanism was to occur in the hypoxic intensive care patient, without com-
promising recovery from critical illness.
Unique Genetic Polymorphisms
The variations in inter-individual adaptations, the propensities to altitude sickness
and the level of neurological function at high altitude are known. [273] In addi-
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tion, numerous genotypes have been explored in this context. [274] For example, an
Angiotensin Converting Enzyme (ACE) polymorphism has been recently studied.
Angiotensin Converting Enzyme limits vasodilation and causes vasoconstriction
through the Renin-Angiotensin system. It has two alleles - insertion (I) and dele-
tion (D). The ACE insertion allele is associated with lower circulating ACE levels
and is more commonly found in elite endurance athletes. [275] Thompson et al
conducted a prospective study to investigate if ACE I allele is overrepresented in
those who successfully climbed over 8000 meters. They observed a statistically
significant association between presence of I-allele and success. [276]
A few mechanisms might explain the above findings. First, the I-allele group seem
to have an enhanced ventilatory response. Second, the I-allele may be protective
against Hypoxic Pulmonary Vasoconstriction Response. Finally, it I-allele groups
might have more diuresis reducing the risk of pulmonary edema. [277] These mech-
anisms may also confer a protective benefit to the hypoxic intensive care patient.
The studies mentioned in this section and the mechanisms explored, support
the relevance of research in a hypobaric hypoxic environment in healthy volun-
teers. Critical illness is characterised by an imbalance between oxygen delivery
and consumption, causing a net oxygen deficit. Therefore, by understanding how
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adaptive mechanisms function in those exposed to hypobaric hypoxia (to pre-
vent oxygen deficit), we can potentially develop therapeutic targets in critically
ill patients to enhance adaptation. In summary, to aid with optimising oxygen
delivery-consumption relationship, within the cell, mitochondrial density is re-
duced, the electron transport chain is downregulated and oxidative phosphoryla-
tion becomes more e cient (more ATP production for the same amount of oxygen
consumed). [186] I will now briefly discuss altitude research in children and the
use of near infrared spectroscopy.
5.1.5 Altitude Research in Children
Children may have a di↵erent response to high altitude exposure compared to
adults secondary to the maturing sympathetic and chemoreceptor reflex systems.
They have less nocturnal periodic breathing at high altitude. [278] Nocturnal pe-
riodic breathing is a commonly noted phenomenon in healthy humans at altitude.
The pattern has periods of hyperventilation and central hypoventilation. It may
cause increased behavioural awakenings at altitude. [279] In addition, the preva-
lence of acute mountain sickness in pre-pubertal children and adolescents may be
less. [280] Yaron investigated the haemodynamic response during acute exposure
to high altitude in 24 children. Children between 3 months and 36 months of age
were accompanied to an altitude of 3109 metres. They demonstrated an increase
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in respiratory rate and a decrease in oxygen saturation at higher altitude. These
changes are similar to adults. [281] Kriemler reported similar results. [282] How-
ever, the e↵ect of sub-acute exposure remained unanswered. The Young Everest
Study (YES) explored this area for the first time.
The YES team trekked to an altitude of 3525 metres over a 4-day period. The
cardio-respiratory responses of 9 children between the ages 6 and 13 years were
measured. An increase in heart rate and drop in oxygen saturation was observed.
The respiratory rate increased marginally and seemed to drop towards sea level
values with longer duration at high altitude. Furthermore the oxygen saturation
increased by the end of their stay at high altitude. This is perhaps due to an
increase in oxygen delivery. The YES study was not designed to measure the
parameters needed to calculate oxygen delivery (DO2) and oxygen consumption
(V O2). [283] The Young Everest Study 2 (YES2) set out to answer some of these
questions.
5.1.6 Near Infrared Spectroscopy at High Altitude
Cerebral near infrared spectroscopy (NIRS) has been employed both in adults
and children visiting high altitude. Yaron studied cerebral NIRS in his study.
He found an age-related drop in tissue oxygen saturations with an acute ascent
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to high altitude (3109 metres). [281] Cerebral NIRS was performed in children
needing air ambulance transfer. They found a statistically significant drop in
cerebral oxygen saturation in children who had a cruising altitude of greater than
5000 metres and in mechanically ventilated children. [284] I have utilised this
technique to objectively estimate static oxygen saturation of the organ. This is
relevant especially when considered in the context of changing cardiac index and
the whole body hypoxia (lower peripheral oxygen saturation).
The second technique that I have utilised is the near infrared spectroscopy with
vascular occlusion test (NIRS VOT). Martin et al performed NIRS VOT at sea
level and at Everest base camp (5600 metres) in 12 healthy adult volunteers.
This study was described earlier under Xtreme everest studies. I performed the
same study in healthy children to evaluate the dynamic oxygen consumption from
forearm muscle.
5.2 Aims
The aims of the Young Everest Study 2 (YES2) were two-fold:
1. To describe the change in the cardiorespiratory parameters in children with a
gradual ascent to a hypobaric hypoxic environment - especially change in periph-
eral oxygen saturations, heart rate, respiratory rate and cardiac index.
2. To investigate if there is a change in the pattern of non-invasive measures of
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DO2 and V O2 under hypoxic conditions in healthy children - Change in cere-
bral near infrared spectroscopy, near infrared spectroscopy vascular occlusion test
(NIRS VOT) and cardiopulmonary exercise test (CPET).
5.3 Methods
The study was conducted as a paediatric subgroup under the auspices of the
Xtreme Everest 2 study. Children were recruited from healthy volunteers. A total
of 12 children participated in the study. The baseline sea level testing (SLT) was
performed in London (altitude - 30 metres) over a two-day period. The sea level
testing involved measurement of cardio-respiratory parameters (pre and post-step
test), cardiac index (measured by USCOM - described in section 2.2) at rest, cere-
bral near infrared spectroscopy and near infrared spectroscopy vascular occlusion
test (NIRS VOT - described in section 2.1) at rest. All the tests were performed
in a laboratory with a set room temperature of 20  C.
The sea level testing was followed (2 months later) by an expedition to the Everest
region in Nepal. The children and their families were accompanied to Nepal by 6
paediatric investigators. The expedition lasted two weeks (27th March - 12th April
2013).
The expedition started with a flight from London to Kathmandu (1400 metres).
In Kathmandu, the heart rate (HR), respiratory rate (RR) and oxygen saturations
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(SpO2) pre and post a 3-minute step test were measured. The cardiac index (CI)
at rest was also measured. After a day’s rest, the team took a short flight from
Kathmandu to Lukla (2860 metres). The team reached Namche Bazaar on day 4
following a 3-day gradual ascent (overnight stopovers at Phakding (2610 metres)
and Monjo (2835 metres)). Figure 4.2 depicts the trek profile (amended from im-
age downloaded from Google images). The sea level tests were repeated over two
days at Namche Bazaar.
Figure 5.6: Trek Profile of the Young Everest Study 2 Team
Amended from image downloaded from Google images. The team travelled from
London to Kathmandu. After an overnight stay, we flew to Lukla. From Lukla,
we reached Namche Bazaar over a three-day period with 2 overnight stops at
Phakding and Monjo.
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5.4 Statistical Analysis
The heart rate, respiratory rate, peripheral oxygen saturation (SpO2) and cardiac
index were compared between altitudes. The analysis was performed using the
repeated measures of ANOVA. Published normal ranges of heart rate in children
were utilised to calculate the heart rate Z scores using the LMS method. [285] [286]
Cerebral NIRS measurements in London and Namche Bazaar were compared with
student t-test. Analysis of near infrared spectroscopy vascular occlusion test (NIRS
VOT) employed the following techniques:
1. Multilevel modelling by considering measurements at di↵erent altitudes as
nested values within an individual child.
2. Functional data analysis by using the full 13-minute curve of NIRS VOT to
compare groups.
5.5 Results
The barometric pressure is 503 mmHg at Namche Bazaar. The PiO2 drops from
150 mmHg at sea level to 96 mmHg at Namche Bazaar.
The age range of the children was between 8 and 16 years (Figure 5.7). There were
7 boys and 5 girls in the group. Most of the children (11) were able to complete
the trek to Namche Bazaar and back successfully. One child became unwell whilst
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in Namche Bazaar (Salmonella typhi gastroenteritis) and was evacuated back to
Kathmandu.
Figure 5.7: Age Distribution of Volunteers in the Young Everest Study 2
The children ranged from 8 years to 14 years. The horizontal line within the box
denotes median value. The whiskers represent 1st and 3rd quartile values.
5.5.1 Peripheral Oxygen Saturation
The SpO2 at rest and exercise dropped with increasing altitude. The SpO2 at
rest decreased from 99 ± 0.79 to 89 ± 2.54 % from London to Namche Bazaar
(p=0.0009). The SpO2 after exercise decreased from 93.5 ± 7.16 to 83.3 ± 5.06
% from London to Namche Bazaar (p=0.008). There was no impact of duration
of stay on the SpO2 at rest and after exercise. This could be the first sign of
acclimatisation with an increase in arterial oxygen content. Figure 5.9 illustrates
changes in resting and exercise oxygen saturation with altitude.
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Figure 5.8: Change in Peripheral Oxygen Saturation with an Ascent to High
Altitude
The plot depicts the decrease in oxygen saturation with an ascent to high altitude.
The y-axis shows peripheral oxygen saturations. The x-axis shows the di↵erent
stages in the ascent. The first measurement was at sea level. After a three-day trek
the children reached Namche Bazaar at an altitude of 3525 metres. At Namche
Bazaar, three days of recording were performed. The red triangles with connecting
black lines depict saturations at rest. The blue circles with connecting black lines
show the saturations after a 3-minute step test. The black vertical lines depict 95%
confidence intervals. The p-value was calculated with repeated measures ANOVA.
The p-value for saturations at rest was 0.0009 and for post-exercise was 0.008.
5.5.2 Heart Rate
Heart rate increased with altitude both at rest and after exercise. There was more
variation in heart rate after exercise. The increase in heart rate was not statisti-
cally significant when Z-scores were used. The heart rate Z-scores at rest changed
from  0.44±0.70 to 0.10±0.76 bpm (p=0.30) whilst the heart rate Z-scores after
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exercise increased from 1.20± 1.30 to 2.07± 1.46 (Figure 5.10).
Figure 5.9: Change in Heart Rate (Z-scores) with an Ascent to High Altitude
The plot depicts the change in heart rate Z-scores with an ascent to high altitude.
The y-axis shows heart rate Z-scores. The x-axis shows the di↵erent stages in
the ascent. The first measurement was at sea level. After a three-day trek the
children reached Namche Bazaar at an altitude of 3525 metres. At Namche Bazaar,
three days of recording were performed. The red triangles with connecting black
lines depict heart rate Z-scores at rest. The blue circles with connecting black
lines show the heart rate Z-scores after a 3-minute step test. The black vertical
lines depict 95% confidence intervals. The p-value was calculated with repeated
measures ANOVA. The p-value for heart rate at rest was 0.30 and for post-exercise
was 0.43.
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5.5.3 Cardiac Index
Cardiac index was measured at rest 3 times every morning and the average consid-
ered the final value. It did not change significantly with an ascent to high altitude.
(Figure 5.11)
Figure 5.10: Change in Cardiac Index with an Ascent to High Altitude
The plot depicts the change in cardiac index with an ascent to high altitude. The
y-axis shows cardiac index. The x-axis shows the di↵erent stages in the ascent. The
first measurement was at sea level. After a three-day trek the children reached
Namche Bazaar at an altitude of 3525 metres. At Namche Bazaar, three days
of recording were performed. The red triangles with connecting black lines depict
cardiac index measured at rest. This measurement was not repeated after exercise.
The black vertical lines depict 95% confidence intervals. The p-value, calculated
with repeated measures ANOVA, was 0.07.
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5.5.4 Respiratory Rate
Respiratory rate after exercise increased consistently from sea level (22.2 ± 4.4)
to Namche Bazaar (27.6 ± 10.9). This is in keeping with the expected increase
in minute ventilation. Table 5.1 enumerates the change in barometric pressure
and partial pressure of inspired oxygen (PiO2). The values of barometric pressure
and PiO2 were referenced from article by Scrase et al. [283] Table 5.1 also gives
values of respiratory rate (at rest and after exercise) and heart rate (at rest and
after exercise). Table 1.2 gives details of the changes in SpO2, heart rate Z-score
(at rest and after exercise), cardiac index and DO2I (oxygen delivery index) with
increasing altitude from sea level to Namche Bazaar (3525 metres).
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5.6 Near Infrared Spectroscopy
5.6.1 Cerebral Near Infrared Spectroscopy
The left frontal tissue oxygen index (TOI) in London was 67.7. The right frontal
TOI in London was 67.7. The left frontal TOI in Kathmandu was 70.2 while the
right frontal TOI was 70.3. The left frontal TOI in Namche Bazaar was 68 while
the right frontal TOI was 68.1. There was no di↵erence between London and
Namche Bazaar (p- value: Left - 0.70, Right - 0.54). (Figures 5.12 and 5.13)
This is interesting as the SpO2 values dropped at high altitude. Therefore, cere-
bral TOI seems to be preserved in the presence of hypoxia.
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Figure 5.11: Left Frontal Cerebral Near Infrared Spectroscopy
The recording is for left frontal near infrared spectroscopy at three altitudes -
London (sea level), Kathmandu (1330 metres) and Namche Bazaar (3525 metres).
The y-axis depicts the tissue oxygen index value from near infrared spectroscopy.
The x-axis denotes the three sites where the recordings were performed. The
bean plot in yellow shows the distribution of the values. The red horizontal lines
within the bean plot show individual subject values. The bold black horizontal line
depicts the median value. T-test comparing values at London to Namche Bazaar
was 0.70.
Page 226
5.6. NEAR INFRARED SPECTROSCOPY
Figure 5.12: Right Frontal Cerebral Near Infrared Spectroscopy
The recording is for right frontal near infrared spectroscopy at three altitudes -
London (sea level), Kathmandu (1330 metres) and Namche Bazaar (3525 metres).
The y-axis depicts the tissue oxygen index value from near infrared spectroscopy.
The x-axis denotes the three sites where the recordings were performed. The bean
plot in yellow shows the distribution of the values. The red horizontal lines within
the beanplots shows individual subject values. The bold black horizontal line
depicts the median value.T-test comparing values at London to Namche Bazaar
was 0.54.
Although I am not presenting data on cerebral oxygen delivery, another member
of the YES2 team measured these by using transcranial doppler. She found no
correlation between the cerebral near infrared spectroscopy values and the cerebral
oxygen delivery measured with transcranial doppler.
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5.6.2 Variation in Oxygen Consumption - Near Infrared
Spectroscopy with a Vascular Occlusion Test Results
Near infrared spectroscopy with vascular occlusion test (NIRS VOT) was used
to assess the oxygen consumption both at sea level and at 3525 metres altitude.
Figure 5.13 shows a recording of NIRS VOT from one of the volunteer children
in London and at Namche Bazaar. The curve is made up of 4 sections - base-
line, downslope, upslope and recovery. The baseline is lower at Namche Bazaar
(red curve) compared to London. Also, the down slopes after the cu↵ inflation
(at about 300 seconds) seem di↵erent. I will analyse this using two techniques: a
multilevel model and functional data analysis.
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Figure 5.13: An Example of Change in the NIRS VOT Curve with Altitude
The blue curve was recorded at sea level (London) and the red curve was recorded
from the same child after ascent to high altitude (Namche Bazaar). Both curves
comprise of 4 sections: baseline, drop, upslope and recovery.
5.6.3 Multilevel Model
The NIRS VOT recordings at the two altitudes from the same participant are likely
to be more similar compared to that from other participants (matched pairs).
Hence, this data should be analysed in a multilevel model. In my model, the
individual participant is placed at level 2 and the recordings are nested within this
at level 1. (Figure 5.14)
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Figure 5.14: Multilevel Model
Organisation of the levels for analysis of YES2 NIRS VOT data
In the multilevel regression model, the tissue oxygen index (TOI) was the outcome
measure. The time variable of the four sections of the NIRS VOT curve was coded
as baseline, downslope, upslope and recovery (for ease we will call this ‘timecode’).
The fixed e↵ects co-variates were cardiac index, altitude, timecode and an inter-
action term between altitude and timecode. An interaction term was needed as
I hypothesised that the timecode would vary between the altitude. Altitude was
used as the random e↵ects co-variate. Table 5.3 gives the beta-coe cients for fixed
e↵ects, standard errors for the coe cient and statistical significance. Due to re-
strictions with R software employed, this multilevel model did not report p-values.
But the statistical significance can be extrapolated from the standard error values.
The coe cients for the downslope, upslope and recovery are normalised for base-
line section of the NIRS VOT curve. Similarly, the interaction term (altitude and
timecode) was normalised for (altitude x baseline).
Page 230
5.6. NEAR INFRARED SPECTROSCOPY
Table 5.3: Multi-level model results
Co-variate Coe cient Standard Statistically
error significant
Downslope - 10.56 0.95 Yes
Upslope - 1.40 0.88 No
Recovery 2.57 0.49 Yes
Altitude - 3.68 1.32 Yes
Cardiac index - 2.31 0.81 Yes
Downslope * Altitude 0.90 0.09 Yes
Upslope * Altitude 2.37 0.19 Yes
Recovery * Altitude 0.67 0.08 Yes
From the table 5.3, let us first look at the value of TOI during baseline. By
keeping every other co-variate the same and changing just the altitude (zero for
London and 1 for Namche), the model shows that baseline TOI falls by 3.68
(95%CI :  6.2; 1.1). In other words, there is a decrease in baseline TOI with
ascent to altitude (Namche - 3525 meters).
The TOI during downslope was analysed next. The downslope has a coe cient
of  10.56 (95%CI :  12.42; 8.7). Hence, as expected, TOI during downslope is
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lower at London (using value of 0 for altitude co-variate) by 10.56 points compared
to baseline. This is the overall downslope value.
To look at the di↵erence in downslope at Namche compared to London, we need to
look at the altitude value and its interaction with downslope. The sum of these two
coe cients gives us a value of  2.8. This means TOI during downslope (marker of
oxygen consumption) relative to baseline decreased on average by 2.8 units more
at Namche Bazaar compared to London. The interpretation of this decrease in
terms of absolute oxygen consumption value is di cult due the significant inter-
action between the TOI and time of recording.
To enable easy visual interpretation of results, predicted values were created from
the multilevel model and plotted (Figure 5.15). These show a wide confidence
interval within the 4 sections.
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Figure 5.15: Predicted Tissue Oxygen Index (TOI) Derived from Multilevel Model
The TOI values were calculated as 4 parts of the NIRS VOT curve. The val-
ues in red are those for sea level and blue represents values at Namche Bazaar.
The shaded circle and triangle denote mean values while the error bars represent
95% confidence intervals. There was statistically significant di↵erence between the
tissue oxygen index during downslope at sea level and Namche Bazaar.
The above analysis utilises summary values for the 4 timecodes. In order to use
all the data points from throughout the NIRS VOT recording of 13 minutes the
method of functional data analysis (FDA) was utilised.
5.7 Functional Data Analysis
Functional data are repeated measurements recorded as a function of a variable
(such as time). Functional data analysis uses non-parametric method to build
functional curves from the dataset using di↵erent basis functions. Notably, the
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whole dataset (each single measurement) is utilised for the analysis. [287].
For trajectory data like NIRS VOT, one option is to employ basis splines to create
functional curves. Basis splines are polynomial curve segments that are joined end
to end. Together they are able to mirror the eventual curve closely. The points
where the segments join are smooth. These are routinely used in all spline-based
analyses.
Functional data analysis (FDA) is a complex analytical tool for large datasets us-
ing basis splines. The reasons to use the functional data analysis (despite being
complex) were two fold:
1. To use all the data points in the NIRS VOT curve (about 1400 data points per
recording) instead of a summary measure that will end up with 4 values for the
four parts of the curve.
2. Functional data analysis (FDA) was suggested by several statisticians as the
best available technique to analyse my data.
Although a simpler method might give the same result, FDA makes the results ro-
bust. In addition, as part of my learning process during this PhD, my supervisors
specifically encouraged me to explore novel ways of analysing these data as part
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of an intended broad training in research methodology.
5.7.1 Method
The YES2 dataset consists of 2 recordings per child across the two altitudes (Lon-
don and Namche Bazaar). A total of 24 NIRS VOT curves were recorded from 12
healthy child volunteers.
The recording consists of data points at 0.5-second intervals. It is separated into
four sections: baseline, drop, upslope and recovery. Data starts at 0.5 seconds
and continues up to 675.5 seconds. This amounts to 1391 rows of data in each
recording for each child.
Baseline data was recorded for about 2.5 minutes. Blood pressure cu↵ was inflated
at 290.5 seconds. This was the transition from baseline to drop. The next change
in the recording was at cu↵ deflation at 458 seconds. The following section of the
recording included a rise in the tissue oxygen index (TOI) followed by normalisa-
tion.
The TOI data was converted into functional form by a two-step process. First was
to create basis splines. For this, I followed regular splines methodology. [288] The
FDA package in R has specific code for this process. The next step is to choose an
Page 235
5.7. FUNCTIONAL DATA ANALYSIS
appropriate linear combination of these splines to result in functional TOI value
[TOI (secs)]. The FDA package in R software was employed to automatically
choose the splines. The final result was a TOI value that could be calculated for
each time point for each recording using an equation. This process was repeated
for all the 12 patient curves at the two altitudes (24 final functional curves).
5.7.2 Results
Figures 5.16 and 5.17 display the functional NIRS VOT curves of all the children
in London and Namche Bazaar. These curves include the sections baseline, drop,
upslope and recovery as described in figure 5.13.
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Figure 5.16: Functional Data Analysis Curves of NIRS VOT in Children in London
The recording starts with a baseline section. This is followed by the downslope on
inflation of the blood pressure cu↵ at 290.5 seconds. The cu↵ is deflated at 458
secs causing the upslope. The final section is the recovery phase.
Figure 5.17: Functional Data Analysis Curves of NIRS VOT in Children in Namche
Bazaar
The recording starts with a baseline section. This is followed by the downslope on
inflation of the blood pressure cu↵ at 290.5 seconds. The cu↵ is deflated at 458
secs causing the upslope. The final section is the recovery phase.
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Comparison of NIRS VOT Recording Between Altitudes
The 12 individual subject data each produced a functional curve for each altitude
level (London and Namche). These were combined (average of each time point)
to plot a predicted average functional curve. This resulted in two curves (one
for London and one for Namche) (Figure 5.19). Next, by comparing the two
predicted curves I could compare the e↵ect of altitude on TOI over the whole
curve. Appendix 4 includes the R code and details of the statistical analysis.
While this technique has the advantage of comparing the whole curves of the group
at each altitude, there is a loss of information in the averaging procedure and not
matching of pairs that prompted a further approach.
Figure 5.18: Predicted Curve for London and Namche Bazaar
Blue curve - London, Green curve - Namche Bazaar, The predicted curves were
created by using all the functional curves for recordings in London and Namche
Bazaar
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Functional ANOVA
The next analysis was to compare all 12 individuals functional curves produced
for each of Namche and London (Figure 5.16 and Figure 5.17). These were as-
sessed as matched pairs. The technique of functional ANOVA was employed for
this analysis (point-by-point comparison of paired data).
The fundamental property of a functional curve is that each data point is rep-
resented as a function (function of time in my case). Therefore, when the two
matched curves (from London and Namche for each participant) are compared we
get a coe cient for each data point of the curve. Eventually I derived a mean
regression coe cient curve. The confidence intervals for this regression curve were
also calculated. (Figure 5.19)
Specific time values were then inputted into the final ANOVA model to derive
actual TOI values for various sections of the NIRS VOT curve (baseline, lowest
and drop TOI).
The forarm TOI was lower in Namche Bazaar compared to London. The baseline
TOI was significantly lower in Namche Bazaar than London (-4.05, 95%CI: -3.23,
-4.86, p <0.001). The lowest TOI was also significantly lower in Namche Bazaar
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(-1.95, 95%CI: -1.13, -2.76, p <0.001). The DropTOI at Namche Bazaar com-
pared to sea level was 2.1 points lower (p <0.0001). This suggests lower oxygen
consumption from forearm muscle at high altitude.
Figure 5.19: Functional ANOVA
Blue curve - mean regression curve, Red curve - upper confidence interval, Green
curve - lower confidence interval, Reg. Coe↵. - Mean coe cient generated by
comparing 12 matched pairs of functional curves between London and Namche.
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Figure 5.20: Healthy Volunteers and Investigators - Young Everest Study 2
The project was possible due to the support from the children and families who
volunteered for the study. (Figure 5.20)
5.8 Conclusions
This study confirms some of the findings from previous reports. To summarise the
findings reported in this chapter:
Peripheral haemoglobin oxygen saturations (at rest and after exercise) drop with
an ascent to altitude. Heart rate z-scores (at rest and after exercise) and cardiac
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index (at rest) do not show a statistically significant change. Respiratory rate (at
rest and after exercise) increases with an ascent to high altitude. These findings
support my first hypothesis that the physiological responses in children are similar
to adults when exposed to hypobaric hypoxic conditions.
Baseline forearm muscle tissue oxygen index (TOI) decreases with ascent to al-
titude. As the partial pressure of inspired oxygen drops with altitude, it is not
surprising that this decrease in baseline TOI was noted. It also correlates with the
drop in peripheral oxygen saturation. The drop in peripheral oxygen saturation
was clearly demonstrated in this study. The aim of the expedition was to expose
healthy children to hypobaric hypoxic conditions. Therefore, the right environ-
mental setting was achieved with this study.
Under normal conditions, oxygen delivery and consumption are uncoupled. [289]
When delivery becomes limited, the relationship may become linear. The full cal-
culation of the oxygen delivery is not possible with the parameters measured. Let
us assume that the duration at altitude was not long enough to cause a raise in
haematocrit. Consequently, the product of cardiac index and peripheral oxygen
saturation could be used as a surrogate marker for oxygen delivery (let us call
it ‘cardiacox’). As peripheral oxygen saturation drops with altitude and cardiac
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index remains the same, cardiaxox drops. Consequently, oxygen delivery does de-
crease under hypobaric hypoxic conditions, assuming haematocrit does not change.
Is this reduction enough to impact oxygen consumption?
To answer this question, I measured Drop TOI (forearm oxygen consumption).
Drop TOI decreases by 2.1 points at altitude compared to sea level in healthy
children. This might suggest a more e cient mitochondrial function. Interest-
ingly, adult lowlanders examined under the Xtreme Everest study did not show a
reduction in oxygen consumption at altitude. [265] This variation in results might
be due to a few reasons. First and foremost, I may be over interpreting the re-
sults from YES2 (with a small sample size and short duration at moderate high
altitude). Second, adults have relatively more subcutaneous fat and this might im-
pede accurate TOI measurement. Third, the adult study had a slightly di↵erent
placement of the NIRS probe (thenar compared to my lateral aspect of forearm
position). Fourth, they noted an increased rate of recovery suggesting a change in
vasomotor response at altitude. This could be due to age-related vascular changes
in adults. In addition, children have a higher sympathetic activity that might
mean they have an inherent increased vasomotor tone. A study in Sherpas has
suggested an more e cient mitochondrial function. [186] This might help explain
my YES2 Drop TOI results.
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Cerebral NIRS does not change with altitude on either side of the cerebral circu-
lation. In addition, nearly all children were able to complete the trek (one was
repatriated due to Salmonella gastroenteritis). These findings suggest that it is
safe for children of ages 8-16 years to trek to an altitude of 3525 metres. The
YES study noted a variation in both middle cerebral artery and anterior cerebral
artery blood flow with cerebral transcranial doppler measurements. [290] Another
member of the YES2 team has recorded these parameters. I intend to analyse
these with the cerebral NIRS values to look for correlations.
Heart rate z-score did not change with altitude. This result is di↵erent to the
previous reports from the YES study. [283] The obvious limitations of small num-
bers, short duration at altitude and moderate high altitude does not explain the
di↵erence in results as both studies have the same limitations. The only di↵erence
that could be significant is that Scrase et al presented absolute numbers whilst I
present z-scores. z-scores are a statistically validated method of presenting physi-
ological data.
The rise in respiratory rate might be in tandem with a need for increase in minute
ventilation for improving gas exchange at the lungs. I do not have blood gas values
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to investigate PaO2 and PCO2 values. These might have given added insight into
gas exchange and function of the respiratory system.
None of the children in my study showed any signs of high altitude pulmonary
edema or high altitude cerebral edema. This might be due to the gradual ascent
profile and the moderate high altitude reached. It would have been interesting to
investigate if any of these children carried the I-allele of ACE gene. Unfortunately,
I was unable to test this given the invasive nature of this test.
Limitations
The main aim of the study was to explore hypoxic adaptive mechanisms. However,
with a short duration of ascent and stay at altitude (5 days) it is unclear if the
long-term adaptive responses would have started to occur. A trek to a higher alti-
tude and a stay for several weeks would be ideal to investigate these mechanisms.
Unfortunately, safety risks restricted our expedition to become more pragmatic.
The aim of exposure to altitude was to reduce oxygen delivery. Although I did
not measure all the values needed for calculation of oxygen delivery, my surrogate
marker suggests a drop with ascent to altitude. Whether this drop was significant
enough to a↵ect the oxygen delivery-consumption relationship is unclear. The
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oxygen consumption does seem to reduce at altitude. However, there are several
limitations such as small number, short duration and moderate altitude that limit
the robustness of results. Therefore, to be certain of a change in the oxygen deliv-
ery - consumption relationship further research would be necessary.
Lower age groups (age 1-5 years) were not tested in this study. The aim was to
utilise the results from this study to understand the patho-physiology of the pae-
diatric intensive care patient. The majority of patients (about 80%) in UK PICUs
are less than 5 years of age. This considerably limits the potential extrapolation
of YES2 findings to the PICU population.
Another limitation of this study was the need to restrict testing to non-invasive
techniques. This led to utilising NIRS VOT that at best is only able to give a
snapshot view into regional (forearm muscle) oxygen consumption. With NIRS
VOT recording I was unable to measure dynamic changes in cardiac output. This
would have enabled a better understanding of the oxygen consumption-delivery
relationship.
The confidence intervals with cardiac index measurements shortened in the later
part of the expedition. This may be due to improvement in my technique and also
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because the children were aware of the position needed for e↵ective test results.
The small sample size makes it di cult to be certain if the cardiac index is in-
creasing with altitude or not.
Ambient and peripheral skin temperature can also have a major e↵ect on the NIRS
VOT measurements. [291] The room temperature setting of 20  C, for the Young
Everest Study 2, standardised the e↵ect of ambient room temperature.
Page 247
Chapter 6
Variation in Oxygen Consumption
During Paediatric Critical Illness
I have previously discussed the ability of humans to adapt to hypoxic conditions
and some of the mechanisms that may be involved in these adaptations. The
possibility that similar processes may be involved during evolving critical illnesses
in which oxygen delivery maybe abnormal was a key motivation behind the work
presented in this thesis.
In chapter 1, I described the methods that might be used to measure oxygen con-
sumption (section 1.5). The tissues from which oxygen consumption is routinely
measured were also detailed. Here, I describe the current understanding of oxygen
consumption - oxygen delivery relationship.
248
6.1. OXYGEN CONSUMPTION - OXYGEN DELIVERY
RELATIONSHIP
6.1 Oxygen Consumption - Oxygen Delivery Relationship
Critical illness challenges physiological mechanisms that balance oxygen delivery
and consumption. Initial studies in critically ill adults with acute respiratory dis-
tress syndrome reported a linear relationship between oxygen consumption (V O2)
and oxygen delivery (DO2). [292] [293] In other words, oxygen consumption was
limited by the supply of oxygen to tissues. Many potential mechanisms might
contribute to this relationship including macro and microvascular changes (altered
regional blood flow and an increased capillary density). [294] However, in adult pa-
tients without respiratory failure undergoing surgery the two variables were noted
to be independent above a critical threshold DO2 value. [295]
After the linear relationship between V O2 and DO2 was noted, e↵orts were di-
rected at optimising oxygen delivery in order to increase oxygen consumption.
These studies displayed mixed results. [296] Soon researchers realised that the
linear association was not true in all clinical scenarios. Only a proportion of
patients with lower than normal oxygen delivery were benefited by therapeutic
strategies that augment this parameter. Hanique et al demonstrated that the
delivery-consumption dependence was more likely to be a consequence of math-
ematical coupling. This association was only noticed when V O2 and DO2 were
calculated rather than being directly measured. [297] As discussed in chapter 1
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(section 1.6.1), oxygen delivery is calculated from the equation:
DO2 = CO x CaO2 measured in mls/min
where
CaO2 (arterial oxygen content) = (SaO2 x Hb x 1.39 + 0.0031 x PaO2) measured
in ml/dl,
SaO2 denotes haemoglobin oxygen saturation,
Hb denotes haemoglobin concentration,
PaO2 denotes partial pressure of arterial oxygen and oxygen consumption is cal-
culated by the equation:
V O2 = CO x AVD measured in mls/min
where
AVD (Arterial-Venous oxygen di↵erence) = CaO2 - CvO2 measured in mls/dl,
CvO2 = SvO2 x Hb x 1.39 + 0.0031 x PvO2 measured in mls/dl
The above equations show that oxygen delivery and oxygen consumption are de-
rived from shared variables. Therefore, the calculated variables co-vary. Cru-
cially when measured, rather than derived this relationship changes. [289] Sup-
ply dependent oxygen consumption has not been demonstrated in children and
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is now thought to be an exception rather than a typical state in adult critical
illness. [298] [299]
Tonsoni recently showed that V O2 and DO2 are independent in children during
extracorporeal membrane oxygenation (ECMO). [289] They manipulated the DO2
directly by alternatively decreasing and then increasing the flow rates by 25% from
the baseline on ECMO. The V O2 was measured using respiratory mass spectrom-
etry. From 11 patients, they demonstrated no change in V O2 between the baseline
values and those recorded after decreasing or increasing DO2 (P = 0.18). The
caveat to note is that these children were already fully resuscitated.
Therefore the current view is that while in a steady state, V O2 and DO2 are in-
dependent at the whole body level. However, in-vitro studies with hepatocytes
have reported a decrease in oxygen consumption with a reduction in oxygen sup-
ply. [300] De Backer observed a similar linear correlation between V O2 and DO2
in the hepato-splanchnic circulation in a subgroup of 42 septic patients. This sug-
gests that regional oxygen delivery dependent oxygen consumption might exist in
some clinical scenarios and perhaps in some organs. [301]
The recognition that V O2 and DO2 are uncoupled at the whole body level has led
to a shift in management aims. The focus has turned to the measurement of oxy-
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gen consumption rather than manipulating delivery. As was mentioned earlier in
section 1.5, the oxygen consumption may be measured by invasive or non-invasive
techniques. The serum lactate, mixed venous saturation and veno-arterial PCO2
di↵erence from blood may be employed as surrogate markers of whole body oxygen
consumption. [302] [303] Further, regional oxygen consumption can be measured
from blood cell components and tissues such as muscle and skin using a technique
that has evolved from the initial Clarke oxygen electrode. [76] [78] In chapter 3,
it was shown that near infrared spectroscopy with a vascular occlusion test may
have some utility as a surrogate marker of regional (forearm) oxygen consumption.
Although there have been advances in techniques that measure oxygen consump-
tion, clinicians still primarily employ peripheral oxygen saturation as a target to
deliver resuscitation and further management in the critically ill patient. In me-
chanically ventilated patients a lower oxygen saturation threshold is usually set at
92%. However, an upper threshold is not routinely prescribed, and observational
studies suggest that upper thresholds are not adhered to even when set. [304] Clin-
icians seem to reduce the upper limit of oxygen saturation as the PaO2/FiO2 ratio
decreases in acute lung injury. This response might be attributed to the perceived
harm due to hyperoxia or an awareness of higher ventilator settings that might
contributor to lung injury. [17] A similar response has been noted in children with
acute respiratory distress syndrome. [305] My systematic review (chapter 3) does
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not clearly point towards harm due to hyperoxia. Hence, the correct oxygen satu-
ration range is still unclear. The impact of varying oxygen saturation, although not
noted as a mortality signal, might be apparent in the morbidity profile. Morbidity
has been suggested as a more relevant outcome measure compared to mortality in
the paediatric intensive care unit. [306] Recent consensus guidelines concur with
this recommendation. [307] The morbidity following critical illness is dependent on
the severity of organ failure. Furthermore, acute mitochondrial dysfunction may
contribute to multi-organ failure during critical illness. Let us now discuss the
evidence behind mitochondrial function in critical illness.
Although it is far from certain what exactly is the accepted signature of hypoxic
adaptation, I will discuss the most up to date understanding of this mechanism
next.
6.1.1 Lessons from Genetics
Numerous genetic studies have compared Tibetan highlanders and low landers
from across the world. Three genes - EPAS1, EGLN1 and PPARA are highly
expressed in Tibetans. [308] These modulate and are in turn controlled by the
hypoxia inducible factor system (HIF). As noted in chapter 1 (section 1.5.1), HIFs
are the key transcription factors regulating oxygen sensing and homeostasis in
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humans. Through the HIF pathway, these genes alter erythropoiesis, the oxygen
cascade and other metabolic processes. These genes may represent evolutionary
modifications in hypoxia-adapted humans. [309]
6.1.2 The HIF System and Mitochondrial Function
Activation of the HIF system is required for mitochondrial homeostasis. [310] Re-
ciprocally, mitochondrial oxygen consumption is necessary for the induction of
HIF system. [311] The HIF system modulates mitochondrial function under hy-
poxic condition by three main modes:
1. Stimulating energy production from glycolysis,
2. Suppressing the Krebs cycle and oxidative phosphorylation and
3. Reducing mitochondrial ROS production. [312]
Furthermore, HIF limits mitochondrial biogenesis. Consequently, mitochondrial
mass and oxygen consumption is reduced. These interactions result in a more
e cient energy production system that also protects the cell from hypoxic dam-
age. [313] How might this knowledge help manage the critically ill patient?
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6.1.3 Mitochondrial Function in Critical Illness
Critically ill adults seem to have an impaired utilisation of oxygen with decreased
production of ATP. Brealey et al observed reduced ATP concentration in skeletal
muscle of septic critically ill patients who died compared to controls (p=0.05) and
those who survived (p=0.0003). The reduced ATP concentration might suggest
mitochondrial dysfunction. [314] Recovery from this mitochondrial dysfunction
may be important for outcome.
Carre et al noted a positive correlation between survival and early activation of
mitochondrial biogenesis. [315] Activation of biogenesis suggests protein synthesis
and up-regulation of gene expression.
In a landmark paper, time-series gene expression profile was performed follow-
ing administration of a dose of endotoxin in 8 healthy volunteers. A transient
bioenergetics failure (decreased expression of oxidative phosphorylation genes -
OXPHOS) was demonstrated by using a genome-wide network analysis. [316] The
transient nature of the bioenergy failure is of particular interest to the intensivist.
An understanding of why this energy failure might be transient and the pathways
involved in its recovery could focus therapeutic interventions in the critically ill
patient.
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Weiss et al have investigated the theory of down regulation of mitochondrial gene
expression in the paediatric septic shock population. By employing gene expres-
sion analysis on data from 180 patients, they were able to demonstrate di↵erential
expression in 118 nuclear coded mitochondrial genes compared to controls. Of in-
terest to my project, the OXPHOS gene set was the most down regulated among
the panel. [317]
To summarize, critically ill patients have mitochondrial dysfunction probably sec-
ondary to down regulation of OXPHOS gene expression. Their survival seems to
be associated with the recovery of mitochondrial function. This recovery might be
modulated (positively adapted) by the hypoxia-sensitive HIF system. Let us now
look at the potential response to hypoxia in the critically ill patient.
6.1.4 How Might Hypoxic Adaptation Present in the Crit-
ically Ill Patient?
If the hypothesis of hypoxic adaptation were to be true, one might observe the
OXPHOS function to drop initially, stabilize, start to increase and plateau with
progression of critical illness. The eventual state might be of an augmented OX-
PHOS function in the context of relative lower oxygen-requirement state.
Page 256
6.1. OXYGEN CONSUMPTION - OXYGEN DELIVERY
RELATIONSHIP
Sjvall et al investigated the functional correlate of the change in OXPHOS gene
expression. They explored platelet mitochondrial function in septic patients and
healthy controls. The Oxidative phosphorylation system was interrogated at 3 time
points day 1/2, day 3/4 and day 6/7 with high-resolution respirometry. They
observed increased uncoupling by day 3/4. Interestingly, non-survivors demon-
strated significantly more uncoupling compared to survivors. [172] These findings
may concur with the hypoxic adaptation theory discussed above. The uncoupled
state is transient causing OXPHOS dysfunction. In patients who survive, this
state transitions into a steady stay and finally increased coupling. The result is
an improvement in OXPHOS function that is mandatory for survival. The Weiss
group has reported similar results in paediatric septic shock. [174]
This chapter describes my attempt to investigate changes in oxygen consumption
in critically-ill children with time.
Three techniques are included:
(1) Serial near infrared spectroscopy with a vascular occlusion test (NIRS VOT)
to assess in-vivo muscle oxygen consumption in critically ill children admitted to
paediatric intensive care (Study 1: The serial NIRS VOT study).
(2) Serial measurement of molecular oxygen consumption of peripheral blood
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mononuclear cells using a high resolution respirometer (Oroboros-2K analyser -
Study 2: The O2K study).
(3) Serial analysis of oxidative phosphorylation gene expression profiles of children
admitted with meningococcal sepsis using Gene Set Enrichment Analysis (GSEA)
(Study 3: The OXPHOS gene expression study).
6.2 Methods
Hypotheses:
1. Serial measurements of drop Tissue Oxygen Index (TOI) during the vascular
occlusion test will not alter during the time course of critical illness in children.
2. Serial measurements of peripheral blood mononuclear cell mitochondrial oxygen
consumption will not alter during the time course of critical illness in children.
3. Gene expression of oxidative phosphorylation genes will not change in the first
48 hours of paediatric critical illness.
6.2.1 Study Design:
Study 1: The serial NIRS VOT study
The serial NIRS VOT was a prospective observational study.
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Study 2: The O2K study
The O2K study was a prospective observational study.
Study 3: The OXPHOS gene expression study
The OXPHOS gene expression study was an in-silico analysis of previously col-
lected gene expression data by Dr Kwan and others.
6.2.2 Inclusion Criteria
Study 1: The serial NIRS VOT study
All children with critical illness admitted to the paediatric intensive care unit with
a diagnosis of systemic inflammatory response syndrome (SIRS) and expected to
be ventilated for >3 days were eligible.
SIRS was defined as a patient who has two or more of the following parameters:
1. Abnormal white cell count ( <4 or >12x109 per l)
2. Temperature instability (<36 or >38.5  C)
3. Tachycardia (mean heart rate >2 standard deviations above normal for age) or
bradycardia (mean heart rate <10th percentile for age) in children <1 yr old.
4. Mean respiratory rate >2 standard deviations above normal for age or mechan-
ical ventilation for an acute process. [318]
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The ideal population to study would be those with problems with oxygenation.
There were four main reasons to choose children with SIRS for this preliminary
study. They were:
1. Systemic inflammatory response syndrome is the underlying process for most of
the causes of admission to intensive care. In addition, previous studies have shown
that the SIRS population can be considered a homogenous group for analysis. [319]
The children with oxygenation problems could be expected to have an exaggerated
response compared to those in the SIRS population.
2. The SIRS criteria could be used as a marker of severity of illness. Therefore,
these children would be expected to need comparatively longer duration of me-
chanical ventilatory / inotropic support. [318] This will enable longer data capture
for this study.
3. Nearly 60% of children admitted to the paediatric intensive care unit fit the
criteria for SIRS. [320] This lent a large patient cohort for recruitment.
4. SIRS patients may have more tissue hypoxia rather than alveolar hypoxia. This
would be ideal to the investigation of tissue oxygen consumption.
Study 2: The O2K study
All children admitted to the paediatric intensive care unit with a diagnosis of the
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systemic inflammatory response syndrome (defined as for study 1 above) with one
or more organ failure (defined as Paediatric logistic organ dysfunction 2 score  7)
were eligible for recruitment.
Study 3: The OXPHOS gene expression study
All children with a presumptive diagnosis of meningococcal sepsis admitted to
the paediatric intensive care unit in Nottingham university hospital were eligible.
Blood samples were collected, from 5 children with Meningococcal sepsis, at 6 time
points: 0, 4, 8, 12, 24, and 48 hours from dose of antibiotics. Details of the sample
preparation and analysis are published in the article by Kwan and include in the
appendix to this thesis. [321]
6.2.3 Exclusion Criteria
Study 1: The serial NIRS VOT study
1. Children who were not mechanically ventilated
2. Ex-premature infants (<30 wks gestation at birth)
3. Children with suspected mitochondrial/metabolic disease
Study 2: The O2K study
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1. Children with no invasive line for access
2. Children transferred from other intensive care units after a prolonged admission
3. Children with traumatic brain injury
4. Children with ethical issues in their management, such as withdrawal of inten-
sive care
5. Children with suspected mitochondrial disease
Paediatric Logistic Organ Dysfunction 2 score
The Paediatric Organ Dysfunction score (PELOD) is a descriptor of the severity
of multi-organ dysfunction. The PELOD score was not created to be a predictor
of mortality. The scoring system includes variables selected by a Delphi consen-
sus method. The alternative strategy of estimating organ dysfunction - PEdiatric
Multiple Organ Dysfunction (PEMOD) system included the probability of mor-
tality. However, the PEMOD system was unable to discriminate between patients
as well as the PELOD score. In addition, the use of a logistic regression analysis
enables the PELOD to di↵erentiate between the individual organ dysfunction and
the varying severity levels within each organ dysfunction system. [322] The score
was validated in 1806 patients’ data collected in a prospective observational co-
hort study conducted across 7 paediatric intensive care units. [323] The updated
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version of the PELOD score is the PELOD2. [324] It incorporates variables ac-
counting for each of the organ systems assessed. These are Glasgow Coma Scale
(GCS), pupillary reaction, Lactate level, mean arterial pressure, creatinine level,
PaO2/F iO2 ratio, PaCO2, ventilation status, white cell count and platelet count.
A daily estimation of PELOD score has been observed to be di↵erent between
survivors and non-survivors. [195] Therefore, the recently updated PELOD2 score
was used to objectively quantify the severity of illness in the recruited children in
both the serial NIRS VOT and O2K studies.
The GCS included in the scoring of PELOD2 is a composite measure. The vari-
ables that make up the GCS include eye opening, a motor and a verbal component.
Sedated and mechanically ventilated patients are non-verbal, may not be able to
open their eyes and may not be able to move (if heavily sedated or paralysed).
Hence, it is not possible to calculate the GCS in this patient population.
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Table 6.1: Paediatric Logistic Organ Dysfunction 2 score
Severity levels
Organ 0 1 2 3 4 5 6
dysfunction
GCS >11 5-10 3-4
Pupillary reaction Both re-
active
Both
fixed
Lactate (mmol/l) <5 5-11 >11
Mean arterial
pressure (mmHg)
0-1 month  46 31-45 17-30 16
1-11 months  55 39-54 25-38 24
12-23 months  60 44-59 31-43 30
24-59 months  62 46-61 32-44 31
60-143 months  65 49-64 36-48 35
 144 months  67 52-66 38-51 37
Creatinine
0-1 month 69  70
1-11 months 22  23
12-23 months 34  35
24-59 months 50  51
60-143 months 58  59
 144 months 92  93
PaO2/FiO2 ratio  61 60
PaCO2 mmHg 58 59-94  95
Invasive ventilation No Yes
White cell count >2 2
Platelet count  142 77-141 76
Legend: Reproduced from the article by Leteurtre. [324], GCS - Glasgow Coma
Scale, PaO2 - arterial partial pressure of oxygen, FiO2 - fraction of inspired oxy-
gen, PaCO2 - arterial partial pressure of carbon dioxide, creatine measured in
micromol/l, white cell count and platelets measured in x 109/l Page 264
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The diagnosis and physiological parameters such as heart rate, blood pressure and
oxygen saturation were collected. For the serial NIRS VOT and O2K studies,
the durations of illness for the patients varied. I was unable to account for these
variations just from the history. Therefore, a pragmatic time code was employed.
‘Day 0’ was defined as the period from admission to the paediatric intensive care
unit to midnight of that day.
Research and Ethics approval
These three studies each obtained formal research ethical and local research gov-
ernance approvals. The serial NIRS VOT and O2K studies were approved in a
combined application (NRES-Hampstead -14/LO/1819). The approvals for the
gene expression study were obtained by Dr Rashid from Queens Medical Centre
PICU, Nottingham University committee (REC reference - 05/Q2403/53). Signed
informed consent was obtained from a parent or guardian for each child included
in these studies.
The ethics application for the serial NIRS VOT and O2K studies included a sta-
tistical analysis plan acknowledging the limited information on which power cal-
culation and sample size estimates could be made with these novel studies.
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Tests performed in the studies
Study 1: The serial NIRS VOT study
Near infrared spectroscopy with a vascular occlusion test (NIRS VOT) was per-
formed daily to measure the forearm muscle oxygen consumption (recorded as
the drop in tissue oxygen index Drop TOI, detailed description in chapter 2.1).
The cardiac index was measured using the suprasternal ultrasound cardiac output
monitor (USCOM - chapter 2.2).
Study 2: The O2K study
Near infrared spectroscopy with a vascular occlusion test (NIRS VOT) was per-
formed daily to measure the forearm muscle oxygen consumption (recorded as
the drop in tissue oxygen index Drop TOI, detailed description in chapter 2.1).
Daily analysis of peripheral blood mononuclear cells oxygen consumption using
the Oroboros analyser was performed. The cardiac index was measured using the
suprasternal ultrasound cardiac output monitor (USCOM - chapter 2.2).
I ascertained that the recruits were clinically stable (after discussion with treating
medical and nursing team) during the NIRS VOT measurements (both study 1
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and 2) and blood sampling (O2K study). This ensured that there were no changes
in infusions of vasoactive agents, no fluid boluses administered and no changes in
ventilatory parameters whilst the tests were performed.
Oxygen delivery
The oxygen delivery was estimated by the equation:
DO2I = CI ⇥ CaO2 (6.1)
where
CI denotes cardiac index (measured using USCOM) and
CaO2 denotes oxygen content of arterial blood measured in mls of O2/decilitre.
The arterial oxygen content was calculated by the equation:
CaO2 = (1.36⇥Hb⇥ SaO2) + (0.0031⇥ PaO2) (6.2)
where
Hb denotes haemoglobin measured in grams/decilitre,
SaO2 denotes saturations from arterial blood gas measured as percentage,
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PaO2 denotes arterial partial pressure of oxygen measured in mmHg and
Haemoglobin concentration, SaO2 and PaO2 were recorded prospectively with
each recording of the NIRS VOT to enable the oxygen delivery calculation.
Power calculation
Study 1: The serial NIRS VOT study
A comparison of two means with two samples and two-sided equality formula was
employed for the sample size calculation. The power was set at 80% and alpha
error was set at 5%. The mean and standard deviation for sample A was chosen
from NIRS VOT measurements in healthy children at sea level (mean: 21.1, SD:
7.09, from the YES2 study). The mean for sample B was empirically chosen as
a reduction of 25% from healthy controls. This was thought to be a clinically
relevant change in oxygen consumption. Around 22 patients were needed for this
study. This is necessarily an approximation because of the novel nature of this
work meaning that prior estimates of likely changes in NIRS VOT could not be
known in advance nor could the variance of these values. A further limitation is
that this estimation ignores the complexity of a time series dataset.
Study 2: The O2K study
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A formal power calculation was di cult as the variability of oxygen consumption
measurement from the O2K analysis in critically ill children was unknown. Weiss
et al have analysed oxygen consumption in peripheral blood mononuclear cells in
critically ill children on day 1-2 and day 6-7 after admission. [174] If I were to
achieve the same percentage change of oxygen consumption as in their report with
a power of 80% and alpha set at 5%; I will need 3 patients for a pairwise com-
parison of day 1 to day 5. As it was unclear if peripheral blood mononuclear cell
extraction would be successful in all patients, I set out to recruit 10 patients.
Study 3: The OXPHOS gene expression study
This study was an in-silico analysis of the dataset from Dr Kwan’s study. [321]
The data from 5 patients’ gene expression was available for analysis.
6.3 Statistical Analysis
The admission baseline characteristics and clinical information are presented as
summary statistics (median with interquartile range or absolute number with per-
centages) for both the serial NIRS VOT study and O2K study.
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6.3.1 Study 1: The Serial NIRS VOT Study
These data were analysed as follows:
1. Univariate distribution of the summary variable DropTOI was compared with
age, sex, weight, day of illness, diagnosis, PELOD2 score, baseline Tissue Oxygen
Index (TOI), cardiac index, CaO2, haemoglobin, PaO2, SaO2, DO2I and status
at discharge.
2. A multilevel linear regression model was employed to analyse DropTOI. The
DropTOI, as the outcome measure, was nested within individual patients. The
co-variates with a statistically significant univariate relationship were included in
the model. The results are presented as individual non-standardised coe cients
with confidence intervals.
3. Multilevel functional data analysis (FDA) was employed by using the whole
curve of NIRS VOT. The NIRS VOT curve has data points recorded at frequency
of 2 per second. However, this high resolution imparts considerable roughness to
the curve. In addition, the curve has 4 phases with di↵erent slopes. The FDA
technique is able to account for all the above unique issues. First, it utillises
all the individual data points. Therefore, there is no loss of data. This would
have been inevitable if I had used a summary measure. Second, the roughness
of the individual curves is counteracted by incorporating a smoothing constant.
Finally, the varying slopes are accounted for by using a spline based approach.
Page 270
6.3. STATISTICAL ANALYSIS
The FDA has found major applications in studies involving brain imaging such as
the study of white matter structures in multiple sclerosis and the geometry of cere-
bral aneurysms. [325] Further details of the code used are included as an appendix.
Functional data analysis of the NIRS VOT curves
Functional data analysis as detailed in section 5.6 was employed. To model the
NIRS VOT functional curves, a cubic spline of the 4th order was employed. A
total of 20 basis splines were created with interior breaks (16) at specific points.
The NIRS VOT recordings consisted of data points at 0.5-second intervals. It is
separated into four sections: baseline, drop, upslope and recovery. Data started
at 0.5 seconds and continued up to 697.5 seconds. This amounted to 1395 rows of
data in each recording for each child. The baseline data was recorded for about
2.5 minutes. The blood pressure cu↵ was inflated at 302.5 seconds. This was the
transition from baseline to drop. The next change in the recording was at cu↵
deflation at 461.5 seconds. The following section of the recording included a rise
in the tissue oxygen index (TOI) followed by normalisation.
6.3.2 Study 2: The O2K Study
Admission age, weight and cardiac index are presented as summary statistics. This
is as median with interquartile range if not normally distributed. PELOD2 scores
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have been reported as a range.
The variables that are relevant for the power of the study are:
1. The wide variety of underlying diagnoses and associated clinical severity of
recruits.
2. The comparison of NIRS VOT and O2k analysis was attempted with the Bland-
Altman method for limits of agreement. But the variability of oxygen consumption
measurement from O2K in this population is unknown. Further, oxygen consump-
tion measured from di↵erent tissues makes the Bland-Altman method inappropri-
ate.
The measurements I made from the O2K experiments are leak control ratio (LCR),
net routine control ratio (NetRCR) and coupling e ciency. As detailed in chapter
2 (section 2.3), LCR is the ratio of LEAK respiration and ETS capacity, NetRCR
is the oxygen consumption due to phosphorylation after normalising for leak respi-
ration and coupling e ciency is the amount of coupling occurring when normalised
for leak respiration.
The change of netRCR and LCR with duration of illness was analysed as a multi-
level model. The NetRCR and LCR were outcome variables and day of illness was
the fixed e↵ect co-variate while the patient was set at level 2. Analysis of variance
of normalised NetRCR, LCR and coupling e ciency to DropTOI was employed to
investigate the relationship between O2K data and NIRS VOT measurements. To
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normalise NetRCR, LCR and coupling e ciency, values were divided by the first
recorded measurement for the patient.
6.3.3 Study 3: Gene Set Enrichment Analysis for OX-
PHOS Gene Expression Study
The time-course of the OXPHOS gene expression in peripheral blood was ex-
plored with Gene Set Enrichment Analysis (GSEA, Broad institute, MIT), at 0,
4, 8, 12, 24, and 48 hours from time of dose of antibiotics in the emergency de-
partment. [326] Extracted RNA was hybridised in A↵ymetrix microarrays by Dr
Kwan. Methodological details are published in her article. [321] The dataset is
available to download from the European Bioinformatics Institute database (Ar-
rayExpress id: E-MEXP-3850). The blood sampled in the emergency department
was assigned as time 0. This was a realistic reference point, but it was noted
that children may have been unwell for varying periods before presentation to the
emergency department.
This technique was chosen, as it is the ideal technique for analysing time series
data. The GSEA ranks gene expression data according to a predetermined class
file. It looks for the distribution of a curated gene set (with close functional ac-
tivity) in this ranked list. The report consists of the correlation to the class file
and orders gene sets according to their Normalised Enrichment Score (NES - nor-
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malised for the length of gene set), nominal p-value, and False Discovery Rate
(FDR).
Continuous phenotype class file
As the gene expression profile was a time series data, a continuous phenotype label
with a decreasing profile was employed. The class file utilised for the analysis was
in the following 3 line code:
#numeric
#LineralyDecreasingProfile
48 44 40 36 24 0 48 44 40 36 24 0 48 44 40 36 24 0 48 40 36 24 0 48 44 40 36 24 0
The linearly decreasing profile code denotes the time points at which the gene ex-
pression profile was measured. As the blood samples were collected at 0,4,8,12,24
and 48, an inverse of this was employed for the decreasing profile. The recurring
numbers are for the 5 di↵erent patients. The code was written as per the rules set
by GSEA. [326]
Gene set file
The publically accessible curated C2 gene sets from version 4 of the molecular
signature database (MSigDb) were utilised as the gene set file. [326] A total of
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3655 gene sets (includes 20693 genes) were used in this analysis. The expression
profile of Reactome tricarboxylic acid cycle and respiratory electron transport
chain (RETC) gene set was investigated. This dataset contains 70 genes. The full
list of the genes included in this dataset is in appendix 3.
6.4 Results
6.4.1 The Serial NIRS VOT Study
Ninety-four NIRS VOT measurements were undertaken in 35 children accounting
for 94 recordings. Eighty-two percent (29/35) of the children survived to intensive
care unit discharge. Just over half the children recruited were admitted with sepsis
(51.4%). The Figure 6.1 below notes the timing and the number of repeats for
each patient.
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Figure 6.1: Timing and number of repeats of NIRS VOT
A GCS of 3 was used for all patients in my study cohort as they were all sedated
and mechanically ventilated. This gave a baseline score of 4 for all patients. For
example, patient 101 (serial NIRS VOT study) was assessed on ‘day 1’. Table 6.2
illustrates the calculation of the PELOD2 score from individual variables.
Page 276
6.4. RESULTS
Table 6.2: An illustrative example of a calculation of the Paediatric Logistic Organ
Dysfunction 2 score
Characteristic Patient’s value Score
GCS 3 4
Pupillary reaction Bilaterally equal and reac-
tive
0
Lactate 2 (< 5) 0
Mean arterial pressure 77 mmHg (>cuto↵ 3) 0
Creatinine 22 (<cuto↵ 1) 0
PaO2/F iO2 ratio 325 (>60) 0
PaCO2 41.8 mmHg (<58) 0
Invasive ventilation Yes 3
White cell count 8.35 (>2) 0
Platelet count 205 (>142) 0
Total score 7
Key: PELOD2 - Paediatric Logistic Organ Dysfunction 2 score, GCS - Glasgow
Coma Scale, PaO2 - Arterial partial pressure of oxygen, FiO2 - fraction of inspired
oxygen, PaCO2 - Arterial partial pressure of carbon dioxide
The PELOD2 score ranged from 7-16 (Figure 6.2). Baseline characteristics and
clinical information are presented in table 6.3.
Page 277
6.4. RESULTS
Table 6.3: Details of children recruited to serial near infrared spectroscopy with a
vascular occlusion test study
Characteristic Value, n = 35
Age (months) 49.2 (IQR:14.5-110)
Weight (Kgs) 15 (IQR:10-28.5)
Cardiac index
(L/min/m2)
5 (IQR:4-5.7)
Sex
Male 19 (54.2%)
Female 16 (45.8%)
Diagnosis
Post-surgical 5 (14.2%)
Respiratory 8 (22.8%)
Cardiac 1 (2.8%)
Sepsis 18 (51.4%)
Others 3 (8.5%)
PELOD2 (range) 7-16
Alive at ICU discharge 29 (82.8%)
Legend: Characteristics are presented as median with interquartile range (IQR) or
absolute number with percentages. PELOD2 - Pediatric logistic organ dysfunction
score 2, ICU - Intensive care unit. PELOD2 was calculated at each point of near
infrared spectroscopy with a vascular occlusion test recording.
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Figure 6.2: Distribution of Pediatric Logistic Organ Dysfunction 2 score
(PELOD2) in the First 5 days of Illness
Box plot of the variation in the PELOD2 score. The bold horizontal line within
the box plots represents median values. The box represents the interquartile range.
The error bars denote the range of values.
The observed median Drop TOI was 21.1 (IQR: 15.6-23.8) on day 0 of illness. This
decreased to 17.6 on day 2 (IQR: 14.1-20.0) and increased again on day 4 to 19.8
(15.2-23.3).(Table 6.4, figure 6.3 and 6.4)
Page 279
6.4. RESULTS
Table 6.4: Median Tissue Oxygen Index values during the first 5 days of critical
illness
Day of illness Baseline TOI Drop TOI
Day 0 70.9 (65.7-75.6) 21.1 (15.6-23.8)
Day 1 74.9 (71.9-78.6) 18.1 (15.8-24.2)
Day 2 73.0 (68.5-78.9) 17.6 (14.1-20.0)
Day 3 76.9(73.2-81.0) 18.4 (17.0-19.6)
Day 4 74.2 (71.7-80.7) 19.8 (15.2-23.3)
Legend: TOI - Tissue Oxygen Index, DropTOI was calculated as the di↵erence
between average baseline TOI and the lowest TOI. Characteristics are presented
as median with interquartile ranges in brackets.
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Figure 6.3: Variation in Baseline Tissue Oxygen Index in the First 5 days of
Critical Illness
Serial baseline tissue oxygen index as measured by NIRS VOT. Blue line repre-
sents the mean baseline TOI. The red dashed line with triangles denotes upper
confidence interval while the red dashed line with squares denotes lower confidence
interval.
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Figure 6.4: Variation in Drop Tissue Oxygen Index in the First 5 days of Critical
Illness
Serial drop tissue oxygen index as measured by NIRS VOT. Blue line represents
the mean drop TOI. The red dashed line with triangles denotes upper confidence
interval while the red dashed line with squares denotes lower confidence interval.
Univariate analysis
The Drop TOI was the outcome measure for the univariate analyses. Age, weight,
CaO2, haemoglobin, baseline TOI and status at discharge had a significant associ-
ation (Table 6.6). The day of illness, PELOD2 score, sex, diagnosis, cardiac index,
PaO2, SaO2 and DO2I did not have a statistically significant association. (Table
6.5)
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Table 6.5: Results of univariate analysis - DropTOI as outcome
Co-variate Coe cient Standard er-
ror
p value
Age (months) -0.02 0.01 0.03
Weight (Kgs) -0.09 0.05 0.05
CaO2 (ml/100ml) -0.01 0.003 0.0001
Haemoglobin (gm/dl) -1.13 0.31 0.0004
Baseline TOI -0.24 0.11 0.03
Alive at ICU discharge -7.43 1.94 0.0002
Key: CaO2 - Arterial oxygen content, ICU - Intensive care unit, TOI - Tissue
Oxygen Index
Multivariate analysis
The multilevel multivariate regression analysis displayed considerable variation in
drop TOI in the first 5 days of illness. The day of illness (despite no association on
univariate analysis) and variables that had an association on univariate analysis
were chosen as co-variates for fixed e↵ects in the final model. Weight was excluded
as it has a co-linear relationship with age. CaO2 was excluded. Only haemoglobin
showed an association in univariate analysis of the three variables that constitute
CaO2. Drop TOI might predict the status at discharge as demonstrated by the
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univariate analysis. But the relationship cannot be reversed. Therefore, this vari-
able was also excluded. The final model shows that only haemoglobin remained a
significant predictor of drop TOI (Table 6.6).
Table 6.6: Multilevel regression analysis - Drop TOI as outcome
Co-variate Beta-
coe cient
Std.err LCI UCI
Day 2 -0.30 1.37 -3.03 2.43
Day 3 -1.59 1.33 -4.27 1.05
Day 4 1.53 1.66 -1.75 4.87
Day 5 0.48 1.63 -2.80 3.72
Age (months) -0.02 0.01 -0.05 0.008
Haemoglobin -0.63 0.21 -1.07 -0.20
Baseline TOI -0.08 0.09 -0.26 0.10
Key: Multilevel model with Drop Tissue Oxygen Index (TOI) as the outcome
measure. The co-variates - day of illness, age, haemoglobin and baseline TOI
- were nested within individuals, LCI - Lower confidence interval, UCI - Upper
confidence interval.
Oxygen delivery and consumption
The cardiac index did not vary during the first 5 days of illness. The USCOM
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estimate of oxygen delivery also remained stable (Figure 6.5).
Figure 6.5: Variation in the mean USCOM estimate of oxygen delivery in the first
5 days of critical illness
The Ultrasound Cardiac Output Monitor (USCOM) estimate of oxygen delivery
was calculated for all patients just prior to the near infrared spectroscopy vascular
occlusion test and then the mean value represented as the blue line in the graph.
Cardiac index was measured by the ultrasound cardiac monitor. The blue line
represents the mean oxygen delivery. The Orange dotted lines represent upper
and lower 95% confidence intervals.
Oxygen consumption (Drop TOI) was plotted against oxygen delivery for the first
5 days of illness. The scatter plot suggests that there may not be an association
between the two variables. This concurs with the univariate analysis.(Figure 6.6)
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Figure 6.6: Relationship Between Drop Tissue Oxygen Index and Oxygen Delivery
The oxygen delivery was calculated for each patient for each recording of Drop
Tissue Oxygen Index (TOI) (surrogate for oxygen consumption). The blue colored
circles are values from day 0, orange circles are day 1 values, green circles are day
2 values, red circles are day 3 values and purple circles represent day 4 values.
Functional data analysis comparing NIRS VOT curves for each day of
illness
The TOI data was converted into functional form as detailed in chapter 5 (section
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5.7.1). The process was repeated for all the 94 patient NIRS VOT recordings in
the first 5 days of illness (94 final functional curves from 35 patients). (Figure 6.7)
The 94 functional curves were combined (average of each time point for each day
of illness) to plot predicted average functional curves. This resulted in five curves
(one for each day from 0 to 4). (Figure 6.8)
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Figure 6.7: Functional Data Analysis Curves of NIRS VOT in the First 5 days of
Illness
Functional curves from first 5 days of intensive care stay are presented in this plot.
The top panel shows curves on day 0 and 1. The middle panel depicts curves from
day 2 and 3. The lower panel depicts day 4 curves. The recording starts with
a baseline section. This is followed by the downslope on inflation of the blood
pressure cu↵ at 302.5 seconds. The cu↵ is deflated at 461.5 seconds causing the
upslope. The final section is the recovery phase.
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Figure 6.8: Average Curves for Each day of Illness Predicted Individual Functional
Curves
Yellow curve - Day 0, Green curve - Day 1, Blue curve - Day 2, Pink curve - Day 3,
Red curve - Day 4. The predicted curves were created by using all the functional
curves for recordings in the intensive care unit for the day of illness from 0 to 4.
The functional curves enabled the comparison of the patient NIRS VOT record-
ings in two ways. The first was with a multilevel functional regression analysis
and the second was with a functional ANOVA. The multilevel functional regres-
sion method was used in this dataset (not used in YES2) as there were several
missing data points for each individual patient as depicted in figure 6.1.
If a functional ANOVA had been employed, the predicted curves for days 1 to 4
would have been individually compared (whole curve) to day 0 curve. This was
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di↵erent to the YES2 data analysis due to missing data points. Of note, using the
predicted curves, rather than individual curves, would result in loss of information
(unmatched data). Therefore, the multilevel model with functional data was cho-
sen as the ideal analysis for this dataset.
Multilevel functional regression analysis - Tissue Oxygen Index vs Day
of illness
The individual functional curves generated (94) were utilised for the multilevel
regression model. The TOI was the outcome measure. The individual patient was
placed at level 2) similar to the YES2 data analysis under section 5.6.3. (Figure
6.9) The day of illness was the co-variate.
Figure 6.9: Multilevel Model for Serial NIRS VOT
Organisation of the levels for analysis of serial NIRS VOT data
From the final model, values for the sections of the NIRS VOT curve were calcu-
lated. The code used by the FDAmixed package to generate these values is detailed
in the appendix. The beta-coe cient for day of illness was  0.34 (95%CI: -1.37,
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0.69, p = 0.31). The table 6.7 enumerates the values. The first row shows the
baseline, lowest and drop TOI on day 0. The next four rows note the di↵erence in
TOI values compared to day 0.
The day of illness had no detectable influence on the shape of the whole NIRS VOT
curve. However, day of illness was associated with di↵erences in the observed drop
TOI with each of days 1-4 being significantly lower than on day 0 in the multiple
level regression analysis.The drop TOI was calculated as the di↵erence between
the baseline TOI and the lowest TOI. The variation in drop TOI might suggest
that oxygen consumption changes during recovery from critical illness. Figure 6.11
was plotted to visualise this variation in drop TOI. No confidence interval has been
reported for the FDA generated drop TOI values. I was unable to calculate the
interval due to limitations of the software package employed in the R software.
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Table 6.7: Multilevel functional regression of the near infrared spectroscopy with
vascular occlusion test curve
Fixed e↵ect Baseline Lowest Drop p-value
TOI TOI TOI
(95%CI) (95%CI)
Day 0 70.88 50.89 19.99
Day 1 4.02 5.06 - 1.04 <0.0001
(3.70-4.33) (4.74-5.37)
Day 2 1.45 4.02 - 2.57 <0.0001
(1.13-1.76) (3.70-4.33)
Day 3 4.61 7.63 -3.02 <0.0001
(4.29-4.92) (7.31-7.94)
Day 4 4.63 5.56 -0.93 <0.0001
(4.31-4.94) (5.24-5.87)
Legend: Multilevel model with the whole near infrared spectroscopy curve as out-
come. The day of illness was included as the fixed e↵ect co-variate. The day of
illness was normalised for day 0. The values of the baseline Tissue Oxygen Index
(TOI) and lowest TOI for day 1 to day 4 are the di↵erence when compared to
day 0 values. The values in brackets denote 95% confidence interval. The drop
TOI value is the calculated di↵erence between baseline TOI and lowest TOI. No
confidence interval has been shown for drop TOI due to inability to calculate the
interval with a restriction within the R software.
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Figure 6.10: Functional Data Analysis Derived Relationship Between Oxygen Con-
sumption and Day of Illness
Functional data analysis (FDA) was employed to calculate the change in oxygen
consumption. Functional curves were created for all 94 recordings of near infrared
spectroscopy with a vascular occlusion test. A multilevel FDA was used to compare
functional curves from each day of illness. The values of Drop Tissue Oxygen Index
(DropTOI) was calculated from the model and plotted against day of illness. No
confidence interval has been shown due to inability to calculate the interval with
a restriction within the R software.
Figure 6.11 shows the regression coe cient curves with upper and lower confidence
intervals estimated by the mutlilevel model. All 4 curves were statistically di↵erent
to day 0 curve as demonstrated in table 6.7.
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Figure 6.11: Functional Regression with Multilevel Model - Day 1-4 vs. Day 0
Regression coe cient generated with multilevel model comparing day 1-4 with
day 0. Blue curve - mean regression curve, Red curve - upper confidence interval,
Green curve - lower confidence interval
To summarize, FDA of NIRS VOT in critically ill children in the first 5 days
shows that forearm dropTOI decreases with duration of illness. Interestingly, the
drop TOI does not revert to day 0 values on day 4 (Figure 6.10). The normal
pre-admission / pre-illness drop TOI value for the ICU patients is not known.
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Therefore, it is unclear which if the two values if any - day 0 or day 4 drop TOI
are equal to normal. The only certain interpretation is that there is variability in
the drop TOI values with duration of illness.
6.4.2 The O2K study
The flowchart depicts the number of children recruited in the study.(Figure 6.12)
Data from 8 patients was used for the final analysis. The median age and weight
were 4.12 years and 15.5 kgs respectively. There were an equal number of boys and
girls in the group. A majority of the recruited children were admitted following
sepsis associated with systemic inflammatory response syndrome. (Table 6.8) The
Figure 6.13 notes the timing and number of repeats for each patient.
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Figure 6.12: Flowchart of Recruits in the O2K Study
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Figure 6.13: Timing and Number of Repeats of O2K Analysis
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Table 6.8: Details of children recruited to serial O2K study
Characteristic Value, n = 8
Age (years) 4.12 (IQR:1.26-7.47)
Weight (Kgs) 15.5 (IQR:10.0-22.7)
Cardiac index (L/min/m2) 3.9 (IQR:3.8-4.6)
Sex
Male 4 (50%)
Female 4 (50%)
Diagnosis
Respiratory 2 (25%)
Sepsis 6 (75%)
PELOD2 (range) 4-12
Alive at ICU discharge 7 (87.5%)
Legend: Characteristics are presented as median with interquartile range (IQR) or
absolute number with percentages. PELOD2 - Pediatric logistic organ dysfunction
score 2, ICU - Intensive care unit. PELOD2 was calculated with each episode of
blood draw for the O2K analysis.
PELOD2
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The median PELOD2 score decreased with duration of illness. (Figure 6.14) It
ranged between 4 and 12.
Figure 6.14: Distribution of Pediatric Logistic Organ Dysfunction 2 score
(PELOD2) in the First 5 days of Illness
Box plot of the variation in the PELOD2 score. The bold horizontal line within
the box plots represents median values. The box represents the interquartile range.
The error bars denote the range of values.
Raw O2K measurements
Table 6.9 shows summative raw measurements from the O2K experiments. The
values were measured in picomols.sec 1.10 6cells. There are two inherent prob-
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lems with these values. First, the measurements are not normalised for the individ-
ual patient. Second, the data were not normalised for the mitochondrial content,
as this variable was not measured. Consequently, the oxygen consumption might
seem to vary between the days and between the patients. Therefore, utilising the
crude measurements for the final analysis would not be ideal. Instead, I have
employed the parameters that are independent of mitochondrial number (the flux
control ratios). These were decreibed in detail in chapter 2 (section 2.3.3).
Table 6.9: The crude O2K measurements
IQR - Interquartile range, ETS - Electron Transport System capacity,
ROX - Residual oxygen consumption. The values were measured in
picomols.sec 1.10 6cells
Day Routine Leak ETS ROX
of illness respiration
(IQR)
respiration (IQR)
Day 0 3.7 (2.9-4.5) 1.4 (0.8-1.9) 4.1 (3.1-5.6) 0.5 (0.4-0.7)
Day 1 6.6 (4.8-7.9) 3.2 (1.2-5.9) 8.9 (7.6-9.6) 1.2 (0.2-3.0)
Day 2 9.9 (4.5-11.6) 7.6 (2.1-9.1) 12.9 (9.4-16.8) 4.9 (0.8-6.4)
Day 3 6.8 (4.7-10.5) 3.7 (0.9-8.3) 8.7 (8.1-12.6) 1.9 (0.3-4.9)
Day 4 15.8 (7.8-22.8) 11.1 (3.8-18.3) 20.3 (13.1-26.4) 6.8 (2.0-11.9)
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Flux Control Ratio results
Net Routine Control Ratio
The Net RCR dropped from day 0 to day 4. Figure 6.15 suggests that the drop
was more marked in the fist 24 hours of illness. The plot is a summative measure
and does not account for the multiple levels in the data. Therefore, a multilevel
model analysis was performed.
The association between Net RCR and day of illness was analysed in a multilevel
regression model. The Net RCR decreased by 0.06 units (95%CI: -0.09, -0.03) for
each additional day of illness compared to day 0 (Figure 6.11). Net RCR [(R-
L)/E] is the di↵erence between routine respiration (R) and leak respiration (L)
as a proportion of maximal stimulated respiration (E). The maximal stimulated
respiration is note expected to change during critical illness. Consequently, the
drop in Net RCR has to be either due to a decrease in routine respiration or an
increase in leak respiration. The decrease in routine respiration during recovery
from critical illness might be due to reduction in the basal metabolic rate and
conversion to a anabolic state. Net RCR might be artificially high on day 0 due to
excessive ATP demand. An increase in leak respiration is unlikely in this scenario
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as the LCR decreases as detailed later.
If hypoxic adaptation were to occur, then one would expect a rise in Net RCR.
Therefore, the Net RCR results do not seem to support the hypothesis of hypoxic
adaptation. But they suggest the patient may have reached a steady state by day
1. On inspection, the figure 6.15 shows that Net RCR drops until day 2 and then
starts to rise again. It is possible that the change in Net RCR is monotonic after
day 2. Irrespective of the type of change (monotonic or non-monotonic), this has
not been captured in the multilevel model. If the measurements were continued
for a longer duration, there may be an increase in Net RCR. However, within the
remit of this project I was unable to investigate this process.
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Figure 6.15: Variation of Net routine control ratio in peripheral blood mononuclear
cells estimated by the Oroboros analyser in the first 5 days of illness
Box plot of the variation in the net routine control ratio. The bold horizontal line
within the box plots represents mean values. The whiskers denote 95% confidence
intervals.
Leak Control Ratio
The Leak Control Ratio (LCR) plot may indicate an increase in value from day
0 to day 4. (Figure 6.16) Similar to the Net RCR plot, this utilised a summative
measure and does not account for the multiple levels in the data. Therefore, a
multilevel model analysis was performed.
The LCR dropped by 0.05 units (95%CI: -0.07, -0.03) for each additional day of
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illness. The LCR (L/E) is the leak respiration (L) as a proportion of the maxi-
mal stimulated oxygen consumption (E). This drop in LCR suggests decrease in
uncoupling and an increase in coupling state. Therefore, the electron transport
chain function may have become more e cient. This result is in keeping with the
hypothesis of hypoxic adaptation.
Figure 6.16: Variation of Leak Control Ratio in Peripheral Blood Mononuclear
Cells Estimated by the Oroboros Analyser in the First 5 days of Illness
Box plot of the variation in the leak control ratio. The bold horizontal line within
the box plots represents mean values. The error bars denote 95% confidence in-
tervals.
Coupling e ciency
Coupling e ciency [(E-L)/E] is the di↵erence between maximal stimulated oxygen
consumption (E) and leak respiration (L) as a proportion of maximal stimulated
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oxygen consumption (E). The mean coupling e ciency increased marginally from
day 0 to day 4. However, there were considerable individual variations and a wide
range of values (<0.1 to >0.9). (Figure 6.14 and 6.15) The results might suggest
that from day 0 to day 4 the amount of coupling increased. This supports the
hypothesis of hypoxic adaptation.
Figure 6.17: Coupling E ciency from O2K Analysis - Mean Values
The plot represents mean data for 8 children over the 5 days of analysis. The
coupling e ciency was calculated by subtracting the leak respiration from Electron
Transport System capacity (ETS) and dividing by ETS. It was normalised for the
first recording of the patient. The mean values were plotted with 95% upper and
lower confidence intervals.
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Figure 6.18: Coupling E ciency from O2K Analysis
The colors represent individual patient data. The coupling e ciency was calcu-
lated by subtracting the leak respiration from Electron Transport System capacity
(ETS) and dividing by ETS.
Times series comparison of O2k and NIRS VOT analysis
The NIRS VOT measurement of the recruits in the O2K study is detailed in table
6.10. The median DropTOI varies from day 0 to day 4.
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Table 6.10: Near infrared spectroscopy with a vascular occlusion test measure-
ments of the O2K study recruits
TOI - Tissue oxygen index, Median values with interquartile ranges are presented.
Day of illness Baseline TOI Lowest TOI Drop TOI
Day 0 64.5 (61.5-70.4) 45.1 (41.3-54.9) 15.1 (12.9-18.5)
Day 1 78.9 (73.6-80.6) 57.4 (45.9-61.8) 21.5 (17.9-27.9)
Day 2 75.0(69.2-77.4) 44.7 (40.3-57.5) 29.7 (14.5-32.7)
Day 3 71.0 (70.4-71.2) 52.4 (43.1-59.6) 17.8 (9.7-28.4)
Day 4 75.6 (72.4-79) 56.8 (53.7-62.1) 18.3 (14.6-20.6)
The comparison of the NIRS VOT measurements and the O2K results was per-
formed in two steps. First, a scatter plot of Drop TOI and Net RCR was created.
(Figure 6.19) This suggested that there was no correlation between the two values.
Next, Spearman correlation analysis was performed. In order to account for the
multiple data points for the same patient, flux control ratios were normalised for
the first value of the patient.
Following this, the Drop TOI was compared to all three flux control ratios. None
of the pairs demonstrated a correlation (Drop TOI with normalised Net RCR , p
=0.09; Drop TOI with normalised LCR, p = 0.7; Drop TOI with coupling e -
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ciency, p =0.9).
The interpretation of this analysis was that the two techniques assess di↵erent tis-
sues in di↵erent ways. Therefore, a comparison is not the ideal mode of analysis.
Figure 6.19: Scatter Plot of the Drop Tissue Oxygen Index (TOI) and net Routine
Control Ratio (net RCR)
The colours represent di↵erent patients.
6.4.3 The OXPHOS Gene Expression Study
The GSEA ranks changes in single gene expression. The focus was on the Reac-
tome TCA cycle and Respiratory Electron Transport Chain (RETC) genes within
the 3655 included gene sets.
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Figure 6.17 shows the heat map of the gene expression profile ordered as a time
series. On the group level analysis, with a False discovery rate (FDR) at <25%
and ranked according to their Normalised Enrichment Score (NES), 1920 out of
3655 gene sets showed a decreasing profile with time. The RETC set was ranked
75th of the 1920 gene sets.(Figure 6.18)
Figure 6.20: Heat map of the Gene Expression
Heat map of the gene expression profile over the first 48 hours measured at 6 time
points in 5 patients.
On the individual level analysis and FDR <25%, 3 patients had a highly ranked
fall in RETC set expression. Patient 1 showed a low correlation of RETC gene
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expression to a decreasing profile. This might be relevant as, unfortunately, this
child died. Atleast half of the gene sets of the RETC gene set had a positive corre-
lation with the class file (decreasing profile in my analysis) in all 5 patients.(Table
6.11)
Table 6.11: Normalised enrichment score, FDR and nominal p values for the RETC
gene set
NES - Normalised Enrichment Score, FDR - False Discovery Rate, RETC - Res-
piratory Electron Transport Chain gene set
Patient NES Nominal
p-value
FDR Position
of
RETC
Number with
positive corre-
lation
1 0.932 0.598 0.710 1648 2017
2 1.006 0.462 0.573 1610 2108
3 1.971 <0.001 0.008 124 1895
4 2.787 <0.001 0 51 1819
5 3.015 <0.001 0 5 2036
The GSEA team (Broad institute, MIT) helped with the analysis of these results.
I analysed the gene expression using GSEA and for external validation contacted
the Broad institute team. They independently analysed and concurred my results.
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Figure 6.21: Enrichment Plot of Respiratory Electron Transport Chain Gene Set
Gene Set Enrichment Analysis (GSEA) compares the variation in the gene ex-
pression in our overall dataset compared to a preselected gene set (Respiratory
Electron Transport Chain gene set) over the time course. The RETC geneset ex-
pression is downregulated more than would be expected by background variation
in expression. The top portion of the plot shows the running enrichment score
(ES) for the RETC gene set. The middle portion of the plot shows where the
members of the gene set appear in the ranked list of genes. The lower portion
of the plot shows the value of the ranking metric as you move down the list of
ranked genes. The ranking metric measures a genes correlation with a phenotype.
For my continuous phenotype (time series), a positive value indicates correlation
with the phenotype profile (decreasing profile). The table shows the Normalised
Enrichment Score (NES), False Discovery Rate (FDR) and nominal p values for
the RETC gene set.
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6.5 Conclusions
The oxygen consumption shows a pattern of variation similar to that described
in adults. [108] The V O2 is high on day 0 of admission to intensive care. By day
3, it has reached a nadir. Following this, V O2 increases. The levels reached on
day 4 are still lower than that on day 0. This may be in keeping with the pri-
mary hypothesis of my thesis i.e. hypoxic adaptation occurs during recovery from
critical illness. The variation in V O2 is unrelated to changes in DO2. As TOI
is calculated as a ratio of oxygenated to total haemoglobin, the association noted
between haemoglobin and DropTOI in the multilevel model is unsurprising.
The PELOD2 score drops from day 0 to day 4. There are two points to consider
here:
1. The decrease in PELOD2 score suggests recovery from critical illness. One
might hypothesise that the basal metabolic rate is also normalising during this
phase. How might this a↵ect the oxygen consumption from the peripheral blood
mononuclear cells? There are several confounders - such as mechanical ventilation,
drugs, feeds etc - that preclude a simple answer. But with a bigger sample size,
these could be accounted for and further interpretation might be possible.
2. If hypoxic adaptation were a mode of recovery from critical illness, then the phe-
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notype would be a drop in oxygen consumption as the PELOD2 score decreases.
As suggested earlier, a larger sample with regular measurements for each patient
might explain these issues.
The serial NIRS VOT findings have to be interpreted with caution as di↵erent
children were studied at di↵erent time points making this a potential confounder.
The NetRCR drops with increasing duration of illness. This suggests that the in-
creased ATP synthesis needed in the first 24 hours of illness might be normalising
by day 2. No firm conclusion can be drawn without further study with a larger
sample size. However, my study lends itself as proof of concept. It is feasible to
measure oxygen consumption from peripheral blood mononuclear cells in critically
ill children.
Mitochondrial function alters during critical illness, but the extent to which this
is adaptive or harmful is unclear. [314] Mitochondrial function changes and fatty
acid oxidation increases with protracted critical illness. This is in the presence of
insulin and glucose. [173] Recently, hypoxia has been used as therapy in mitochon-
drial disease in an animal model. [246] Reduced mitochondrial oxygen utilisation
and gene expression have been observed in established sepsis in adults and chil-
dren. [317] Following an intravenous administration of endotoxin dose, Calvano et
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al profiled gene expression in white blood cells in 8 adult volunteers at predeter-
mined time intervals. By using a genome-wide network analysis, they demonstrate
a transient bioenergetics failure in the white blood cells in these volunteers. [316]
My OXPHOS gene expression analysis concurs with these reports. The downreg-
ulation of OXPHOS genes fits with the theory of mitochondrial dysfunction in the
initial phase of critical illness. Unfortunately, I did not have the gene expression
profile for the later half of intensive care stay.
I hypothesise that perhaps the relative increase in drop TOI seen on day 5 might
be secondary to the upregulation of OXPHOS genes. However, only a more ex-
tended gene expression study will be able to investigate this theory further.
It is probably simplistic to correlate gene expression to oxygen consumption. In
addition, the clinical implication of my gene expression finding is di cult to ex-
trapolate from the small sample size. Notwithstanding, my study is suggestive of
decreased oxygen consumption in the first 48 hours of critical illness.
Limitations of O2k technique
The main limitation of the O2K project was its small sample size. This severely
restricts the ability to extrapolate findings. One of the strengths of the O2K anal-
yser is that it can measure oxygen consumption from permeabilized tissues. This is
also a limitation as there is an extrapolation of the measured oxygen consumption
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from cells to the whole body.
The L/E ratio can increase if ETS capacity reduces. The abnormalities in ETS
capacity can be investigated by comparing it to citrate synthase activity. I did
not undertake this part of the experiment and would like to include this analysis
in future work. [327]
Another parameter that can be a limitation is the vasomotor tone. The vasomotor
tone of the critically ill patient can be labile especially in the first 48 hours of
illness. This might create variation in oxygen delivery to the tissues. Further,
the e↵ect of intensive care management strategies such as mechanical ventilation,
use of inotropes, mode of nutrition, blood transfusion and fluid resuscitation may
have an e↵ect on the analysis. Mode of nutrition becomes relevant as blood glucose
concentration a↵ects oxygen consumption by mitochondria. [328]
There is no correlation between measures of oxygen consumption by NIRS VOT
and O2K. Even if there were to be an association, the relationship would need
to be analysed with caution as the measurements are from di↵erent tissues and
di↵erent techniques.
Limitations of NIRS VOT
Ambient and peripheral skin temperature can have a major e↵ect on the NIRS
VOT measurements. [291] I measured the temperature of the child in the intensive
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care at the time of the NIRS VOT recording. This value was then incorporated
into the regression model as one of the co-variates.
NIRO-NX 200 uses multichannel measurements to reduce regional variations in
skeletal muscle oxygenation. This is pertinent for the serial measures of TOI in
the intensive care patients. Despite the possibility of probe placement at di↵erent
sites, I have demonstrated reproducible and comparable TOI values.
6.5.1 Do my Results Support the Hypoxic Adaptation Hy-
pothesis?
With the serial NIRS VOT study, I have demonstrated that the oxygen consump-
tion from forearm muscle drops until day 3. Most importantly, day 4 values are
lower than day 0 values. This suggests reduced oxygen consumption that might
suggest a more e cient mitochondrial function. One hypothesis could be that mi-
tochondria are able to produce the required ATP with a lower amount of oxygen
consumption due to hypoxic adaptation.
The key result from the O2K study is the drop in leak control ratio with duration
of illness. This drop may be due to a decrease in uncoupled respiration in favour of
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a more coupled state. If this result were shown to be reproducible, then it would
support the hypothesis of hypoxic adaptation.
The OXPHOS gene expression study showed a decrease in gene expression up to
48 hours of onset of sepsis associated critical illness. This is one part of the story
for hypoxic adaptation. Ideally, gene expression profiles should be extended for
a longer duration to observe if there is normalisation of expression. Further, a
functional correlate is needed to assess recovery and relative level (compared to
healthy controls) of mitochondrial function.
In summary, my projects have provided some insights that are suggestive of hy-
poxic adaptation.
Page 317
Chapter 7
Conclusions and Future Plan
7.1 Cohort Study
From my national survey, it is evident that the oxygen delivery practices in paedi-
atric intensive care units in the UK vary widely. The retrospective observational
study showed that hypoxia is not a good predictor of outcome. Furthermore, there
is a ‘U’ shaped relationship between PaO2 and mortality in critically ill chidlren.
The systematic review shows that the evidence for harm with hyperoxia is equiv-
ocal.
My observational study also suggests that the coeficient of PaO2 in the hyperoxic
range in the paediatric index of mortality 2 model may not be accurate. I would
like to work with the national paediatric intensive care audit network (PCIANet)
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to explore this further in the future.
My study was on data from a single centre over a 10-year period. The PICANet
database holds data from all paediatric intensive care units across the UK from
November 2002 to present date. The first step would be to use the significantly
larger dataset to ascertain if the ’U’ shaped relationship I observed in my study
is reproducible. As a second step, I would like to investigate if this relationship
persists after case-mix adjustment and accounting for confounders. Finally, if step
one and two were successful, I would like to explore the possibility of changing the
FiO2/PaO2 coe cient in the PIM2 model. My theory is that there needs to be
three coe cients for FiO2/PaO2; one for the hypoxic range, one for the normoxic
range and one for the hyperoxic range. This I believe will make the PIM2 model
robust. To achieve this, I will need the statistical support and expertise of the
PICANet team.
7.2 Children with Suspected Mitochondrial Dis-
ease
Children with mitochondrial diseases are a heterogeneous group. In keeping with
this, the NIRS VOT does not show a clearcut threshold for diagnosis of this disease.
However, the real niche of the NIRS VOT technique is perhaps in the prognosis
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of the disease and as part of the outcome scale assessment tool. The utility in
monitoring response to treatment strategies such as riboflavin supplementation
needs further research. It would be prudent to validate the technique in another
clinic on children with suspected mitochondrial disease before their muscle biopsy.
Despite the limitations of the patient profile, NIRS VOT seems to be able to reflect
oxygen consumption from forearm muscle.
7.3 Young Everest Study 2
The YES2 study suggests that it might be safe for children between 8-16 years to
trek to an altitude of 3500 metres with a gradual ascent profile. The forearm oxy-
gen consumption did not show a statistically significant di↵erence under hypobaric
hypoxic conditions when compared to sea level values. However, there seemed to
be a trend towards a decrease. This finding needs to be repeated in another study.
Future work should include a larger sample size, longitudinal studies, additional
altitudes, younger age groups and comparisons of oxygen consumption of healthy
lowland children to indigenous Sherpa children. To further confirm my NIRS VOT
findings, I would like to compare the NIRS VOT results with V O2 max measure-
ments measured at both altitudes from a formal cardiovascular exercise testing.
Another member of the YES2 team has performed these tests. I would like to
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compare my results with her’s when they are available.
If invasive testing were possible, Oroboros-2k analysis of peripheral blood mononu-
clear cells and muscle fibres might allow better characterisation of the mitochon-
drial function in this population.
7.4 Children with Critical Illness
Critically ill children are a heterogeneous population. The etiology of admission to
the intensive care unit can be varied such as infection, trauma, and post-operative
recovery. However, the process of recovery once systemic inflammatory response
(SIRS) sets-in is probably similar for all children. Due to the limitations of NIRS
VOT, the sequential, parallel measurement of oxygen extraction with NIRS and
the Oxygraph-2K (O2K) analyser was performed. These two measurements cannot
be compared as they interrogate di↵erent tissues. However, the O2K experiments
showed that these were feasible in this population of critically ill children.
A larger dataset with a more varied patient profile may well help distinguish the
adaptive physiological response that occurs during resolution of critical illness.
The methods employed in my projects on critically ill children have shown favourable
results. Therefore, I would like to extend these studies as follows:
Page 321
7.4. CHILDREN WITH CRITICAL ILLNESS
1. Serial oxygen consumption The key would be to find a technique that gives
reproducible results. Although NIRS VOT seems promising, ideally I would like
to employ a method such as indirect colorimetry to measure serial oxygen con-
sumption. All patients admitted to PICU who are expected to be ventilated for
at least 48 hours would fit the inclusion criteria. The data should be captured
everyday until day 7 or until hospital discharge (which ever is longer).
In addition to this, I would measure the oxygen delivery continuously whilst the
oxygen consumption is measured. This will need a gold standard, dynamic cardiac
output monitor. The best available technique for this might be echocardiography.
Finally, a measure of reactive oxygen species levels is mandatory. This will ascer-
tain that hypoxic adaptation is not harmful to the patient in the short and long
term.
2. In tandem with whole body oxygen consumption, I want to measure consump-
tion from several tissues. The O2K is a good method to perform this investigation.
First, I want to perform oxygen consumption measurements from peripheral blood
mononuclear cells in cyanotic congenital heart disease children and matched acyan-
otic congenital heart disease children. This might highlight the duration of hypoxic
exposure needed for hypoxic adaptation to occur in critically ill patients.
Next, I would measure oxygen consumption from several tissues such as peripheral
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blood mononuclear cells, muscle fibres, skin and cardiac muscle (from those un-
dergoing cardiac surgery). This will answer two questions: a) How to account for
mitochondrial heterogeneity? and b) Is there a linear relationship between oxygen
delivery and consumption at the tissue level?
All the studies on O2k will need to have a measure of mitochondrial content (per-
haps a measure of Cardiolipin as a surrogate marker).
On the general PICU, I would like to recruit a larger sample of patients who maybe
ventilated for longer than 2 days.
3. To understand the pathophysiological basis of adaptation at the cellular level,
I would like to investigate the HIF pathways as part of future studies in critically
ill children.
4. The last part of the project would be to assess gene expression. I would focus
on EPAS1 and OXPHOS genes. The expression profile would need to be extended
to about 7 days.
Another project would be to review genes that are up regulated in hypoxia adapted
mammals. Following this, I would search for orthologues in human genome. Fi-
nally, I would focus on these genes on all patients admitted to the intensive care
unit. The aim would be to compare survivors and non-survivors to assess if these
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specific genes are di↵erently expressed.
A metobolomics approach has to be performed along with the gene expression
study to ensure we have link between the gene expression and its functional cor-
relate.
Leading on from this thesis, Prof Peters is due to start a feasibility study for a
randomised control trial (GOSH Charity grant). The OXY-PICU is a feasibility
study intended to inform a future randomised control trial of liberal vs. restrictive
oxygen target. It is set out to investigate if:
1. Oxygen saturation targets of 88-92% and  95% are achievable in PICU pa-
tients.
2. It is possible to recruit the required number of patients.
3. It is safe for children to remain in the lower oxygen saturation category.
My systematic review, cohort study and the national survey set up the background
for the OXY-PICU study. The review and cohort study demonstrated a U shaped
relationship between PaO2 and mortality. The survey established the variability
in oxygen administration across the PICUs in UK. In addition, it highlighted the
equipoise in oxygen saturation targets for critically ill children (section 3.6).
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Survey of oxygen targets used in
paediatric intensive care units
across the United Kingdom
Survey of oxygen targets used in paediatric intensive care units across the United
Kingdom We are an intensive care team working in Great Ormond Street Hospi-
tal, London, UK. Although there is some evidence on the detrimental e↵ects of
hyperoxia, we think there may be an equipoise on the accepted oxygen delivery
targets.
We would like to survey the prevelant practice across the ICUs. The survey should
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take no more than 5 minutes. Thank you for taking the time to fill out this survey.
A.1 Characteristics of ICU and respondent
1. How many admissions does your ICU have in a year?
a. < 500
b. 500 - 1000
c. 1000 - 1500
d. > 1500
2. Is your ICU a cardio-surgical center?
a. Yes
b. No
3. Is your ICU a neuro-surgical center?
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a. Yes
b. No
4. Age of respondent
a. 20 - 30 years
b. 31 - 40 years
c. 41 - 50 years
d. > 50 years
5. Grade of person filling the survey
a. Consultant
b. Senior nurse
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c. Junior nurse
d. Senior fellow
e. Junior fellow
6. Number of years of practice in intensive care
a. < 2 years
b. 2 - 5 years
c. 5 - 10 years
d. > 10 years
7. Do you have alarm targets on your oxygen saturation monitors?
a. Yes
b. No
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c. Do not know
8. Do you have an oxygen weaning protocol for mechanically ventilated patients
in your unit?
a. Yes
b. No
c. Do not know
A.2 Clinical scenario
A 1 year old male infant is mechanically ventilated. He has no premorbid condi-
tions.
R/S:
BIPAP/ASB: PIP = 28 cm H2O, PEEP = 6 cm H2O, ASB = 18 cm H2O, Rate
= 20 breaths per min, FiO2 = 0.8, Saturations (Pulse oxymetry) = 94%.
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CVS: HR = 125 beats per min, Art BP = 85/56 mm Hg, MBP = 66.
Neurology: Pupils - 3 mm, bilaterally equal and reactive, Morphine = 20 mcgs/kg/hr,
Midazolam = 2 mcgs/kg/min. Not paralysed.
Arterial blood gas: pH: 7.32, PCO2: 6.2, PaO2: 10, BE: -ve 4, Lactate: 1.5.
Cardiac output- 4.6 l/min.
PIM2 predicted risk of mortality: 8.8
He has been ventilated for 2 days.
9. What are your PaO2 targets for this patient?
a. < 8 kPa
b. 8.1 - 10 kPa
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c. 10.2 - 13 kPa
d. > 13 kPa
e. I do not follow PaO2 targets
10. Which combination of PaO2 and FiO2 targets would be more acceptable
to you if he was admitted with Acute respiratory distress syndrome? (You may
choose more than one combination)
Table A.1: Oxygen delivery in Acute respiratory distress syndrome
PaO2 < 8 kpa PaO2 = 8.1 to 10 kpa PaO2 = 10.1 to 13 kpa PaO2 > 13 kpa I do not follow PaO2 targets
FiO2= 0.21
FiO2 = 0.22 to 0.4
FiO2 = 0.41 to 0.6
FiO2 = 0.61 to 0.8
FiO2 = 0.81 to 1
I do not follow FiO2 targets
11. Which combination of PaO2 and FiO2 targets would be more acceptable to
you if he was admitted following a Traumatic brain injury? (You may choose more
than one combination)
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Table A.2: Oxygen delivery in Traumatic brain injury
PaO2 < 8 kpa PaO2 = 8.1 to 10 kpa PaO2 = 10.1 to 13 kpa PaO2 > 13 kpa I do not follow PaO2 targets
FiO2= 0.21
FiO2 = 0.22 to 0.4
FiO2 = 0.41 to 0.6
FiO2 = 0.61 to 0.8
FiO2 = 0.81 to 1
I do not follow FiO2 targets
12. Which combination of PaO2 and FiO2 targets would be more acceptable to
you if he was admitted
Post cardiac arrest? (You may choose more than one combination)
Table A.3: Oxygen delivery in Post cardiac arrest
PaO2 < 8 kpa PaO2 = 8.1 to 10 kpa PaO2 = 10.1 to 13 kpa PaO2 > 13 kpa I do not follow PaO2 targets
FiO2 = 0.21
FiO2 = 0.22 to 0.4
FiO2 = 0.41 to 0.6
FiO2 = 0.61 to 0.8
FiO2 = 0.81 to 1
I do not follow FiO2 targets
13. Which combination of PaO2 and FiO2 targets would be more acceptable
to you if he was admitted with Sepsis associated multi-organ failure? (You may
choose more than one combination)
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Table A.4: Oxygen delivery in Sepsis associated multi-organ failure
PaO2 < 8 kpa PaO2 = 8.1 to 10 kpa PaO2 = 10.1 to 13 kpa PaO2 > 13 kpa I do not follow PaO2 targets
FiO2= 0.21
FiO2 = 0.22 to 0.4
FiO2 = 0.41 to 0.6
FiO2 = 0.61 to 0.8
FiO2 = 0.81 to 1
I do not follow FiO2 targets
14. Which combination of PaO2 and FiO2 targets would be more acceptable to
you if he was admitted with Pulmonary hypertension? (You may choose more
than one combination)
Table A.5: Oxygen delivery in Pulmonary hypertension
PaO2 < 8 kpa PaO2 = 8.1 to 10 kpa PaO2 = 10.1 to 13 kpa PaO2 > 13 kpa I do not follow PaO2 targets
FiO2 = 0.21
FiO2 = 0.22 to 0.4
FiO2 = 0.41 to 0.6
FiO2 = 0.61 to 0.8
FiO2 = 0.81 to 1
I do not follow FiO2 targets
A.3 Further progress:
The child does not improve despite instituting and continuing intensive care for
24 hours. You have not been able to wean ventilation. The blood gases remain
similar to those on admission. There is no change in the CXR.
15. Would you consider lowering the PaO2 targets now?
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Table A.6: Amended PaO2 targets
Yes No I do not follow PaO2 targets
Acute respiratory distress syndrome
Traumatic brain injury
Sepsis associated multi-organ failure
Post cardiac arrest
Pulmonary hypertension
16. What FiO2 range would you accept to achieve your amended PaO2 targets?
a. 0.21
b. 0.21 - 0.4
c. 0.41 - 0. 6
d. 0.61 - 0.8
e. 0.81 - 1
Page 334
A.4. RANDOMISED CONTROL TRIAL:
f. I will not amend my PaO2 targets
g. I do not follow PaO2 targets
A.4 Randomised control trial:
17. Is it ethical to perform a RCT with tight arterial oxygenation in critically ill
children?
a. Yes
b. No
c. Maybe
d. Do not know
18. Do you believe that there is a need for a RCT aiming for tight arterial oxy-
genation?
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a. Yes
b. No
c. Maybe
d. Do not know
19. Comments
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Appendix B
Systematic review
B.1 MEDLINE search strategy
(”hypoxaemia”[All Fields] OR ”hypoxia”[All Fields] OR ”anoxia”[MeSH Terms]
OR ”Hyperoxia”[Mesh] OR ”anoxia”[All Fields] OR ”hypoxemia”[All Fields] OR
”hyperoxia”[All Fields] OR ”hyperoxaemia”[All Fields] OR ”hyperoxemia”[All
Fields]) AND (”mortality”[Subheading] OR ”mortality”[All Fields] OR ”morbid-
ity”[All Fields] OR ”morbidity”[MeSH Terms] OR ”survival”[All Fields] OR ”sur-
vival”[MeSH Terms]) NOT noninvasive[All Fields] NOT preterm[All Fields] NOT
(”surface-active agents”[Pharmacological Action] OR ”pulmonary surfactants”[Pharmacological
Action] OR ”surface-active agents” [MeSH Terms] OR (”surface-active”[All Fields]
AND ”agents”[All Fields]) OR ”surface-active agents”[All Fields] OR ”surfac-
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tant”[All Fields] OR ”pulmonary surfactants”[MeSH Terms] OR (”pulmonary”[All
Fields] AND ”surfactants”[All Fields]) OR ”pulmonary surfactants”[All Fields])
AND ((”1950/01/01”[PDAT] : ”2015/12/31”[PDAT]) AND ”humans”[MeSH Terms]
AND English[lang] AND (”infant”[MeSH Terms] OR ”child”[MeSH Terms] OR
”adolescent”[MeSH Terms] OR ”infant”[All Fields] AND ”newborn”[All Fields])
OR ”newborn infant”[All Fields] OR ”neonates”[All Fields]) AND ”humans”[MeSH
Terms] NOT (”hypoxic ischaemic encephalopathy”[All Fields] OR ”hypoxia-ischemia,
brain”[MeSH Terms] OR (”hypoxia-ischemia”[All Fields] AND ”brain”[All Fields])
OR ”brain hypoxia-ischemia” [All Fields] OR (”hypoxic”[All Fields] AND ”is-
chemic”[All Fields] AND ”encephalopathy”[All Fields]) OR ”hypoxic ischemic en-
cephalopathy”[All Fields]) NOT perinatal[All Fields] AND (”infant”[MeSH Terms]
OR ”child”[MeSH Terms] OR ”adolescent”[MeSH Terms]) AND (”infant”[MeSH
Terms] OR ”child”[MeSH Terms] OR ”adolescent”[MeSH Terms]) NOT (”adult”[MeSH
Terms] OR ”adult”[All Fields]) AND (”infant”[MeSH Terms] OR ”child”[MeSH
Terms] OR ”adolescent”[MeSH Terms]) NOT (”extracorporeal membrane oxy-
genation”[MeSH Terms] OR (”extracorporeal”[All Fields] AND ”membrane”[All
Fields] AND ”oxygenation”[All Fields]) OR ”extracorporeal membrane oxygena-
tion”[All Fields] OR ”ecmo”[All Fields]).
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B.2 EMBASE search strategy
Figure B.1: Snapshot of Embase search for the systematic review
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Figure B.2: Snapshot of Embase search for the systematic review
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Appendix C
Respiratory Electron Transport
Chain gene set
Figure C.1: Enrichment plot of Respiratory Electron Transport Chain gene set
Legend: RETC gene set1.
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Figure C.2: Enrichment plot of Respiratory Electron Transport Chain gene set
Legend: RETC gene set2.
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Figure C.3: Enrichment plot of Respiratory Electron Transport Chain gene set
Legend: RETC gene set3.
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Figure C.4: Enrichment plot of Respiratory Electron Transport Chain gene set
Legend: RETC gene set4.
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Appendix D
Functional data analysis of the
YES2 dataset
D.1 Fitting individual curve
D.1.1 a. Smoothing spline approach (lambda specifica-
tion, knots positioning, penalisation argument)
1. Data:
We have NIRS VOT curves from 12 children at two altitudes (London and Nam-
che). The range of our values will be:
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rangeval = c(0.5,675.5) (1)
All 24 records with Time as rows and IDs as di↵erent columns were collated to
create a CSV file. We use R software for this analysis. Changing the CSV file into
a matrix and removing the Time column from it creates a matrix (toimatrix).
2. Basis splines:
Sequence of Knots The Knotvec
A vector containing the time points where we want knots to be placed is created.
This vector starts at 0.5 and ends at 675.5. The breaks are at 290.5 and 458. We
will place knots at each observation time point. Consequently, we have a total of
1349 interior knots are placed.
Knotvec (breaks) = c(0.5,150, 290.5,290.5,290.5,375,458,458,458,475,500,525,550,575,600,625,650,675.5)
(2)
Order
Ours is a cubic spline, hence of degree 3 and order 4 (norder).
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Number of basis functions (nbasis) = Order + Number of interior knots
nbasis = 4 +16 = 20
Creating the basis system
basisspline = create.bspline.basis(rangeval, nbasis, norder, breaks)
basisspline = create.bspline.basis(c(0.5,675.5,15,4,knotvec) (3)
3. Creating functional curves for our data
R creates smoothing curve by using regression analysis.
smooth.basis(argvals, y, fdParobj, wtvec=rep(1, length(argvals)), fdnames=NULL)
toicurve = smooth.basis(Time, toimatrix, basisspline) (4)
toifd = toicurvefd
toiy2cmap = toicurvey2cmap
Page 348
D.1. FITTING INDIVIDUAL CURVE
Roughness penalty
Roughness penalty needs to added because the smoothing function creates a curve
that may be too smooth and overfitted to the data. To define roughness penalty,
we need to construct a functional parameter object. We need to define three pa-
rameters.
1. Basis object: In our case, this would be the basisspline we created earlier (equa-
tion 3).
2. The derivative of order m (or linear di↵erential operator) to be penalized: Order
2 in for our data.
3. A smoothing parameter (lambda): For now, we will set lambda at 0.1. We will
discuss this later.
So the equation becomes:
toifdPar = fdPar(basisspline, 2, 100.25) (5)
Now, we use the fdpar object in the equation 4 and change it to:
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toicurve = smooth.basis(Time, toimatrix, toifdPar) (6)
To create a functional data object from within this function, we use $fd.
toicurvefd = toicurve$fd
toicurveSSE = toicurve$SSE
toicurvedf = toicurve$df
toicurvey2cmap = toicurve$y2cmap
Choosing a smoothing parameter
A vector of generalized cross-validated measure (GCV) for Log10lambda values -18
to 9 was created. The lowest GCV was at 0.25.
Hence, was set at 100.25. This is the value used in equation (5). With the above
equations, the predicted curves for all 12 children at both the altitudes are pro-
duced.
Labelling functional data objects
We need three labels. A label for domain (Time), a label for replication dimension
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(Child) and a label for the range (Tissue oxygen index TOI)
fdnames = vector(”list”, 3)
fdnames[[1]] = ”Time (secs)”
fdnames[[2]] = ”Child”
fdnames[[3]] = ”Tissue oxygen index (TOI)”
Child = vector(”list”, 12)
Child[[1]] = ”ID1”
.
.
.
Child[[12]] = ”ID12”
D.1.2 Series of figures showing the original points and the
fitted curve with a measure of fit.
2. Estimate the e↵ect of altitude with FANOVA
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a. Coe cient function with its confidence intervals for the two places
I set the altitude as the exposure and compare the two altitudes. By considering
the fitted curves as a regression, we get coe cients for each of the curves (equation
7).
sample.coef = toifd$coef (7)
We have to augment the columns by one (equation 8).
sample.coef.aug = cbind(sample.coef,matrix(0,1353,1)) (8)
toi.aug = fd(sample.coef.aug, splinebasisall) (9)
predic.toi.aug = eval.fd(table1$Time,toi.aug) (10)
fRegressionaltitude = fRegress(toi.aug, altitudelist, betalist) (11)
The altitudelist is a vector of the two altitudes.
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coefnum = eval.fd(Time, betaestlistaltitude[[2]]$fd) (12)
Equation 12 gives us the coe cients for the two altitudes. At the lowest point of
TOI, it is 1.2957.
b. Predicted curves in the two altitudes
altitudefit = fRegressionaltitude$yhatfd (13)
c. Functional F test
F.resaltitude = Fperm.fd(toi.aug, altitudelist, betalist) (14)
Fstatisticsaltitude = F.resaltitude$Fobs (15)
The Fstatisticaltitude value is 19.97127.
ninetyfivethquartilealtitude = F.resaltitude$qval (16)
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The ninetyfivethquartilealtitude value is 0.2427882.
D.1.3 3. Functional Data Analysis with Mixed e↵ects
x = Time
y = table1a[,2]
for (i in 2:24)
y = c(y,table1a[,i+1])
test.frame = data.frame(y,x,id,sample,Sex, Altitude) (17)
Altitude0 = as.factor(table5$Altitude)
Sex0 = as.factor(table5$Sex)
sample0 = as.factor(c(1:12,1:12))
id0 = as.factor(1:24)
est = fdaLm(y—id0 Altitude0+Sex0—0+sample0,data=test.frame) (18)
est$betaHat
est$betaVar
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est$Ghat
est$uBLUP
plot(x,est$betaHat[,”Altitude01”])
matplot(x, cbind(est$betaHat[,”Altitude01”],
est$betaHat[,”Altitude01”] + 2*(sqrt(est$betaVar[2,2])),
est$betaHat[,”Altitude01”] - 2*(sqrt(est$betaVar[2,2]))), type=”l”,lty=c(1,4,4), xlab=”Time”,
ylab=”Reg.Coe↵.”)
summary(est) (19)
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Purpose.Administration of supplemental oxygen is common in paediatric intensive care.We explored the current practice of oxygen
administration using a case vignette in paediatric intensive care units (PICU) in the united kingdom. Methods.We conducted an
online survey of Paediatric Intensive Care Societymembers in the UK.The survey outlined a clinical scenario followed by questions
on oxygenation targets for 5 common diagnoses seen in critically ill children. Results. Fifty-three paediatric intensive care unit
members from 10 institutions completed the survey. In a child with moderate ventilatory requirements, 21 respondents (42%) did
not follow arterial partial pressure of oxygen (PaO2) targets. In acute respiratory distress syndrome, cardiac arrest, and sepsis, there
was a trend to aim for lower PaO2 as the fraction of inspired oxygen (FiO2) increased. Conversely, in traumatic brain injury and
pulmonary hypertension, respondents aimed for normal PaO2 even as the FiO2 increased. Conclusions. In this sample of clinicians
PaO2 targets were not commonly used. Clinicians target lower PaO2 as FiO2 increases in acute respiratory distress syndrome,
cardiac arrest, and sepsis whilst targeting normal range irrespective of FiO2 in traumatic brain injury and pulmonary hypertension.
1. Introduction
The administration of supplemental oxygen is common in
the critically ill. The aim is to augment oxygen delivery to
the tissues [1]. Hyperoxia can lead to production of reactive
oxygen species and cell injury [2, 3]. Conversely, hypoxia
causes cell death. The “ideal” PaO2 target range is unclear.
Consequently clinical practice varies.
Eastwood et al. reported that 77% of intensivists in Aus-
tralia and New Zealand prescribed oxygen saturation targets.
Clinicians working in regional centers were less concerned
with oxygen toxicity [4]. De Graaff et al. explored the
response of Dutch clinicians to arterial blood gas values
(ABG) in tertiary intensive care units.The FiO2 was reduced
in only 25% of situations with a PaO2 > 16 kPa [5].
The etiology and evolution of paediatric critical illness are
different to adults. Multiorgan failure (MOF) occurs early in
children and they have better survival [6, 7]. Nonetheless, the
duration of mechanical ventilation and length of stay in the
paediatric intensive care unit is increasing [8]. This survey
aimed to describe prevalent paediatric intensive care practice,
existence of weaning protocols, and if a clinical equipoise
exists between liberal and restrictive oxygenation targets.
2. Material and Methods
All the members of the Paediatric Intensive Care Society
(PICS), UK, were requested to complete an online survey.
PICS consists of nursing, medical, and allied health pro-
fessionals working in paediatric intensive care units. The
practitioners from the neonatal intensive care units in UK
were not approached, as their patient profile is significantly
different.
The survey was designed by the authors and published
using a survey website (https://opinio.ucl.ac.uk). Demo-
graphic data including age, ICU type, their seniority, and
years of practice were sought. The study was discussed with
the chair of Bloomsbury Research and Ethics Committee
(London, UK). We were advised that a formal ethics review
was not required.
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Table 1: Characteristics of respondents.
Number of admissions/year to your intensive care
unit Number (%)<500 9 (17.6)
501–1000 24 (47)
1001–1500 13 (25.5)>1500 5 (9.8)
No response 2
Cardiosurgical center 33 (66)
Neurosurgical center 35 (67)
Grade of respondent
Consultant 25 (48)
Senior nurse 10 (19.2)
Senior fellow 12 (23)
Junior fellow 5 (9.6)
No response 1
Number of years of practice in intensive care
2–5 years 13 (25.5)
5-6 years 13 (25.5)>10 years 25 (49)
No response 2
The survey outlined the following clinical scenario: a 1-
year-old patient with no premorbid conditions is ventilated
with peak inspiratory pressure of 28 cm H2O, positive end
expiratory pressure of 6 cm H2O, respiratory rate of 20
breaths per min, and FiO2 of 0.8. His peripheral oxygen satu-
ration (pulse oximetry), heart rate, blood pressure, and mean
blood pressure are 94%, 125 beats per min, 85/56mmHg,
and 66mmHg, respectively. He has bilaterally equal and
reactive pupilsmeasuring 3mm.He is sedated on intravenous
morphine andmidazolam. He is not paralysed. Latest arterial
blood gas values are as follows: pH: 7.32, PCO2: 6.2 kPa, PaO2:
10 kPa, BE: -ve 4, and lactate: 1.5mmol/L.The PIM2 predicted
risk of mortality is 8.8%. He has been ventilated for 2 days.
With the same clinical history, clinicians were asked
to decide on the oxygenation targets when the potential
diagnosis is ARDS, CA, Sepsis, TBI, or PHTN.
A further question explored if weaning protocols were in
place in their units. The need for a randomised control trial
(RCT) with tight arterial oxygenation targets was explored.
3. Results
Only 30% (53) of those whom were invited to participate
in the online survey responded. The majority of respon-
dents worked in moderate sized ICUs, with admission rates
between 500 and 1000 patients per annum. The characteris-
tics of the respondents are presented in Table 1.
The majority of units (96%) had an alarm target on their
oxygen saturation monitor. Thirty-eight respondents (73%)
worked in units that did not have an oxygen weaning
protocol for mechanically ventilated patients.The units with
admissions more than 1500 were less likely to have a weaning
protocol compared to those between 500 and 1500 admis-
sions.
For the given clinical scenario, 21 respondents (42%)
did not follow PaO2 targets. Of the rest, 21 clinicians (42%)
targeted PaO2 between 8.1 and 10 kPa. Only 8 (16%) aimed
for the normal range (10.1–13 kPa).
In ARDS, CA, and sepsis, there was a tendency to aim for
lower PaO2 (<10 kPa) as the FiO2 increased.This was notice-
able when the FiO2 was more than 0.4 (45%) which equates
to a PaO2/FiO2 ratio of less than 200. Following TBI and
in PHTN, there was a propensity to aim for normal PaO2
(10.1–13 kPa) even as the FiO2 rose (28–33% when FiO2 >
0.4). In TBI, the proportion of respondents targeting a lower
PaO2 increased when the FiO2 was more than 0.8 (8%). A
proportion of respondents targeted PaO2 ranges above nor-
mal (15%). In PHTN, normal range remained the preferred
range throughout the range of FiO2 (Figure 1).
The initial scenario was further extended as “no improve-
ment after 24 hours of intensive care.” The management
strategy did not change in this setting.
Thirty-nine percent considered it ethical to conduct a
RCTwith tight arterial oxygenation target whilst 11%did not.
The remaining respondents were undecided.
4. Discussion
Our survey shows that, practice variation notwithstanding,
there seems to be a general consensus to aim for lower PaO2 in
the setting of ARDS, CA, and sepsis.The results are consistent
with higher PaO2 targets being chosen in children following
TBI and in PHTN. Only a small proportion of respondents
felt a RCT with tight oxygenation target would be unethical.
Paediatric intensivists tolerate a low SpO2 target (88%)
with a low tidal volume strategy for ARDS [9]. Our findings
concur. A recent point prevalence study reported that adult
intensive care practitioners aim to prevent low oxygen satu-
ration (SpO2 < 90%) but fail to address high saturations [10].
This is in the face of mounting evidence of harm from hyper-
oxia [11]. Should we aim for a restrictive oxygenation target
in critically ill patients?The “HOT or NOT” trial showed that
separation between titrated oxygen target and standard target
is possible in intensive care [12]. A recent multicenter study
demonstrated no difference in 90-day mortality between
mechanically ventilated patients randomised to a conserva-
tive (pulse oximetry: 88–92%) and liberal oxygenation targets
(>96%) [13]. A larger randomised control trial is awaited.
The main limitation of this survey is the likely low
response rate. At the time of the survey the membership of
the society was not well defined. Responses were not sought
beyond a single e-mail.The low number of respondents from
junior staff perhaps suggests that considerable experience
is needed to set distinct targets in these clinical scenarios.
Despite this limitation, the results indicate that restrictive
targets are aimed for in certain scenarios.
We had intended to analyse Cohen’s kappa to look at
interrater agreement. However, due to the small sample size
a formal statistical analysis was not attempted.
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Figure 1: The profile of PaO2 (푦-axis) and FiO2 (푥-axis) targeted in 5 clinical scenarios in a child with moderate ventilatory requirements.
The PaO2 ranges from <8 kPa in the bottom panel to >13 kPa in the top panel within each scenario. FiO2 ranges from 0.21 (blue) through to
0.81–1 (purple).The three scenarios in the upper section show a pattern of more restrictive PaO2 targets with increasing FiO2.The 2 scenarios
in the lower section show that higher normal PaO2 ranges are targeted irrespective of increasing FiO2.
5. Conclusions
In this study variability and lack of consensus are consistent
with an assumption of clinical equipoise. Supplemental oxy-
gen administration practices andoxygenation target practices
vary. A majority of respondents worked in units with no
oxygen weaning protocol. A proportion of clinicians do not
follow PaO2 targets. Clinicians aim for lower PaO2 thresholds
in ARDS, CA, and sepsis whilst aiming for the normal range
in TBI and PHTN. The lack of consensus and the large
variability in practice demonstrate equipoise. This should
be addressed with a feasibility trial comparing restrictive to
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standard oxygenation targets in critically ill children to lead
up to a future RCT.
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Dear Editor,
Sepsis-induced critical illness differs
between adults and children. Children
deteriorate more quickly and exhibit a
‘cold shock’ haemodynamic pattern
more often. Organ failure scores
characteristically peak earlier in sep-
tic children (\2 ICU days) than adults
(days 3–4). A high proportion of
deaths in children occur very early
[1]. Yet, ICU stays are shorter and
survival better in children [2]. Might
these differences in clinical pheno-
type—more rapid onset and
recovery—be due to differences in
the underlying mechanisms of multi-
organ failure (MOF)?
Acute mitochondrial dysfunction
may contribute to MOF. Reduced
mitochondrial oxygen utilisation and
gene expression has been observed in
established sepsis in adults and chil-
dren [3]. There is an association
between recovery of mitochondrial
function and survival but the contri-
bution to the onset of organ failure is
less clear. We investigated whether
mitochondrial oxidative phosphory-
lation gene expression (Oxphos)
alters early enough in the clinical
course of sepsis to remain a candidate
element of MOF pathophysiology. To
do this, we selected a population with
the most rapid onset of profound
sepsis-MOF: previously healthy chil-
dren with acute meningococcal
septicaemia. We investigated the
time-course of gene expression in
peripheral blood with gene set
enrichment analysis (GSEA), at 0, 4,
8, 12, 24, and 48 h from time of ad-
mission to the emergency room.
Extracted RNA was hybridised in
Affymetrix microarrays. Method-
ological details are published
elsewhere [4]. The dataset is available
to download from the European
Bioinformatics Institute database
(ArrayExpress id: E-MEXP-3850).
Emergency room venesection was
designated time 0 as a pragmatic
Fig. 1 Enrichment plot of the Respiratory Electron Transport Chain (RETC) gene set
showing the normalised enrichment score (NES), the false discovery rate (FDR) and
nominal p values for the gene set. Gene set enrichment analysis compares the variation in
the gene expression in our overall dataset compared to a preselected gene set (RETC gene
set) over the time-course. We have observed that RETC gene set expression is down-
regulated more than would be expected by background variation in expression. The top
portion of the plot shows the running enrichment score (ES) for the RETC gene set. The
middle portion of the plot shows where the members of the gene set appear in the ranked
list of genes. The lower portion of the plot shows the value of the ranking metric as you
move down the list of ranked genes. The ranking metric measures a gene’s correlation with
a phenotype. For our continuous phenotype (time series), a positive value indicates
correlation with the phenotype profile (decreasing profile)
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reference time point while acknowl-
edging that children may be at
different stages of illness at
presentation.
The GSEA ranks changes in single
gene expression. It notes the distri-
bution of elements of a predefined
gene set in this overall ranked list. We
focused on the Reactome TCA cycle
and respiratory electron transport
chain (RETC) genes within the 3655
included gene sets. GSEA describes
the probability of a non-random dis-
tribution of RTEC elements within
the ranked list [5].
On the group level analysis, with a
false discovery rate (FDR) at\25 %
and ranked according to their nor-
malised enrichment score (NES),
1039 out of 3655 gene sets showed a
decreasing profile with time. The
RETC set was ranked 75th of the
1039 gene sets.
On the individual-level analysis
and FDR\25 %, all five patients had
a highly ranked fall in RETC set ex-
pression. Patient 1 showed a low
correlation of RETC gene expression
to a decreasing profile. This might be
relevant as, unfortunately, this child
died. Figure 1 shows the NES, FDR
and nominal p values for the RETC
set for the individual patients and the
overall group.
Oxidative phosphorylation gene
expression reduced early and contin-
ued to decrease for at least 48 h in
septic critically ill children. These
findings are consistent with mito-
chondrial dysfunction contributing to
the development of organ failure in
both adults and children despite the
differences in sepsis phenotype in
these groups.
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